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SUMMARY
Intracellular free calcium ions, ([Ca2+]j), and sodium/ hydrogen ion exchange, 
(Na+/H+ exchange), across the cell membrane play important second messenger 
roles in platelet activation and vascular smooth muscle cell contraction and growth. 
Changes in the normal activity of these second messengers may be responsible for 
enhanced platelet aggregability and increased vascular smooth muscle tone and 
hypertrophy which are associated with two major CHD risk factors, hypertension 
and dyslipidaemia. Several studies were undertaken using human platelets to 
identify possible pathophysiological control processes involved in cation transport.
1. Two methods for studying the Na+/H+ exchanger in human platelets were 
investigated, i) Amiloride-sensitive 22Na uptake was measured in platelets which 
had been acid loaded, by suspension in isotonic potassium propionate buffer (pH 
6.7), to stimulate Na+/H+ exchange. Intraplatelet radioactivity was used to calculate 
the affinity (Km) and the capacity (Vmax) of Na+ uptake, ii) Binding studies using the 
radioactive amiloride analogue 3H-5'-(N-methyl-N-isobutyl)amiloride (MIA), to 
identify Na+/H+ exchanger numbers in platelet plasma membranes, were 
unsuccessful.
2. Platelet calcium metabolism was measured using three different 
techniques, i) [Ca2+]j was measured basally and after addition of 1 pmol/l AVP in the 
presence and absence of 5mmol/l EGTA, was determined using the calcium- 
sensitive fluorescent probe Quin-2, ii) Calcium uptake was measured 1-30 min after 
adding 0.1ml aliquots of washed platelet suspensions (20x106cells) to buffer
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containing 0.15MBq 45Ca, with and without the presence of 1pmol/l arginine 
vasopressin (AVP). iii) Ca2+ efflux was measured in platelets loaded with 45Ca (30 
min incubation with 0.48MBq/ml). After removal of excess 45Ca by washing and 
resuspension in fresh platelet buffer, aliquots were harvested at 5 min intervals.
3. Part of the protective effect of high density lipoproteins (HDL) in 
cardiovascular diseases may be due to their anti-aggregatory properties. These 
properties were examined in platelets by comparing the effects of HDL2 and HDL3 
on (i) basal and AVP-stimulated changes in [Ca2+]j , (ii) 45Ca uptake and (iii) 45Ca 
efflux. In addition the effects of HDL2 and HDL3 on platelet Na+/H+ exchange 
kinetics were examined.
Platelets from normal volunteers were preincubated with vehicle, HDL2 (50- 
500^ig protein/ml) or HDL3 (500-3000pg protein/ml) for 30 min during Quin-2 or 
45Ca loading periods, or for 30 min prior to Ca2+ uptake or Na+/H+ exchange 
measurements. Amiloride-sensitive 22Na uptake was measured as previously 
described.
HDL2 reduced and HDL3 (500^g protein/ml) enhanced AVP-stimulated 
increases in [Ca2+]j by 21% and 30% respectively (p<0.05). Since neither HDL 
fraction altered the [Ca2+]j response to AVP in platelets treated with EGTA, the 
differential effects of HDL appear to be due to changes in Ca2+ influx or efflux rather 
than release of stored Ca2+. Both HDL2 and HDL3 reduced the initial rate of basal 
45Ca uptake in a dose-dependent manner (p<0.01); uptake by AVP-stimulated 
platelets was similarly reduced but the effect was not statistically significant. The 
Ca2+ content of platelets equilibrated with 45Ca for 30 min was less in the presence
17
of either HDL2 or HDL3. Neither HDL2 nor HDL3 appeared to significantly affect 
platelet 45Ca efflux rate. Km and Vmax values for platelet Na+/H+ exchange in the 
presence of HDL2 were not different from that in untreated platelets (38.3±4.5 
mmol/l and 377.4±29.6 pmol/106cells/min versus 46.5±6.3 mmol/l and 428.8±25.5 
pmol/106cells/min respectively). Vmax was increased in the presence of HDL3 
(545.9±43.5 pmol/106cells/min) compared to that in untreated platelets (p<0.05). 
Km values remained unchanged (48.1 ±2.7 mmol/l).
The present results showing increases and decreases respectively in AVP- 
stimulated increases in [Ca2+]j in response to HDL2 and HDL3 explain previous 
observations of pro- and anti-aggregatory effects of these HDL subfractions. Effects 
on transport of calcium in and out of the cell might account for differences in 
responses to HDL subfractions. Na+/H+ exchanger activity, which may enhance 
Ca2+ mobilization through increases in pHj, was enhanced by HDL3 but not by 
HDL2.
4. In view of the in vitro findings of lipoproteins (above) we investigated 
whether relationships between circulating lipids and cation transport might explain 
aspects of cardiovascular disease and diabetes. Na+/H+ exchange and [Ca2+]j 
metabolism in platelets from normotensive subjects were compared with plasma 
lipoprotein and apolipoprotein profiles from normotensive subjects. In the same 
subjects, the impact of Apo E phenotype on plasma lipids and platelet cation 
transport were also considered. In addition the relationships between platelet 
Na+/H+ exchange, serum lipids and platelet membrane microviscosity in essential 
hypertensive and type 2 diabetic patients were examined.
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4.1 Analysis of data for normotensive subjects revealed several important 
points, i) No significant correlations were identified by single linear regression 
between platelet [Ca2+]j and plasma lipids, ii) Significant positive correlations were 
identified between age and [Ca2+]j (basal and AVP-stimulated ± EGTA) in female 
subjects. This relationship may be a function of the female sex hormone, oestrogen,
iii) Vmax of Na+/H+ exchange, in males, was negatively correlated with HDL (r=- 
0.364, p=0.018) and systolic blood pressure (r=-0.330, p=0.031) and positively 
correlated with Cholesterol:HDL ratio (r=0.376, p=0.014). Cholesterol:HDL, acting 
as a marker of net cholesterol transport, might reflect cholesterol content of the 
platelet plasma membrane and hence platelet reactivity, iv) Multiple regression 
analysis indicated that three lipid components, triglyceride, VLDL and Apo B, 
accounted for a significant proportion of the variation in both calcium metabolism 
and Vmax of Na+/H+ exchange in female subjects. The influence of these lipids was 
less apparent in males. Control of Na+/H+ exchanger activity via Ca2+-calmodulin 
binding may provide the link between lipid-induced variations in platelet cation 
transport, v) When subdivided into their respective Apo E phenotype, those 
subjects bearing Apo E4/E3 had lower Km values (42.6±4.6 v 54.2±2.7 mmol/l, 
p=0.025) and lower basal [Ca2+]j (70.4±7.7 v 90.1 ±3.9 nmol/l, p=0.014) than Apo 
E3/E3 individuals. In Apo E4/E3 subjects Vmax of Na+/H+ exchange was positively 
correlated with HDL3 (r=0.523, p=0.046) and Lp(a) (r=0.532, p=0.050). In Apo 
E3/E3 subjects basal [Ca2+]j was negatively correlated with HDL2 (r=-0.368, 
p=0.042). It is proposed that the differential influence on platelet cation transport by 
Apo E phenotype may be due to alterations in certain aspects of reverse
19
cholesterol transport (i.e. cholesterol esterification and Apo E content of HDL 
particles) from individuals of different Apo E phenotype. This, in turn, may explain 
the differential risk levels associated with these subgroups and the development of 
premature atherosclerosis and myocardial infarction (Ml).
4.2 Neither platelet membrane microviscosity, Km nor Vmax of Na+/H+ 
exchange were significantly different between essential hypertensive patients and 
matched controls. Km of Na+/H+ exchange was negatively correlated with HDL2 (r=- 
0.550, p=0.034) and positively correlated with Apo B (r=0.591, p=0.016) in 
hypertensive subjects. These associations are discussed in relation to the supply 
and removal of free cholesterol to the platelet plasma membrane. Membrane 
micoviscosity data do not confirm this theory, however, since microviscosity was not 
significant correlated with either Na+/H+ exchange kinetics or plasma lipids in 
hypertensive subjects.
Plasma [triglyceride], [VLDL], systolic and diastolic blood pressure were 
significantly elevated in type 2 diabetic subjects compared with controls. Km, Vmax 
and membrane microviscosity were unchanged. Plasma triglycerides and VLDL 
were negatively correlated with Vmax of Na+/H+ exchange (r=-0.546, p=0.024 and 
r=-0.560, p=0.019 respectively) in diabetics. These relationships may relate to 
effects of triglycerides on membrane phospholipid turnover leading to altered 
diacylglycerol levels, or may indirectly reflect non-enzymatic glycosylation on a 
critical binding domain of the Na+/H+ exchanger. Membrane microviscosity was 
inversely correlated with plasma cholesterol (r=-0.513, p=0.042) and LDL (r=-0.520, 
p=0.039) in diabetic subjects. These relationships may reflect altered sensitivity of
20
platelet membrane receptors for plasma cholesterol, and changes to endogenous 
cholesterol synthesis and/or reverse cholesterol transport by platelets in type 2 
diabetics. Membrane microviscosity and Apo Al were negatively correlated (r=- 
0.735, p=0.010) in control subjects indicative of the role that Apo Al plays in reverse 
cholesterol transport.
5. Pregnancy-induced hypertension (PIH) results from increased vascular 
resistance. Since intracellular pH and [Na+] influence smooth muscle contractility we 
investigated whether Na+/H+ exchange activity might be affected by measuring 
amiloride-sensitive Na+ uptake in platelets from hypertensive and normotensive 
subjects.
Platelet Na+/H+ exchange was characterised in normotensive, primagravid 
women, for whom a normal outcome was established, and from patients with non- 
proteinuric PIH. Measurements were made at 12-16 (n=7), 24-28 (n=7) and 38-42 
weeks (n=9) gestational age and 6 weeks postnatally (n=3) and at 34-40 weeks 
gestation in patients with PIH. Km and Vmax of amiloride-sensitive 22Na uptake 
were measured as described above. Plasma cholesterol was measured by an 
enzymic method using a commercial kit.
In normotensive women, Vmax (±SEM) for 1st, 2nd and 3rd trimesters and 6 
weeks postpartum were 452±46, 469±33, 713±101 and 562±77 pmol 
Na+/106cells/min respectively. 3rd trimester values were higher (p<0.05) than those 
in the 1st and 2nd trimester and were also higher than those of non-pregnant women 
(415±20). Vmax of patients with PIH in the 3rd trimester (712±44) were not different 
from gestational age-matched controls. Affinity (Km) for Na+ was not affected by
21
gestational age or PIH. Plasma cholesterol concentration was positively correlated 
with Vmax values during normotensive pregnancy (r=0.493, p<0.05).
The capacity for amiloride-sensitive Na+ uptake by platelets correlates 
positively with gestational age during normal pregnancy. However, neither the 
capacity of Na+ uptake nor affinity for Na+ was altered in PIH, suggesting that 
Na+/H+ exchange is not involved in the aetiology of this disease.
In summary, the present studies demonstrate that cellular cation transport is 
influenced by environmental factors. In particular we have shown that i) platelet 
Na+/H+ exchange and [Ca2+]r metabolism are influenced by HDL subfractions both 
in vivo and in vitro, ii) In type 2 diabetics, essential hypertensives, and in subjects 
with particular Apo E phenotype some of the relationships between cation transport 
and circulating lipids are altered, possibly as a result of changes to supply, 
synthesis and removal of cholesterol from the cell (ie reverse cholesterol transport),
iii) platelet Na+/H+ exchanger activity is altered during pregnancy and is apparently 
related to cholesterol concentration, iv) Na+/H+ exchanger activity is not altered 
under all pathophysiological circumstances since no changes were observed in 
platelet cation transport between normal pregnant and gestationally age matched 
PIH patients.
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CHAPTER 1
LITERATURE REVIEW
1.1 HISTORY OF CATION TRANSPORT ABNORMALITIES AND ESSENTIAL 
HYPERTENSION
Since the mid 1970's extensive data have accumulated indicating 
abnormalities in plasma membrane cation transport in various cell types from 
essential hypertensive subjects and from animals with genetic or experimental 
hypertension. The specific transport pathways affected and the type of cell studied 
vary considerably. Alterations in plasma membrane permeability and intracellular 
content of Na+, K+ and Ca2+ have been demonstrated in erythrocytes [1, 2, 3, 4, 5], 
lymphocytes [1, 2], leucocytes [1, 2], platelets [6] and vascular smooth muscle cells 
[2, 4, 7, 8] from hypertensive individuals. Some of the results are contradictory, 
suggesting that the nature of these changes are very much dependent upon the 
cell type. Also variations may be due to differences between populations [9].
In the early 1980's several hypotheses were put forward to account for the 
relationship between abnormal cation transport and essential hypertension [3,10]. It 
was suggested that the association could occur in one of three ways, i) Cation 
transport abnormalities could be the result of hypertension itself. This seems 
unlikely since the same abnormalities were demonstrable in the cells of 
normotensive relatives as well as in cells not obviously under the influence of 
elevated blood pressure, ii) Abnormalities could represent a genetic trait in close 
linkage dysequilibrium with a gene controlling hypertension, without being the cause
23
of hypertension (i.e. a genetic marker), iii) Cation transport abnormalities could 
participate in the mechanism responsible for blood pressure elevation or be 
associated with it.
In the early 1980's our knowledge of cellular biochemistry was limited, thus 
linking cation transport changes to specific pathophysiological processes proved 
difficult. Measurement of cation transport was, at that time, used largely as a 
method for screening individuals predisposed to the development of essential 
hypertension. More recently, as understanding of the biochemical processes 
involved in cell communication and function has progressed, we have begun to 
identify possible pathophysiological roles for altered cation transport in essential 
hypertension.
1.2 SIGNIFICANCE OF TRANSPORT PROCESSES IN THE CONTROL OF CELL 
FUNCTIONS
Numerous mechanisms are involved in the movement of Na+, K* and Ca2+ 
across the plasma membranes of various cells. Figure 1.1 illustrates a number of 
these transport mechansims in a generalized cell, each of which have been 
investigated with respect to abnormalities occurring in essential hypertension [3, 10, 
11]. Under normal circumstances a change in the activity of one of the membrane 
transporters will usually result in the compensatory activation of one or more of the 
other transport systems to maintain homeostasis. It is essential that cell cation 
homeostasis is strictly maintained because changes in intracellular cation 
concentrations form part of the signal transduction processes which control cell
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function.
1.3 SIGNAL TRANSDUCTION
Communication between cells is required to control cell growth and division 
and to co-ordinate diverse cellular activities. Co-ordination in an organism is 
controlled by 'messenger molecules', usually peptides, that are secreted by 
specialised cells into the blood stream (endocrine factors), by neighbouring cells 
(paracrine factors), or by the cell itself (autocrine factors) [12]. The majority of 
circulating messenger molecules which carry information for cell activation are 
unable to permeate the cell plasma membrane barrier. Receptors (usually 
glycoprotein in nature) on the outer surface of the cell detect incoming messages 
and activate a signal pathway that ultimately regulates cellular processes such as 
secretion, contraction, metabolism or growth. Transduction mechanisms within the 
plasma membrane translate external signals into internal signals which are carried 
by so called 'second messengers' [13].
Signal transduction across the plasma membrane depends on a series of 
proteins (i.e. G-proteins), which couple the receptor to second messenger systems 
within cells [14], The G-proteins are a family of closely related heterotrimeric 
proteins that are composed of a, ft and 8-subunits. When a first messenger (such 
as a hormone or other agonist) interacts with its specific receptor, the receptor itself 
acquires the capacity to catalytically activate adjacent G-proteins [15]. Activation 
involves a conformational change which permits the G-protein to exchange GDP for 
GTP at a guanine nucleotide-binding site on the a-subunit. This phosphorylation of
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the a-subunit causes the dissociation of the (J-5 subunit from the trimer, leaving the 
a-subunit-GTP complex free to interact with other signal transduction enzymes 
situated in the membrane e.g. adenylate cyclase (as illustrated in Figure 1.2) or 
phospholipase C. Activation of the transduction enzymes results in an increase in 
the concentration of certain small molecules or ions within the cell cytoplasm, the 
second messengers. These messengers diffuse and rapidly propagate a signal 
throughout the cell. Second messengers induce structural changes in proteins 
which then influence cell function. Second messengers function in one of two ways. 
Firstly they may act directly by binding with a protein and triggering a conformational 
change. Secondly, they may act indirectly by activating enzymes (protein kinases) 
which are responsible for protein phosphorylation. Protein kinases carry out 
phosphorylation through the transfer of phosphate (P04) from ATP (and other high 
energy compounds) to the serine and threonine residues of specific proteins, 
resulting in protein shape change [16].
1.4 ROLE OF CALCIUM AS A SECOND MESSENGER IN SIGNAL 
TRANSDUCTION
Calcium serves as an almost universal ionic messenger. It is involved in such 
diverse processes as the regulation of muscle contraction, the secretion of 
hormones, digestive enzymes and neurotransmitters, the control of cell growth and 
proliferation, the regulation of cell volume and the transport of salt and water across 
the intestinal lining [17],
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Figure 1.2 Relationship between a membrane receptor and a G-protein before (A) 
and after (B) the receptor interacts with a hormone. An example of adenylate 
cyclase (AC) activation.
A wealth of evidence (see reviews [17, 18, 19]) supports the theory that, in 
many systems, cellular activation initiated by direct interaction of hormones, growth 
factors and neurotransmitters with plasma membrane receptors results in an 
increase in intracellular free Ca2+. Intracellular Ca2+ concentration is regulated by a 
particular signal transduction mechanism involving the inositol lipid pathway.
1.5 INOSITOL LIPID PATHWAY
Cell membranes contain three inositol lipids, the major proportion is 
phosphatidylinositol (PI), with smaller contributions from phosphatidylinositol 4- 
phosphate (PIP), and phosphatidyl 4,5-bisphosphate (PIP2). Kinase enzymes are 
present in the membrane that can phosphorylate PI at the 4 position, thereby 
producing PIP and then in the 5 position of this lipid to yield PIP2 [20]. 
Phosphomonoesterases are also present in the membrane which dephosphorylate 
the inositol lipids so that even when unstimulated membrane inositol lipids are 
constantly turning over in a futile cycle (see Figure 1.3) [21].
The first indication that inositol lipids might mediate hormone actions dates 
from 1953 when Hokin & Hokin [22] discovered that acetylcholine stimulated the 
incorporation of radioactive phosphorous into phosphatidylinositol (PI) in the 
pancreas. The function of this increase in PI remained a mystery until Michell (1975) 
[23] suggested that membrane inositol phospholipid turnover, triggered by external 
signals, was responsible for generating internal calcium signals. It was 
subsequently shown that inositol trisphosphate (IP3) was the second messenger 
responsible for mobilising ionized calcium from intracellular stores [13, 24].
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The first event in the inositol lipid signal transduction pathway, (after agonist- 
receptor interaction), is the hydrolysis of one of the minor membrane phospholipids, 
phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C. PIP2 is cleaved 
into two parts, the hydrophobic diacylglycerol (DG) portion remains within the 
membrane while the water soluble inositol trisphosphate (IP3) is released into the 
cytoplasm [13, 17]. The two second messengers have different functions. IP3 
releases Ca2+ from intracellular stores (endoplasmic reticulum), while DG activates 
protein kinase C which in turn activate specific proteins e.g. the Na+/H+ exchanger. 
Protein kinase C activation and Ca2+ release are both essential and act 
synergistically to elicit a full physiological response [25, 26, 27, 28].
As well as acting as a second messenger, DG can also be metabolised via 
DG kinase to form phosphatidic acid (PA), which has also been ascribed numerous 
second messenger roles. PA appears to have effects on calcium channels and can 
provoke some calcium release from stores, it can alter protein kinase C activity and 
may potentiate phopholipase C activity [29].
1.6 REGULATION OF INTRACELLULAR CALCIUM CONCENTRATION AND 
TRANSPORT ACROSS THE PLASMA MEMBRANE
Total intracellular calcium concentration, based on estimates in a number of 
different cell types, is approximately 1mmol/l. Intracellular free calcium, [Ca2+]j, 
within cells is very low, i.e. in the order of 10-100 nmol/l. The vast majority of 
intracellular calcium is associated with calcium binding proteins, or held in non­
ionized states within intracellular calcium stores. There is a considerable
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electrochemical gradient driving Ca2+ into the cell, since extracellular Ca2+ 
concentration is approximately 1mmol/l (compared to 10-100 nmol/l [Ca2+]j and the 
interior of the cell is negatively charged. This electrochemical gradient is maintained 
by the plasma membrane which is relatively impermeable to Ca2+ [30, 31]
Intracellular calcium concentrations are regulated by mechanisms that allow 
the movement of calcium across the plasma membrane and from sequestered 
intracellular stores.
Ca2+ can enter a cell in two ways; i) Ca2+ leak down the electrochemical 
gradient across the plasma membrane, and ii) influx via specific channels in the 
plasma membrane. Ca2+ channels are divided into two main categories which are 
either voltage-operated (VOC) or receptor-operated (ROC) [30].
At least three types of voltage-sensitive channels have been identified in 
neuronal and non-neuronal cells as T, N and L types [32]. Each type is 
distinguished by its sensitivity to a family of dihydropyridine compounds, which 
include both Ca2+ channel blockers (e.g. nifedipine) and agonists (e.g. BayK8644) 
that enhance Ca2+ current.
The T channel gives rise to small and transient increases in Ca2+ current as 
a result of small depolarisation steps. T channels from non-neuronal cells 
demonstrate sensitivity to dihydropyridine antagonists. The N channel is opened by 
stronger depolarising steps, inactivates less readily than the T channel and is 
insensitive to inhibition by dihydropyridines. This type of channel appears to be 
closely linked to neurotransmitter release. The third, or L channel, found in both 
neuronal and non-neuronal (e.g. smooth muscle) cells, is also activated by strong
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depolarisation. The dihydropyridine agonist Bay K8644 increases L-type channel 
opening in neurons and cardiac cells [32].
Receptor operated channels open in response to hormone-receptor 
interaction, independent of change in membrane potential. The mechanism of their 
opening may be either by a direct coupling of receptor with the channel (via a G- 
protein) [33], or by an indirect coupling via generation of an intracellular messenger 
such as cAMP or IP3 [34].
When a cell is activated by a hormone or other extracellular messenger, a 
common event is a 2-4 fold increase in Ca2+ influx via plasma membrane channels 
[31]. This causes only a transient increase in cellular Ca2+ concentration because of 
the existence of an elegant autoregulatory system in the plasma membrane which 
acts to pump Ca2+ out of the cell [31].
There are two energy dependent mechanisms by which Ca2+ is extruded 
from the cell: i) Na+/Ca2+ exchanger which uses the Na+ gradient across the 
membrane (maintained by the activity of the Na+/K+ ATPase pump) to drive Ca2+ 
efflux [35, 36, 37, 38]; ii) a plasma membrane Ca2+ ATPase pump which is crucial 
for long-term maintenance of cellular Ca2+ homeostasis [39, 40]. Another Ca2+ 
ATPase pump, identified by its sensitivity to thapsigargin, is present in the 
endoplasmic reticulum [40, 41], This ATPase causes the accumulation of Ca2+ in 
the intracellular store. The plasma membrane Ca2+ ATPase pump is activated by 
the intracellular Ca+ binding protein, calmodulin (CaM). An increase in the Ca2+ 
concentration of the cytoplasm promotes the formation of the Ca2+-calmodulin
33
complex, which when associated with the Ca2+ ATPase pump, brings about its 
activation [31].
In operational terms the existence of autoregulatory systems for Ca2+ means 
that following hormone-stimulated increase in Ca2+ influx, there is a compensatory 
increase in efflux. Thus, during the sustained phase of many cellular responses the 
overall rate of Ca2+ cycling across the plasma membrane is increased with little or 
no change in intracellular free Ca2+. This cycling of calcium across the plasma 
membrane may act as a messenger during a sustained phase of the reponse 
perhaps by changing the [Ca2+] in a subdomain just beneath the plasma membrane 
[17].
1.6.1 INTRACELLULAR Ca2+ STORES (ENDOPLASMIC RETICULUM)
Non-mitochondrial, intracellular calcium stores play an important role in 
activation of many tissues including smooth and skeletal muscle. In skeletal muscle 
the store (known as sarcoplasmic reticulum) is relatively large and provides a 
reservoir of Ca2+ needed to regulate contraction. In non-muscle and smooth muscle 
cells, the stores are smaller and their location less obvious. The Ca2+ within these 
stores may be rapidly released causing a transient, 5-10 fold increase in cytosolic 
Ca2+ concentration [31]. Agonist-stimulated Ca2+ release is induced by IP3) while 
refilling of the store is driven by a distinct, thapsigargin-sensitive, Ca2+ ATPase [41].
1.6.2 MITOCHONDRIAL MATRIX Ca2+ STORES
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Ca2+ uptake by mitochondria occurs via a uniporter in the inner mitochondrial 
membrane and is driven by a proton-electrochemical gradient [42]. The 
mitochondrial matrix Ca2+ store is rapidly exchanged with cytosolic Ca2+. Upon cell 
activation, by a Ca2+ dependent hormone, the mitochondrial matrix [Ca2+] rises as 
the cytosolic [Ca2+] rises. This leads to the activation of three Ca2+ sensitive 
mitochondrial enzymes; pyruvate, NAD-linked isocitrate and a-ketaglutarate 
dehydrogenases.
The mitochondria plays a second homeostatic role in cellular processes by 
serving as a sink for Ca2+ during times of excessive Ca2+ influx [31].
1.6.3 MEMBRANE BOUND Ca2+
Ca2+ binds in specific and non-specific ways to both external and internal 
surfaces of the plasma membrane. Membrane binding sites include phospholipids, 
proteins (e.g. Ca2+ binding proteins or glycoproteins), enzymes (e.g. Ca2+ ATPase) 
or other non-membranous moieties anchored to the membrane (e.g. myofilaments). 
Superficially bound Ca2+ serves as a membrane stabiliser. For example, calcium 
overload is prevented by a membrane stabilisation process whereby extracellular 
calcium renders the membrane less permeable, not only to calcium but, to all other 
ions [43],
1.7 SODIUM ION TRANSPORT ACROSS THE PLASMA MEMBRANE AND ITS 
ROLE IN SIGNAL TRANSDUCTION
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Sodium ions (Na+) are extremely important for maintaining membrane 
potential (together with K+) and for controlling osmolarity of the cell cytosol. The net 
sodium content of the cell is determined by relative rates of influx and efflux of Na+ 
across the plasma membrane. Most sodium enters the cell via passive Na+ 
diffussion (Na+ channels) and by Na+/H+ exchange. The major extrusion 
mechanism is the sodium pump (see below).
1.7.1 SODIUM PUMP
The sodium pump opposes the tendency for Na+ and K+ concentrations to 
leak across the membrane gradients. Under normal conditions, 3 Na+ are extruded 
and 2 K+ are pumped inwards, utilizing energy released by the hydrolysis of ATP. 
The reaction is catalysed by a membrane-bound magnesium-dependent enzyme, 
Na+/K+ ATPase which is specifically inhibited by the glycoside, ouabain, and hence, 
is often described as the ouabain-sensitive sodium pump [44]. Because pumping of 
cations in the two directions is unequal, the sodium pump is electrogenic, i.e. it 
generates a potential difference across the cell membrane (hyperpolarisation) as 
long as this is not compensated for by movements of an anion such as Cl'. 
Conversely, inhibition of the sodium pump produces membrane depolarisation.
1.7.2 Na+/Na+ EXCHANGE
Na+/Na+ exchange is an example of exchange diffusion [45] whereby an 
equal flux of a single ion species occurs in both directions across the plasma 
membrane, mediated in each case by the same carrier and not therefore inducing
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any net transport. Technically, exchange diffusion is demonstrated by observing 
equal movements of an isotopically labeled ion (e.g. 22Na or 24Na) in each direction.
Erythrocyte Na+/Li+ countertransport, which is considered a genetic marker 
for essential hypertension and hyperlipidaemia probably represents Na+/Na+ 
exchange [10, 46]. Na+/Li+ countertransport is not a physiological process since Li+ 
is not normally present in the body. It has been suggested by some [47] that Na+/Li+ 
countertransport reflects the activity of another Na+ transport mechanism, the 
Na+/H+ exchanger.
1.7.3 Na+/KV2Cr CO-TRANSPORT
Co-transport is the movement of an ion species in one direction obligatorily 
coupled to the movement of a different ion species in the same direction. 
Na+/K+/2CI' co-transport has been measured as potassium-stimulated Na+ influx or 
sodium-stimulated K+ efflux [48]. Alternatively, it can be measured as efflux of Na+ 
or K+ from sodium-loaded cells [49], Na+/K+/2CI' co-transport is inhibited by 
furosemide.
1.7.4 Na+/Ca2+ EXCHANGE
Na+/Ca2+ exchange contributes to the regulation of cytosolic Ca+ 
concentration and depends on the electrochemical Na+ gradient [34], Normally the 
exchanger extrudes Ca+ from the cytosol in exchange for extracellular Na+. 
However, the exchanger can operate in the reverse mode (i.e. Na+ out/Ca2+ in) 
when intracellular Na+ is raised during the inhibition of the Na+/K+ ATPase by
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ouabain [36]. The exchanger is inhibited by specific analogues of the K+ sparing 
diuretic drug, amiloride e.g. dichlorobenzamil.
1.7.5 Na7H+ EXCHANGE
The Na+/H+ exchanger has been detected in practically every cell type 
examined. It is an electroneutral countertransport system that, under physiological 
conditions, mediates 1:1 exchange of extracellular Na+ for intracellular H+ [50]. The 
exchanger is inhibited by amiloride [53]. Specific analogues of amiloride, e.g. 
ethylisopropylamiloride (EIPA), have a more potent inhibitory effect than amiloride 
itself [51,52, 53].
The Na+/H+ exchanger has a number of different physiological roles. The 
exchanger not only plays an important part in plasma membrane Na+ transport (e.g. 
in vascular smooth muscle cells (VSMC), 80% of basal Na+ entry is via Na+/H+ 
exchange) [54], but also participates in intracellular pH (pHj) homeostasis, cell 
volume regulation and the transepithelial transport of Na+ and acid-base 
equivalents [50]. Through the regulation of pHip the Na+/H+ exchanger plays either 
an essential or permissive role in mitogenesis, secretion, and receptor-mediated 
signal transduction [55],
The thermodynamic driving force for the exchanger is the electrochemical 
gradient generated by Na+/K+ ATPase. In addition, cytosolic H+ allosterically activate 
the exchanger by interacting with an internal modifier site, independent of the 
Na+/H+ exchanger site [56, 57]. In most cell types the exchanger is virtually 
quiescent at the physiological pHj of 7.3, but is rapidly activated by a reduction in
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pHj below this 'set point' (activation threshold). Regulation of Na+/H+ exchanger 
activity through receptor-mediated mechanisms may occur by altering the affinity of 
the modifier site for H+ thereby shifting the pH sensitivity (set point) of the 
exchanger [57, 58]. In addition to intracellular acidification, non-receptor mediated 
activation of Na+/H+ exchange can be produced by suspending cells in 
hyperosmotic (hypertonic) media which results in cell shrinkage. Shrinkage-induced 
activation (in parallel with CI7HC03' exchange) produces a net cellular gain of Na+, 
Cl- and H20  [51].
To date, there is no evidence from amiloride analogue binding studies, to 
suggest that activation of transport results from recruitment of Na+/H+ exchangers to 
the membrane (i.e. an increase in numbers). However binding of amiloride 
analogues to inactive transporters has not been ruled out. Stimulation of transport 
could result from activation of previously quiescent exchangers.
At least two distinct types of Na+/H+ exchanger exist, with different patterns 
of distribution and distinctive pharmacological and regulatory properties [57, 59]. 
One type is found in the apical membrane of renal, intestinal and gall bladder 
epithelia, and acts primarily to regulate Na+ reabsorption and proton secretion. This 
exchanger is relatively insensitive to inhibition by amiloride and the amiloride 
analogue EIPA. The second type is localized on the basolateral membrane of 
epithelial cells and on the plasma membrane of non-epithelial cells, and has a 
greater sensitivity for EIPA than that of the apical exchanger. This second type is 
important in the regulation of pHj and signal transduction.
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The molecular cloning and sequencing of the human Na+/H+ exchanger has 
identified several isoforms termed NHE-1, NHE-2, NHE-3 and NHE-4. The NHE-1 
isoform corresponds to the Na+/H+ exchanger localized in the basolateral 
membranes of epithelial cells and the plasma membrane of non-epithelial cells. It is 
the only isoform present in plasma membranes of vascular smooth muscle cells 
and platelets. NHE-1 is a 110kDa glycoprotein, which is predicted to contain 10 
transmembrane spanning segments and two potential glycosylation sites [60]. The 
NHE-2 isoform is found in kidney, intestine (ileal villus epithelia), adrenal gland and 
also in small amounts in skeletal muscle. NHE-3 and NHE-4 are expressed in the 
kidney and the gasterointestinal tract. NHE-3 is believed to be the apical-restricted 
form of the Na+/H+ exchanger involved in Na+ absorption [61, 62, 63].
NHE-1 is activated by growth factors, peptide hormones and numerous 
other agonists. Agonist-induced activation appears to be mediated by two 
independent pathways: i) a protein kinase C-dependent pathway; ii) a protein 
kinase C-independent pathway which involves Ca2+/calmodulin-dependent kinase 
[27, 64, 65, 66, 67, 68]. Specific binding sites for Ca2+/calmodulin have recently 
been identified in the middle of the carboxyl-terminal cytoplasmic domain of NHE-1 
[69]. It is proposed that in resting cells, when calmodulin is not bound to the NHE-1 
COOH-terminal, this domain functions as an intrinsic 'autoinhibitor1 preventing 
alkaline shift of the pHj activation curve. After cell stimulation, the increase in [Ca2+]j 
induces a Ca2+/calmodulin complex to bind to the 'autoinhibitory' region thereby 
switching off intrinsic inhibition and allowing cation exchange [70]. Recently it has 
been inferred that a specific class of G proteins, Gai2 and Gai3, may be involved in
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the activation of NHE-1 by mediating protein kinase C-dependent and independent 
pathways respectively [71].
It has been demonstrated that thrombin-stimulated protein kinase C- 
dependent exchanger activation in vascular smooth muscle cells [65], and 
cyclosporin stimulated protein kinase C-dependent exchanger activation in platelets 
[72] are Ca2+-independent. It is suggested that this may be due to DG derived from 
a source other than PI. For example, it has been shown that, many hormones, 
growth factors and neurotransmitters stimulate the breakdown of another 
membrane phospholipid, phosphatidylcholine (PC) [73], PC hydrolysis by 
phospholipase A2 is an important source of arachidonic acid which is subsequently 
metabolised to a variety of eicosanoids (leukotrienes, prostaglandins etc.), which 
are potent regulators of various physiological responses including platelet 
activation. PC can also be hydrolysed by phospholipase C and D to yield DG and 
phosphatidic acid (PA) respectively [29]. Compared with PIP2, PC hydrolysis yields 
a relatively large amount of DG for a longer period of time possibly because the 
cellular content of PC is several hundred-fold higher than that of PIP2. It is 
suggested that the physiological function of agonist-induced PC hydrolysis is 
related to its ability to generate DG for prolonged periods of time and thus cause 
sustained activation of protein kinase C [73].
1.8 ROLE OF INTRACELLULAR pH IN SIGNAL TRANSDUCTION
Changes in intracellular pH represent part of the signal transduction pathway 
involved in cell growth and proliferation. Vascular smooth muscle contraction also
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involves pHs [74]. There are three transport pathways which regulate intracellular 
pH: i) Na+/H+ exchange, ii) chloride-bicarbonate exchange (HC03'/Cr exchange), 
and iii) Na+-dependent HC037Cr exchange [51, 74].
The relative importance of each of these pathways is very much dependent 
on cell type and intracellular/extracellular conditions. For example HC037CI' 
exchange may play a role in acidifying alkaline-loaded cells, (CNn/HC03‘ out), at pHj 
values where both the Na+/H+ exchanger and the Na+-dependent HC037CI' 
exchanger are largely quiescent [51].
In many cell types, under conditions where Na+/H+ exchange is impaired (i.e. 
in the presence of amiloride and amiloride analogues) pHj can be maintained within 
the physiological range if HC03' is present (reflecting operation of the I n ­
dependent HC037CI'exchange system) [51]. Most investigations of Na+/H+ 
exchange have been carried out in the absence of bicarbonate since its presence 
appears to compromise measurements of amiloride-sensitive Na+/H+ exchange. In 
unstimulated cells pHj is higher in the presence of bicarbonate than in its absence 
[51]. This could be explained if the Na+-dependent HC037CI' exchange system was 
still operative at pHj levels above the set point (activation threshold) of the Na+/H+ 
exchanger.
1.9 pH AND CELL GROWTH (THE ROLE OF Na+/H+ EXCHANGE)
The coupling of growth factors to membrane receptors, (with intrinsic 
tyrosine kinase activity), initiates a sequence of events including phosphoinositide 
hydrolysis, an increase in [Ca2+]j, activation of protein kinase C, intracellular
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alkalinization and the induction of cellular proto-oncogenes such as c-fos and c- 
myc.
In many cell types, growth factor-induced increases in intracellular pH, (in 
bicarbonate-free media), are thought to result from Na+/H+ exchanger activation. 
This hypothesis is supported by in vitro observations that amiloride and its 
analogues in bicarbonate-free media prevent growth-factor induced alkalinization 
and DNA synthesis [75, 76, 77, 78, 79]. Furthermore, mutant cell lines devoid of 
Na+/H+ exchanger activity fail to initiate cell division or DNA synthesis in neutral or 
acidic, bicarbonate-free media in response to growth factors [80]. However, under 
physiological conditions (i.e. in the presence of bicarbonate), inhibition of Na+/H+ 
exchange has little or no effect on mitogenesis [77, 81, 82] and has no effect on 
mitogen-induced expression of the proto-oncogenes c-myc and c-fos in either the 
absence [83, 84] or presence [83, 85] of bicarbonate. Taken together these data 
suggest that the Na+/H+ exchanger plays a permissive (rather than essential) role in 
the proliferative response to growth factors, perhaps by optimizing growth 
conditions by preventing H+ accumulation resulting from increased metabolic 
activity during cell stimulation.
1.10 cAMP SIGNAL TRANSDUCTION PATHWAY
The cAMP (adenosine 3 5 cyclic monophosphate) pathway has both 
stimulatory receptors (Rs) and inhibitory receptors (Rj) which communicate with the 
membrane bound enzyme, adenylate cyclase (a signal amplifier), via Gs and Gj - 
proteins respectively. Adenylate cyclase uses ATP as a precursor to generate
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cAMP which activates the enzyme, protein kinase A. The activation of protein 
kinase A subsequently sets up an intracellular cascade mechanism, involving 
protein phoshorylation, which leads to specific cellular responses [13].
Gs-proteins stimulate adenylate cyclase activity and may regulate the gating 
of certain Ca2+ channels to promote membrane depolarisation, whereas Gr proteins 
inhibit adenylate cyclase and influence the gating of inward rectifying K+ channels to 
reinforce the resting potential of cells. These two classes of G-proteins are 
distinguished by the fact that Gs is sensitive to cholera toxin whereas Gj is sensitive 
to pertussis toxin.
1.11 cGMP SECOND MESSENGER
guanosine 3’ 5 cyclic monophosphate (cGMP), also plays a second 
messenger role in the control of cell function. Various agents e.g. sodium 
nitroprusside, nitrates, atrial natriuretic peptide, activate guanylate cyclase which 
converts GTP (guanosine triphosphate) to cGMP. Guanylate cyclase exists in two 
distinct forms, one of which is membrane-bound and the other soluble. In tissues 
such as platelets the soluble form predominates and is located almost exclusively in 
the cytosol, whereas in the kidney the particulate, membrane-bound, form 
predominates [86].
1.12 SIGNIFICANCE OF SECOND MESSENGER PROCESSES IN THE 
CONTROL OF VASCULAR SMOOTH MUSCLE CELL AND PLATELET 
FUNCTION
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Intracellular second messenger systems, including cation transport, are 
responsible for controlling the function of the various cell types which make up the 
cardiovascular system. VSMC and platelets are important in the regulation of two 
different aspects of cardiovascular function. Nevertheless they appear to be 
controlled by very similar signal transduction processes.
1.12.1 VASCULAR SMOOTH MUSCLE
The arterial wall is divided into three layers. The outermost layer, the 
adventitia, is a loose mixture of smooth muscle cells, fibroblasts and connective 
tissue separated from the middle layer, the media, by an external elastic lamina. 
The media, consists of layers of smooth muscle cells which contain the contractile 
'machinery' responsible for maintaining vascular tone. The smooth muscle cells are 
surrounded by collagen and proteoglycan connective tissue. The innermost section 
of the vessel wall, the intima, consists of a luminal layer of endothelial cells and a 
layer of elastic tissue, the internal elastic lamina. Separating the two structures is 
the subendothelium containing connective tissue components such as collagen, 
microfibrils and proteoglycans. The endothelium, which produces a wide spectrum 
of vasoconstrictor and vasodilator substances, plays an active role in the regulation 
of vascular tone and also functions as a selectively permeable barrier to plasma 
components [87].
An increase in [Ca2+]j is essential for activation of the contractile mechanism 
of vascular smooth muscle. Electron microscopy reveals that the contractile 
mechanism is composed of thick (14.5 nm) and thin (6.4 nm) filaments. Shortening
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and force generation is produced in a manner similar to the classic sliding filament 
model of skeletal muscles. Filaments do not change in length but slide in parallel 
alignment to shorten the length of the cell. In smooth muscle cells the thin and thick 
filaments consists of the proteins actin and myosin, respectively. Myosin is rod­
shaped with two elongated globular 'heads' at one end and comprises six separate 
protein chains. Two of these, the heavy chains, form the myosin rod, while the light 
chains are associated with the myosin heads. Interaction between the myosin 
heads (also known as crossbridges) and the actin filaments generates smooth 
muscle force. Crossbridges attach to adjacent actin filaments, then change their 
angle of attachment, causing relative sliding of the actin and myosin filaments. The 
crossbridges then detach and reset themselves ready for a further 
attachment/detachment cycle at a further point along the actin filament. Activation of 
the myosin crossbridge requires phosphorylation of the myosin light chains by the 
enzyme, myosin light chain kinase (MLCK) which in turn is activated by Ca2+ in the 
presence of the calcium binding protein, calmodulin. An increase in [Ca2+]j is 
therefore the initial trigger for smooth muscle contraction. Relaxation of smooth 
muscle follows the restoration of resting [Ca2+]j by extrusion of Ca2+ from the cell. 
MLCK is then rapidly inactivated by the dissociation from calmodulin, and myosin is 
dephosphorylated by myosin light chain phosphatase (MLCP) [88, 89]. The 
molecular events involved in the contraction and relaxation of smooth muscle are 
illustrated in Figure 1.4.
The contractile state is regulated by a number of different factors including 
vasoconstrictor agents; angiotensin II, norepinephrine (noradrenalin) and
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Figure 1.4 Molecular events involved in the contraction and relaxation of vascular 
smooth muscle cells.
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vasopressin and vasodilators; prostaglandins, nitric oxide and atrial natriuretic 
hormone. A diagramatic representation of the intracellular signalling pathways 
controlling vascular smooth muscle tone is shown in Figure 1.5. The effects of both 
vasoconstrictors and vasodilators are ultimately mediated by changes in 
intracellular Ca2+ concentration affecting phosphorylation of the contractile proteins. 
The signalling processes which precede change in intracellular Ca2+ are complex. In 
general vasoconstrictors alter Ca2+ through the IP3 pathway and/or changes in 
membrane potential. Vasodilator actions are mediated by several processes. 
Prostacyclin modulates responsiveness to vasoconstrictors through the cAMP 
pathway. cAMP may exert a direct inhibitory effect on the contractile proteins (e.g. 
possibly by phosphorylation of MLCK) and/or may inhibit vasoconstrictor-induced 
increases in intracellular Ca2+ [90]. Nitric oxide (NO, a product of the L-arginine 
pathway) and atrial natriuretic hormone effects on vasodilation are mediated via 
elevations in cGMP levels which inhibit phosphoinositide hydroysis[91, 92, 93]. In 
addition to its direct acute pressor action angiotensin II has a much slower blood- 
pressure elevating action [94]. Hypertrophy, as a result of increased vascular 
smooth muscle cell growth and proliferation, has been suggested as one of the 
ways by which angiotensin II may produce this slow pressor effect [95]. Smooth 
muscle cell Na+/H+ exchanger activity is enhanced by angiotensin II and may play 
an important role in the development of hypertrophy since intracellular alkalinization 
is necessary for cell growth and proliferation [96, 97].
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Cation transport also plays an essential role in the maintenance of vascular 
smooth muscle tone by the sympathetic nervous system. The action potential 
triggered by noradrenalin at smooth muscle synapses causes membrane Ca2+ 
channels to open, and the resulting increases in Ca2+ bring about contraction [98, 
99],
Many of the various stages involved in the control of vascular tone are 
influenced by pH. For example pH affects membrane potential which is a strong 
determinant of vascular smooth muscle contraction [74], Protons open K+ channels 
leading to hyperpolarisation and vasodilation [74]. Cellular calcium metabolism is 
also effected by changes in pH. ATP-dependent calcium uptake into intracellular 
Ca2+ stores and influx across the smooth muscle cell plasma membrane has a pH 
optimum of approximately 6.8 and a steep dependence on pH [100]. Patch clamp 
studies also indicate that protons have an inhibitory effect on calcium currents [74].
1.12.2 ALTERED SECOND MESSENGER PROCESSES IN HYPERTENSION
Changes in the normal regulatory mechanisms of vascular smooth muscle 
contraction and growth can lead to the development of hypertension, which has 
been identified as one of the major risk factors of cardiovascular disease [101]. 
Hypertension can be divided into two main categories, namely essential 
hypertension and secondary hypertension. Secondary forms of hypertension are 
related to alterations in hormone secretion and/or renal function. Renal disease 
results in either (i) a derangement in the renal handling of sodium and fluids leading 
to volume expansion or (ii) an alteration in renal secretion of vasoactive hormones
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resulting in a systemic or local change in arteriolar tone [102]. The underlying 
mechanisms responsible for essential hypertension are not yet clearly understood 
although changes in the normal functioning of the second messenger systems and 
ion transport processes which mediate vascular reactivity, cell growth and 
contraction may be important. Such changes could bring about i) enhanced 
sensitivity to vasoactive agents, ii) increased contractility (as a result of enhanced 
neurogenic influences), iii) hypertrophy/hyperplasia. Vascular hypertrophy results in 
an increase in resistance vessel wall:lumen ratio. In resistance arteries and 
arterioles the process of hypertrophy comprises of increases in the size of muscle 
cells and in the cellular content of contractile protein, DNA (polyploidy) and collagen 
[103, 104], Collagen contributes to resistance by stiffening the vessel. Vascular 
hypertrophy is sometimes accompanied by cell proliferation (hyperplasia). Vascular 
hypertrophy/hyperplasia may be involved in a positive feedback effect which is 
responsible for the slow progressive development of high blood pressure observed 
in both essential and secondary hypertension [95].
It is difficult to obtain vascular smooth muscle tissue samples from living 
human subjects for in vitro investigation, therefore many studies have used 
vascular smooth muscle cells from rats and other laboratory animals. For 
investigations in humans a more easily accessible source of cellular material are 
blood cells e.g. platelets, red blood cells, lymphocytes, leucocytes etc. Platelets 
have often been used as a model for vascular smooth muscle cells since both cell 
types contain contractile mechanisms and are regulated by the same vasoactive
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hormones acting through similar intracellular pathways. Platelets are important in 
their own right because of their role in the development of atherosclerosis.
1.12.3 PLATELETS
Platelets are discoid cytoplasmic particles without a nucleus, approximately 2 
to 4nm in diameter. They originate as portions of the cytoplasm of megakaryocytes 
(50pm in diameter) which are synthesized in bone marrow [105], The anatomy of a 
resting platelet is illustrated in Figure 1.6. Note that upon activation the platelet 
secretes a number of substances from a variety of granules, (cc-granules, dense 
granules, lysosomes and peroxisomes). Platelets also contain a number of tubular 
systems, one of which consists of a band of microtubules encircling the cell, in the 
plane of the largest diameter, beneath the plasma membrane. A second tubular 
system is the surface connected canalicula system (SCCS), an invagination of the 
plasma membrane that plays an important role in secretion. Associated with the 
SCCS is yet another membrane system, the dense tubular system (smooth 
endoplasmic reticulum) that has the capacity to sequester Ca2+ and to release it 
upon platelet activation.
The process of activation, which can be measured by aggregometry, occurs 
in two phases. The first phase (reversible aggregation) includes platelet shape 
change and adhesion (the latter is due to the appearance of adhesive proteins on 
the cell surface) [106]. The second phase (irreversible aggregation) involves the 
production and release of secretory substances such as prostaglandins, 
thromboxane A2, and ATP, which promote aggregation. During the second phase of
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Figure 1.6 The anatomy of a resting platelet.
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activation, the randomly distributed granules are moved towards the centre of the 
platelet (in single cells), or to the site of cell-cell attachment (in cell aggregates) by 
actin-myosin contraction (a process similar to that involved in the contraction of 
smooth muscle cells) [107]. The granule membranes fuse with the membranes of 
the SCCS and the secretory substances are extruded as a result of the continued 
compression of the granules by the contracting actin-myosin complex.
Basically, agonist-induced platelet activation is controlled by the opposing 
influences of the inositol lipid pathway and the cAMP and/or cGMP pathways (see 
Figure 1.7 which illustrates some of the main signal transduction pathways involved 
in platelet activation). Platelet agonists such as thrombin, fibrinogen, Von 
Willebrand factor, arachidonic acid, angiotensin II and vasopressin stimulate the 
hydrolysis of PIP2 to produce IP3 and DG, which raise intracellular [Ca2+]i. 
Consequent activation of protein kinase C, induces shape change and granule 
secretion through contraction of the actin-myosin complex. cAMP and cGMP 
antagonise pro-aggregatory responses. Anti-aggregating agents such as 
prostacyclin (prostaglandin) PGI2, PGEi, or PGD2 increase platelet cAMP content 
[108]. At high levels, cAMP decreases the density of receptors to various 
aggregating agents and delays the onset and reduces the rate of thrombin-induced 
increases in [Ca2+]j. cAMP also mediates inhibition of phospholipase C, influences 
inositol phospholipid metabolism and antagonises protein kinase C activation [109]. 
Nitric oxide (NO, released from endothelial cells and also produced by platelets 
themselves) inhibits thrombin-induced platelet aggregation by inhibiting platelet 
phospholipase C via elevation of cGMP levels [110,111,112].
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1.12.4 PHYSIOLOGICAL ROLE OF PLATELETS
Platelets are essential in preventing and staunching haemorrhage. They seal 
off small breaks in blood vessels, they participate in blood coagulation, and they 
maintain the competence of the endothelium. Endothelial injury, from whatever 
cause, results in platelets adhering to the area of damaged endothelium, having 
been attracted by the exposure of subendothelial collagen fibrils. Platelet shape 
change and release of secretory substances, which promote aggregation, result in 
the formation of a hemostatic platelet plug. Plasma factors released from the 
damaged vessel promote blood coagulation. The sequential interactions of up to 
thirteen plasma proteins ultimately lead to the conversion of the plasma protein 
fibrinogen to fibrin through the action of the enzyme thrombin. Fibrin forms an 
interlacing network of slender fibres, running among aggregated platelets and 
trapping erythrocytes and other blood cells. The result is a jelly-like clot that together 
with the platelet plug serves to block bleeding.
In addition to promoting platelet aggregation, certain secretory substances 
released by activated platelets are potent vasoconstrictors e.g. thromboxin A2, and 
stimulators of vascular smooth muscle cell proliferation e.g. platelet derived growth 
factor (PDGF) [113].
1.12.5 PATHOPHYSIOLOGICAL ROLE: PLATELETS AND ATHEROSCLEROSIS 
The relationship between platelets and the pathogenesis of atherosclerosis
and coronary artery disease (CAD) has been recognised ever since the 
'thrombogenic theory' was proposed in 1844 [114]. Atherosclerosis is the irregular
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thickening of the inner wall of the artery which reduces the size of the arterial lumen. 
The thickening is caused by the accumulation of plaque, consisting of smooth 
muscle cells, connective tissue, mucopolysaccharides, fat-filled foam cells (in which 
the predominant lipid is cholesteryl ester) and deposits of calcium. The artery wall is 
thickened locally and loses elasticity.
Platelets contribute to the development of atherosclerosis in two ways: i) by 
releasing chemical mediators which damage the vessel wall or alter its metabolism 
(e.g. PDGF, thromboxane A2, beta thromboglobulin, serotonin etc.) and ii) by 
repeated microthrombus and microembolus formation which augment occlusion of 
already damaged arteries [115, 116]. Fragmentation of platelet and fibrin 
aggregates at the site of endothelial cell damage produces microemboli which 
circulate until becoming lodged in microvascular beds. This obstruction of blood 
flow causes tissue damage in oxygen-sensitive tissues such as myocardium or 
cerebrum [116].
Initiation of smooth muscle cell proliferation in the arterial wall, one of the 
earliest stages of atherosclerosis, is platelet dependent. Such proliferation occurs in 
response to platelet derived growth factor (PDGF) released from alpha granules of 
activated platelets [117]. Vascular smooth muscle proliferation, which is further 
enhanced by elevated low density lipoprotein-cholesterol levels, leads to secretion 
of collagen and proteolglycans in the vessel wall; the latter binds cholesterol. The 
proliferating smooth muscle cells invade the endothelial intima and thus an 
atherosclerotic plaque is established.
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1.13 A GENERALIZED MEMBRANE DEFECT MAY LINK ABNORMAL CATION 
TRANSPORT AND HYPERTENSION
The diversity of abnormal membrane cation transport that has been 
observed in essential hypertension has led to the hypothesis that generalized 
dysfunction is caused by a fault in the matrix in which all the protein transport 
systems function, i.e. the lipid bilayer of the plasma membrane [9,118].
Membranes participate in many essential cellular activities including barrier 
functions and transmembrane signalling. They form a locus for metabolic reactions, 
energy transduction, cell compartmentalization and intracellular recognition.
Plasma membranes comprise a double layer (bilayer) of lipid molecules, the 
commonest lipids of which are the phospholipids. They are amphipathic, with a 
hydrophilic head group made up of a phosphate linked to a residue of either 
choline, ethanolamine, serine or inositol and a tail consisting of two hydrophobic 
fatty acid chains (see figure 1.8) [119]. Phospholipids form the membrane bilayer by 
arranging their hydrophilic polar heads outwards, in contact with the surrounding 
aqueous phase, and their hydrophobic fatty acid chains inwards, to form a 
protected inner membrane area isolated from the aqueous environment (see figure 
1.9) [119, 120]. Two other kinds of lipids are found in the membranes of animal 
cells, namely glycolipids and cholesterol. Glycolipids represent a small fraction of 
the total membrane and are confined to the outer monolayer. Their hydrophobic 
end is composed of a variety of simple sugars joined to form a branching structure 
called an oligosaccharide. Cholesterol is a major membrane lipid. It is a large, disk­
shaped molecule with four carbon rings that are fused together, giving the molecule
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a rigid structure. Cholesterol is an amphipathic molecule and its hydrophobic region 
embeds itself in the hydrophobic part of the lipid bilayer [119]. The amount of 
cholesterol in the membrane influences membrane fluidity (see below).
While lipids form the structural barrier of the membrane, functional 
properties of the membrane are attributed to proteins. These proteins include 
enzymes, receptors, pumps and channels within the membrane matrix and are 
attached to the lipid bilayer in a variety of ways. They may be integral (traversing the 
bilayer or extending across a monolayer from the hydrophobic core of the 
membrane), peripheral (usually associated with the inner face of the membrane) or 
glycophosholipid-linked (always associated with the outer face of the membrane) 
(see figure 1.9). Some proteins are tightly bound to phospholipids, whereas others 
are mobile within the membrane matrix. Proteins which penetrate right through the 
bilayer provide the structural basis for ionic and molecular movements across the 
plasma membrane [121],
1.14 MEMBRANE FLUIDITY
The lipid bilayer is not a rigid structure. The lipid molecules within the bilayer 
can diffuse freely within their own monolayer hence each monolayer is a two 
dimensional liquid. Membrane fluidity is altered by temperature or by membrane 
composition (i.e. cholesterol, phospholipids and their fatty acid chains) [122]. When 
exposed to an increase in temperature, phospholipids change from a crystalline-gel 
to a liquid-crystal state. The temperature at which this change occurs is referred to
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Figure 1.9 Cross section of the lipid bilayer, illustrating arrangement of amphipathic 
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as the transition temperature. The change in structure occurs chiefly in the fatty- 
acid chains, which become more mobile in the liquid-crystal state. The transition 
temperature is influenced by the degree of unsaturation and length of the fatty-acid 
chain (i.e. fluidity is increased by the presence of unsaturated bonds in the fatty- 
acid chains). Transition temperature is also influenced by both water and 
cholesterol. Strong binding of water molecules to the polar groups of the lipids 
stabilizes the membrane structure. Cholesterol also increases stability by fitting 
between the fatty-acid chains and preventing the formation of either a true liquid- 
crystal or crystalline-gel formation. Cholesterol reduces the area occupied by each 
phospholipid molecule inducing tighter phospholipid packing and decreased 
membrane fluidity (ie. greater membrane microviscosity).
There is extensive evidence that the functions of membrane proteins are 
influenced by properties of the lipid bilayer. For example the coupling of the fl- 
adrenergic receptor to adenylate cyclase is enhanced by decreasing membrane 
microviscosity [123]. In addition Na+/K+ ATPase activity is accelerated when the 
membrane microviscosity is low [124]. Membrane microviscosity is influenced in 
vitro by cholesterol enrichment. It has been demonstrated that overnight incubation 
of vascular smooth muscle cells with cholesterol-rich liposomes significantly 
increases microviscosity and raises Ca2+ influx into these cells [125]. Furthermore, 
erythrocyte plasma membrane lipid content in normal men has been shown to be 
associated with an increased activity of the erythrocyte Na+/Li+ countertransport, 
Na7K+ cotransport, and Na+/K+ ATPase pump activity in vivo [126].
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Studies in erythrocytes and platelets from patients with essential 
hypertension and in erythrocytes, platelets and vascular smooth muscle cells from 
spontaneously hypertensive rats have shown increased membrane microviscosity 
as compared with normotensive controls [118, 127, 128, 129, 130]. It is possible 
that altered membrane microviscosity may be the cause of abnormal cation 
transport in hypertension. A defect in membrane handling of circulating lipids could 
be the cause of these changes.
1.15 ORIGINS OF PLASMA MEMBRANE CHOLESTEROL: PHYSIOLOGICAL 
FUNCTION OF LIPOPROTEINS
There are two sources of plasma membrane cholesterol, i) endogenous 
production by cells involving acetyl coenzyme A (acetyl CoA) (see Figure 1.10) 
[131] and ii) from the blood stream (which transports both endogenous cholesterol 
and cholesterol obtained from dietary sources after absorption via the jejunum and 
ileum). Plasma cholesterol concentrations remain fairly constant because of 
feedback regulation, whereby the rate limiting enzymatic step in cholesterol 
biosynthesis, involving 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) 
reductase, is inhibited by cholesterol itself [132].
Since cholesterol is a weakly amphipathic molecule, to enable it and other 
water-immiscible lipids such as triglycerides to be transferred within the aqueous 
environment of the blood they are coated with a variety of amphiphilic compounds 
namely phospholipids and proteins. The resulting particles are the lipoproteins 
(Figure 1.11) [133].
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There are several types of lipoproteins with different chemical composition, 
physical profiles and metabolic function but their common role is by transporting 
lipids from one tissue to another, to supply the lipid needs of different cells (for 
review see [134]). Lipoproteins differ according to the ratio of lipid to protein within 
the particle as well as having different proportions of lipids, including triacylglycerols, 
esterified and non-esterified cholesterol and phospholipids. These compositional 
differences influence the density of the particles. As density increases, particle size 
decreases and so does the ratio of lipid to protein and the ratio of triacylglycerols to 
phospholipids and cholesterols. It is usual to classify plasma lipoproteins according 
to density. From the lowest to the highest density the classes are: chylomicrons, 
very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high 
density lipoproteins (HDL).
Chylomicrons are triglyceride-rich particles synthesized in the intestine that 
transport lipids of dietary origin.
VLDL are rich in triacylglycerides but transport lipids of mainly endogenous 
origin synthesized in the liver or small intestine. VLDL are spherical particles with a 
core consisting of triacylglycerol and cholesterol esters, with cholesterol, 
phospholipids and protein mainly on the surface.
LDL are cholesterol-rich particles which are derived largely from VLDL 
particles circulating in the plasma. A series of degradative steps involving the 
enzyme lipoprotein lipase progressively removes triacylglycerols from VLDL to 
produce intermediate density lipoproteins (IDL) and eventually triglyceride-poor 
LDL. LDL play a vital role in the transport of cholesterol to the peripheral tissues. In
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addition to being an essential component of all cell membranes cholesterol is also 
used by the adrenal glands and the gonads to manufacture steroid hormones such 
as testosterone and cortisol. Cells take up cholesterol from the blood using LDL 
receptors, which bind to the protein moiety of the LDL particle.
HDL are small, dense spherical particles consisting of 50% lipid and 50% 
protein. They are usually divided into two subclasses, namely HDL2 and HDL3, 
because, rate zonal centrifugation of blood gives rise to a bimodal distribution in the 
HDL fraction. A major function of HDL is to remove unesterified cholesterol from 
peripheral cells (where it may have accumulated in subcellular compartments such 
as endoplasmic reticulum and plasma membranes) [135] and transport it to the liver 
where it can be degraded and utilized (e.g. synthesized into bile acids). This 
process is generally termed reverse cholesterol transport (Figure 1.12) [136, 137, 
138]. Translocation and efflux of intracellular cholesterol by HDL takes place by 
means of HDL-receptor-mediated formation of DAG and protein kinase C 
activation. Thus HDL displays 'hormonal' actions by triggering receptor-mediated 
intracellular events [135,139].
1.16 APOLIPOPROTEINS
The protein moieties of lipoproteins, known as apolipoproteins, are 
responsible not only for solublization of the lipid component but for determining 
specificity, allowing particles to be recognised by specific receptors on cell surfaces. 
The apolipoproteins are divided into different classes and sub-classes, identified by
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the letters A-E. An active interchange between the protein and lipid components of 
the lipoprotein takes place in the blood as part of the metabolism of these particles 
[140].
Some apoproteins e.g. Apo E, show polymorphism (i.e. their structure shows 
well-defined variations that are genetically determined) [141]. Apo E is located on 
the surface of triglyceride-rich lipoproteins, and interact with the LDL-receptors and 
Apo B receptor (remnant receptor) on the surface of hepatic and peripheral cells. 
There are three main isoforms of Apo E, designated Apo E2, Apo E3 and Apo E4 
which are structurally different as a result of single amino acid substitutions (e.g. 
cystein for arginine) [142]. These isoforms are coded by three common alleles E2 
(the least frequent), E3 (most frequent) and E4. These alleles in turn determine six 
phenotypes. Homozygous individuals who express only one isoform display 
phenotype E2/E2, E3/E3 or E4/E4. Others express two isoforms (i.e. they have 
different alleles) and display phenotype E4/E3, E3/E2 or E4/E2. The structural 
differences in amino acid sequence between Apo E isoforms affect the ability of 
Apo E to bind normally to lipoprotein receptors, resulting in either reduced 
conversion of VLDL to LDL (Apo E2) or enhanced VLDL conversion to LDL (Apo 
E4). Thus Apo E polymorphism has an impact on plasma lipid levels in the 
population [141].
Hyperlipidemia, occurring as a result of abnormalities in the production and 
circulation of various lipids and lipoproteins, contributes to the development of 
atherosclerosis and is one of the major risk factors of cardiovascular disease [101, 
143]. Raised circulating levels of LDL (especially oxidised LDL) are responsible for
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enhanced uptake and accumulation of cholesterol ester in the vessel wall which 
leads to the production of fatty streaks [144]. Fatty streaks are the early precursor 
lesions which lead to atherosclerotic plaques [143]. Since lipid apolipoproteins 
confer specificity for lipoprotein receptors and other lipid metabolizing enzymes it is 
not suprising that defects in the synthesis of some apolipoproteins e.g. Apo A1, Apo 
B, are implicated in the pathogenesis of cardiovascular disease. For example Apo 
A1 is the major apolipoprotein of HDL and serves as a cofactor in the LCAT 
reaction [145], which esterifies free cholesterol during the formation of HDL2 from 
HDL3. Genetic defects in the synthesis of Apo A1 result in very low HDL levels and 
premature atherosclerosis [137, 138, 145]. Overproduction of Apo B, the major 
apolipoprotein of LDL, raises plasma LDL levels and is responsible for familial 
combined hyperlipidaemia [146, 147, 148]. Due to its impact on plasma lipid levels, 
Apo E polymorphism has also been implicated in the pathogenesis of 
cardiovascular disease. For example, Apo E4, which is associated with elevated 
circulating levels of LDL and cholesterol has been linked with coronary artery 
disease (CAD) and myocardial infarction (Ml). In addition, Apo E2, which is 
associated with elevated plasma levels of triglyceride-rich lipoproteins (i.e. VLDL), 
plays a permissive role in the development of type 3 hyperlipoproteinemia, a 
condition associated with the development of xanthomas and premature 
atherosclerosis [149].
Evidence indicates that lipoproteins are involved in the process of 
cardiovascular disease not only through alterations in their transport and/or 
metabolism and through their influence on plasma membrane composition but also
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because of their ability to exert direct 'hormonal' actions on circulating blood cells 
and vascular cells [87].
1.17 AIMS OF THE STUDY
Changes in the normal second messenger function of Na+/H+ exchange and 
[Ca2+]j may be responsible for the enhanced platelet aggregation and increased 
vascular tone and hypertrophy observed in hypertension and dyslipidemia. 
Accordingly, several different studies, using human platelets and rat vascular 
smooth muscle cells, were undertaken to identify possible cation transport 
abnormalities and their underlying causes.
Methods were developed for the measurement of platelet Na+/H+ exchanger 
activity and platelet Ca2+ metabolism. These methods were subsequently used for:
i) identifying the relationships between cation transport and plasma lipids (both in 
vivo and in vitro)] ii) evaluating platelet Na+/H+ exchange in essential hypertension, 
type 2 diabetes mellitus, normal pregnancy and pregnancy-induced hypertension.
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CHAPTER 2
METHODS: MEASUREMENT OF PLATELET Ca2+ METABOLISM AND Na+/H+ 
EXCHANGE KINETICS
2.1 INTRODUCTION
Intracellular [Ca2+], [Na+] and pH function as second messengers which 
mediate agonist-induced physiological responses. Elevation of [Ca2+]i is a crucial 
initial step for diverse cellular functions. For example, in platelets, an increase in 
Ca2+ produces tubule disruption, contraction of actin-myosin complexes (shape 
changes), fusion of dense granules and plasma membranes (secretion process), 
thromboxane synthesis and release of platelet activating factor (aggregation) [150]. 
Extracellular Na+ influx and cytosolic alkalinization are regulated by the activity of 
the plasma membrane Na+/H+ exchanger. The exchanger has been implicated in a 
variety of physiological roles including regulation of the action of certain hormones, 
growth factors and tumour promoters and the regulation of cell volume [50, 51]. The 
measurement of cell Ca2+ metabolism and Na+/H+ exchanger activity are useful in 
the study of cell function and can indicate the state of cell activation. This chapter 
concerns the development of methodology for measuring platelet Na+/H+ 
exchanger kinetics and Ca2+ metabolism.
2.1.1 Na+/H+ EXCHANGE
The thermodynamic driving force for the plasma membrane Na+/H+ 
exchanger is the electrochemical Na+ gradient generated by the Na+/K+ ATPase
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pump [50, 57], Cytosolic H+ allosterically activates the exchanger by interacting with 
an internal modifier site independent of the Na+/H+ exchanger site [151]. Regulation 
of Na+/H+ exchange activity through receptor driven mechanisms occurs by protein 
phosphorylation which alters the affinity of the regulatory site for H+ and shifts the 
pH sensitivity of the exchanger [57]. An important consequence of the operation of 
a modifier site is the relationship between pHj and the rate of Na+/H+ exchange, 
whereby the exchanger becomes inactivated above pHj 7.3 [152]. Because this 
activity threshold or 'set point' coincides with normal intracellular pH, the Na+/H+ 
exchanger is virtually quiescent under normal physiological conditions.
In order to stimulate exchange for investigation purposes, the cytoplasmic 
pH is lowered either by the use of salts of weak organic acids such as propionate 
[153] or by the use of the electroneutral K+/H+ exchange ionophore, nigericin [154, 
155, 156]. Once activated the operation of the Na+/H+ exchanger can then be 
detected either as an amiloride-sensitive increase in Na+ influx (eg 22Na) [54, 157], 
as a Na+ induced cytoplasmic alkalinization (eg measurement of proton efflux rate 
using the pH sensitive fluorescent probe BCECF) [158, 159], as an acidification of 
external medium (eg pH electrode) [160] or by electronic cell sizing [153, 161] ie. 
during exchanger activation in acid-loaded cells, the intracellular accumulation of 
sodium propionate results in the uptake of osmotically obliged water leading to cell 
swelling which is detectable using a Coulter Counter and Channelyser combination.
The diuretic drug amiloride is an inhibitor of extracellular Na+ transport [162, 
163, 164, 165] and is very useful as an experimental probe of the Na+/H+ 
exchanger. Its competitive nature, however, can be a drawback in that at
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physiological Na+ concentrations its effectiveness is somewhat reduced unless 
used at relatively high concentrations (>0.1-1 mmol/l). At high concentrations, 
amiloride may have additional effects such as inhibiting Na+/K+ ATPase activity, 
acting as a weak base (thereby altering transmembrane pH gradients) and 
inhibiting protein synthesis [50]. To overcome these problems Na+/H+ exchanger 
studies are usually carried out in media containing relatively low Na+ concentrations 
(eg 10-15 mmol/l Na+). Chemical manipulation of the amiloride structure has led to 
synthesis of analogues which are able to block specifically and with high affinity one 
or another of the Na+ transport mechanisms. Phenamil and benzamil (which are 
produced from hydrophobic substitutions of the guanidino moiety of amiloride), are 
highly specific inhibitors of the epithelial Na+ channel, whereas dichlorobenzamil 
(also substituted on the guanidino moiety) is one of the more potent inhibitors of the 
Na+/Ca+ exchanger [53, 165, 166]. Substitution of the 5-amino group of amiloride 
with alkyl or alkenyl groups, eg. 5'-(N-methyl-N-isobutyl)amiloride (MIA), (see Figure 
2.1) increases potency as an inhibitor of Na+/H+ exchange more than 100 times 
[167]. Radiolabelled (tritiated) forms of these analogues are potentially very useful 
for characterising and measuring the tissue distribution of the exchanger.
2.1.2 Ca2+METABOLISM
The measurement of cytosolic Ca2+ concentration was made possible by the 
synthesis of Ca2+-sensitive fluorescent probes. Quin-2 was the first probe to be 
synthesised by Tsien in 1980 [168]. It is loaded into cells in the form of the 
acetoxymethylester (quin-2 AM) which because it is lipophilic, diffuses readily
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isobutyl)amiloride, MIA.
across the plasma membrane. In the cytosol, the ester is hydrolysed to the 
hydrophilic Ca2+-responsive quin-2 form. Since 1980 a number of different probes 
have been synthesised, including fura-2 [169], indo-1 [169] and fluo-3 [170, 171], 
which are considered to have improved fluorescent properties. Aequorin, a Ca2+- 
sensitive photoprotein, harvested from photocytes of jellyfish, has also been used 
for [Ca+]j measurement [172]. Aequorin is loaded into cells by permeabilization of 
the plasma membrane with EGTA and ATP after which the membrane is repaired 
using Mg2+. None of the various types of fluorescent probes or photoprotein are 
ideal for every experimental situation. Each has its drawbacks and should be 
carefully chosen depending on experimental conditions and cell type.
The measurement of plasma membrane Ca2+ flux is less well documented 
than that of intracellular Ca2+ concentration measurement. However Ca2+ influx is 
important because intracellular Ca2+ may, in part, be increased by Ca2+ influx 
across the plasma membrane. Previous investigations have used radioactive 45Ca, 
to trace Ca2+ transport [173, 174, 175], The role of membrane Ca2+ channels in the 
Ca2+ influx process can be determined using Ca2+ channel blockers (eg. verapamil, 
diltiazem, nifedipine etc.) [175, 176]. Other pharmacological agents which act on 
intracellular Ca2+ stores to either inhibit Ca2+ uptake (eg thapsigargin, inhibitor of 
Ca2+ ATPase pump) or block agonist-induced Ca2+ mobilization (eg. 3,4,5- 
trimethyloxybenzoic acid 8-(diethylamino) octyl ester (TMB-8)) have also proved 
useful in the investigation of cellular Ca2+ metabolism [177,178,179].
This chapter describes the development of methods to investigate the kinetic 
properties of the Na+/H+ exchanger in acid loaded human platelets. Three aspects
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of platelet Ca2+ metabolism have also been investigated, including measurement of 
basal and agonist-stimulated [Ca2+]i, using quin-2, basal and agonist-stimulated 
Ca2+ influx and efflux using 45Ca.
During Ca2+ metabolism investigations arginine vasopressin (AVP) was used 
as the agonist for platelet activation. AVP binds to the V-1 vasopressin receptor on 
platelets and stimulates PIP2 hydrolysis via a Gs protein [180], AVP-induced 
increases in platelet Ca2+ concentrations are due to both a stimulation of the 
release of stored calcium via the IP3 pathway and also an increase in uptake from 
extracellular medium [181]. AVP was the prefered agonist for this investigation of 
platelet Ca2+ mobilization because with most other platelet agonists Ca2+ influx 
appears to have little effect on the increase in [Ca2+]j. This may be due to immediate 
refilling of depleted calcium stores or to "calcium cycling" whereby efflux is 
increased simultaneously with influx [17, 182]. When efflux is not concurrent with 
influx, [Ca2+]i is increased.
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2.2 MATERIALS AND METHODS
2.2.1 REAGENTS AND EQUIPMENT
All chemicals, unless otherwise stated, were purchased from Sigma.
Amiloride, (supplied by Hoechst UK Ltd, Middlesex).
[Arg8] Arginine vasopressin acetate salt (AVP).
Bovine serum albumin (fraction V).
45Ca, (specific activity 5-50mCi/mg Ca), (Amersham).
Digitonin.
Ecoscint liquid scintillator.
Manganese chloride.
22Na, (specific activity 100-1000mCi/mg Na), (Amersham).
NE-260 liquid scintillator (NE Technology Ltd).
5(N-methyl-N-isobutyl)amiloride (MIA), (synthesised by E.J.Cragoe Jr. 
Pennsylvania, USA).
Ouabain.
Polyethylenimine (PEI).
Quin-2 acetoxymethylester (Quin-2 AM).
Tritiated MIA, (specific activity 28.2 Ci/mmol), (Amersham).
Propionate buffers consisted of (in mmol/l) 140 Na+/K+ propionate, 1 CaCI2, 1 
MgCI2, 1 KCI, 20 HEPES, 10 glucose, pH 6.7 (adjusted with 1M KOH).
Lysing (TRIS) buffer consisted of (in mmol/l) 10 TRIS, 1 EDTA, pH 7.5
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Choline chloride wash solution consisted of (in mmol/l) 50 TRIS/HCI buffer, 115 
choline chloride, 17.1 NaCI (0.1%).
Platelet buffer (containing in mmol/l: 140 NaCI, 1 KCI, 1 MgCI2) 0.1 CaCI2, 10 
glucose and 20 HEPES, pH 7.3).
Calcium poor platelet buffer (containing in mmol/l: 140 NaCI, 1 KCI, 1 MgCI2, 10 
glucose and 20 HEPES, pH 7.3).
I EC Centra-8R Centrifuge.
JJ Instuments CR 452 Chart recorder.
LKB Wallac, 1217 Rackbeta liquid scintillation counter.
Packard 300C liquid scintillation counter.
Perkin Elmer LS-3B fluorescence spectrometer.
Technicon H-1 coulter counter.
Titertek Cell Harvester (Flow Laboratories) & Vacuum pump.
12 well manifold apparatus (Millipore).
Whatman cellulose nitrate filter circles (pore size 1 ^ trn) (Millipore).
Whatman GFB filter paper (Millipore).
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2.2.2 Na+/H+ EXCHANGER KINETICS
i) PLATELET PREPARATION
Platelets were prepared from 40ml fresh, citrated (1ml of 3.9% Na+ 
citrate/9ml blood) whole blood. Platelet rich plasma was obtained by centrifugation 
of the whole blood at 600g for 6 minutes at room temperature. The platelets were 
then pelleted by a second centrifugation at 600g for 10 min at room temperature. 
The platelets were washed and resuspended (600g, 10min, room temp) in isotonic 
K+ propionate buffer for the removal of extracellular Na+ and for intracellular 
acidification.
ii) PLATELET MEMBRANE PREPARATION
Platelet rich plasma was prepared as described above. The plasma was 
then centrifuged at 30,000g for 15 min. at 4°C. The supernantant was discarded 
and the platelet pellet homogenised in 3ml lysing buffer and then centrifuged again 
at 30,000g for 15 min at 4°C. The membrane pellet was washed once with TRIS 
buffer and centrifuged at 30,000g, 15 min, at 4°C. The pellet was finally 
resuspended in approximately 2ml TRIS buffer and aliquoted into suitable fractions. 
Aliquots were stored at -70°C.
iii) ACID-LOADING
Activation of Na+/H+ exchange was achieved by acid-loading using the salt 
of a weak organic acid, K+ propionate as illustrated in Figure 2.2. The free anion of 
K+ propionate is in equilibrium with the protonated acid which is lipid soluble and
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Na'
Na'
CH3CH2COO' + H 
(Propionate)
► CH3CH2COOHCH3CH2COOH 
(Propionic acid)
Figure 2.2 Diagramatic representation of the process involved in activation of 
platelet Na+/H+ exchange by acid loading. (1) Protonation of extracellular 
propionate. (2) Propionic acid crosses the cell membrane. (3) Dissociation of the 
acid results in an accumulation of non permeable propionate and a lowering of 
intracellular pH. (4) Activation of the Na+/H+ exchanger in the presence of 
extracellular Na+.
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can therefore cross the platelet plasma membrane. Intracellular dissociation of the 
acid produces an accumulation of non permeable propionate and H+. Following 
intracellular acidification, the exchanger can be activated by adding Na+ propionate 
buffer.
iv) 22Na UPTAKE EXPERIMENTS
The activity of the exchanger was determined by measuring amiloride- 
sensitive 22Na uptake into acid-loaded platelets in the presence of 0.5mmol/l 
ouabain. Ouabain was necessary to prevent Na+ efflux by the Na+/K+ ATPase 
pump. Na+/H+ exchange was initiated by the addition of sodium propionate buffer 
containing 0.016MBq 22Na. The platelets were incubated for one min (unless 
otherwise stated) at 37°C with and without 0.1 mmol/l amiloride. In initial 
experiments, the reaction was stopped after the required incubation period, by 
separating the platelets from medium by washing and filtering through Whatman 
cellulose nitrate filters (pore size 1pm) using a Millipore 12 well manifold and 
vacuum pump. The platelets were washed a total of 5 times with 3ml aliquots of 
choline chloride wash solution. In later experiments, the efficiency of sampling was 
markedly improved by using a Flow Laboratories cell harvester with Whatman glass 
fibre filters. Intraplatelet 22Na retained on the filter papers was counted, in plastic 
vials containing 5ml Ecoscint, using a Packard ft liquid scintillation counter.
To fully characterise membrane transport processes both the Vmax and the 
Km for Na+ of the transporter were estimated. Vmax is the maximum rate of Na+ 
uptake that the exchanger can support and Km is the external Na+ concentration at
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which the rate of uptake is half maximal. Several studies of the Na+/H+ exchanger 
[161, 183, 184] have described exchanger kinetics solely in terms of an apparent 
'maximal' rate of Na+ influx or H+ efflux, measured at one extracellular Na+ 
concentration. The apparent 'maximal' rate only approaches the true Vmax when 
molar concentrations of extracellular Na+ are saturating. For example, it has been 
demonstrated [185] that the apparent 'maximal' rate of the Na+/Li+ cotransporter is 
greatly influenced by the Km for external sodium. In the absence of a measurement 
of Km, it is impossible to tell whether observed rate changes at a fixed 
concentration of Na+ are due to changes in the true Vmax or the Km of the 
exchanger. For full kinetic characterisation of the exchanger, Na+ influx or H+ efflux 
should be measured at a range of external Na+ concentrations.
The rate of Na+ uptake (in both the presence and absence of amiloride) was 
calculated as follows:
Rate Na+ uptake = filter counts x specific activity of incubation medium (cpm /pm oi Na+) 
platelet number
The relationship between the influx of Na+ and its external concentration is 
hyperbolic and is described by Michaelis Menton kinetics: 
v = Vmax x [si 
Km + [s]
where, in the case of the Na+/H+ exchanger, v = the rate of Na+ uptake, and [s] = 
the external Na+ concentration.
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Km (in mmol/l) and Vmax (in pmol/106cells/min) were calculated for amiloride 
sensitive Na+ uptake in acid loaded-platelets using the direct linear plot method 
[186, 187]. The direct linear plot provides a simple graphical procedure for 
estimating Vmax and Km. It identifies aberrant observations and provides unbiased 
estimates of the kinetic constants.
The inhibition constant (Ki) for amiloride inhibition of Na+ uptake into acid- 
loaded platelets was calculated using the Dixon plot [187a].
Intra-assay variability and day to day intra-subject variation for amiloride- 
sensitive N a + uptake were 6.5% and 9% respectively.
v) 3h -m ia  b in d in g  e x p e r im e n t s
Binding characteristics of 5(N-methyl-N-isobutyl) amiloride (MIA) were 
measured by homologous competition for specific 3H-MIA sites under steady state 
conditions. Approximately 3x10® platelets were incubated with 5 nmol 3H-MIA 
(specific activity; 28.2 Ci/mmol) and a range of concentrations of unlabelled MIA for 
40 min, usually at 37°C. In initial experiments, platelets were trapped and washed 
on cellulose nitrate filters, using a Millipore 12 well manifold. In later experiments 
platelets were harvested on Whatman GFB filters, using a Titertek cell harvester. 
Various efforts were made to reduce non-specific binding to glassware and filters 
during binding experiments including; i) pretreatment of glassware with 0.1% bovine 
serum albumin (BSA), ii) addition of 0.1% BSA to choline chloride wash solution, iii) 
2h pretreatment of filterpapers with 0.3% polyethylenimine (PEI), prior to harvesting 
(platelet membrane experiments only). PEI has been shown to increase retention of
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detergent solubilized membranes to filters and results in very low non-specific 
binding of the ligand to filter papers [188].
Binding constants were calculated using the LIGAND-PC computer 
programme (1987 version) [189,190] which includes a co-operativity option.
2.2.3 PLATELET Ca2+ METABOLISM
i) PLATELET PREPARATION
Platelets were isolated from the blood of normal volunteers as previously 
described or from buffy coats provided by the Blood Transfusion Service, Law 
Hospital. The buffy coat is that fraction of whole blood, which is taken from the 
interface between the red cell layer and the plasma layer after centrifugation and 
which contains concentrated numbers of platelets and white blood cells. The buffy 
coat was prepared from a litre of whole blood. Platelet rich plasma was prepared 
from the buffy coat by centrifuging at 600g for 10 min at room temperature. To 
remove white cells from the platelet-rich plasma, the supernatant containing 
platelets and white blood cells was mixed with calcium-poor platelet buffer (final 
volume 40 ml) and centrifuged at 200 g for 10 min at room temperature. Platelet- 
rich supernatant was carefully removed and either used immediately or stored at 
4°C for up to 2 days. The white cell pellet was discarded.
ii) MEASUREMENT OF PLATELET [Ca2*]:
Platelet-rich plasma from normal volunteers was incubated for 30 min at 
37°C with 10 pmol/l quin-2. EGTA was added to to the platelet-rich plasma (final
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concentration 5 mmol/l) which was then centrifuged at 600 g for 10 min at room 
temperature. The supernant was removed and the platelet pellet resuspended in 
calcium-poor buffer at 37°C. The cells in suspension were counted in a Coulter 
Counter (Technicon H-1™ system) and the concentration adjusted to approximately 
2 x 108 cell/ml and divided into 2 ml aliquots. Immediately before measurement of 
fluorescence, the calcium concentration of the buffer was adjusted to 1 mmol/l by 
adding CaCI2. Fluorescence was measured with a Perkin-Elmer LS-3B 
spectrofluorometer at 339 nm excitation and 492 nm emission wavelengths. [Ca2+]j 
was calculated from the equation:
[Ca2+]j = 115(F - Fmin/Fmax - F) 
where 115 represents the equilibrium dissociation constant of quin-2 for Ca2+ (in 
nmol/l), F the fluorescence of the intact cell suspension, Fmax the maximum 
fluorescence obtained after the cells were solubilized with digitonin (50 nmol/l) and 
Fmin the minimum fluorescence obtained in the presence of 2 mmol/l MnCI2. 
Manganese displaces calcium from the chelator (quin-2) and gives a very low 
fluorescence signal.
The platelet [Ca2+]j response to 1 nmol/l AVP was measured in the presence 
of 1 mmol/l extracellular Ca2+ and also when the extracellular Ca2+ concentration 
was maintained at nanomolar concentrations ( 1 0 - 2 0  nmol/l) by the presence 5 
mmol/l EGTA.
Intra-assay variability was 7% and day to day intra-subject variation was
10%.
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iii) MEASUREMENT OF Ca2* UPTAKE
Fresh or stored platelets, isolated from buffy coats, were resuspended in 
platelet buffer and incubated for 30 min at 37°C. Basal Ca2+ uptake at 37°C, over 
60s was measured after adding aliquots of platelet suspension to buffer containing 
45Ca (0.15 MBq). The reaction was stopped by harvesting the cells onto Whatman 
GFB filters and washing with ice-cold platelet buffer (containing 5 mmol/l CaCI2). 
Cell 45Ca content of trapped platelets was counted using a IS liquid scintillation 
counter. The effect of AVP concentration, (10 -1  nM), on 45Ca uptake was also
investigated.
iv) MEASUREMENT OF PLATELET Ca2+ EFFLUX
Platelets, prepared from the blood of normal volunteers or buffy coats, were 
preincubated with 45Ca, in platelet buffer containing 0.48 MBq 45Ca for 30 min at 
37°C. Platelets were then centrifuged (10 min, 600g), washed and resuspended in 
fresh non-radioactive platelet buffer. At 5 min intervals, aliquots of platelet 
suspension were harvested (using a Titretek Cell Harvester) with ice-cold platelet 
buffer.
2.2.4 ELECTRON MICROSCOPY
Electron microscopy was carried out by Dr I Downey, Electron Microscopy 
Unit, Department of Pathology, Western Infirmary, Glasgow, using routine methods. 
Briefly, platelet samples (suspended in (i) K+ propionate buffer only, and (ii) after 
addition of Na+ propionate buffer) were fixed in 3% (v/v) glutaraldehyde buffered
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with phosphate to pH 7.4. The samples were dehydrated through ethanol mixtures 
and critical-point dried before being coated in carbon and gold. The platelets were 
viewed in a Phillips EM 301 G scanning microscope.
For clarity, platelets will be referred to as cells in this and subsequent chapter 
figures.
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2.3 RESULTS
2.3.1 Na+/H+ EXCHANGE KINETICS
Figure 2.3 shows the time course of 22Na uptake into platelets in the 
presence and absence of 0.5 mmol/l amiloride at extracellular Na+ concentration of 
15 mmol/l. In the absence of amiloride, 22Na uptake remained linear for 60s but 
reached a plateau after approximately 2-3 minutes. Amiloride inhibited 
approximately 85% of uptake. A period of one minute was chosen as a suitable 
incubation period for subsequent measurements of initial rates of 22Na uptake.
Figure 2.4 illustrates a double-reciprocal plot of the results for amiloride- 
sensitive (0.5mmol/l) 22Na uptake over a range of extracellular Na+ concentrations 
( 5 -1 2 0  mmol/l). Km and Vmax values, for Na+ uptake were 25.2±6.0 mmol/l and 
108.9±17.1 pmol/106cells/min respectively.
A Dixon plot of the results for 22Na uptake measured over a range of 
amiloride concentrations (6-100 pmol/l) is illustrated in Figure 2.5. From this plot the 
Ki value, (inhibition constant), for amiloride effects on Na+ uptake was calculated to 
be 16 pmol/l.
Certain amiloride analogues are known to be more potent inhibitors of 
Na+/H+ exchange. Inhibition of 22Na uptake by 5(N-methyl-N-isobutyl)amiloride 
(MIA) is shown in figure 2.6. MIA appeared to be approximately 50 times more 
potent than amiloride (Ki = 0.3 pmol/l).
The above Na+/H+ exchanger kinetics results were made using the Millipore 
12 well manifold apparatus.
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2.3.2 ELECTRON MICROSCOPY
Electron microscopy demonstrates platelet shape changes, as a result of 
washing and resuspension in K+ propionate buffer (Figures 2.7-2.9) and formation 
of platelet clumps (i.e. aggregation) on the addition of Na+ propionate buffer 
(120mmol/l) (Figure 2.10). The EM photographs illustrate, that during the process of 
Na7H+ exchange activation by acid-loading, platelets lose their smooth disc shape 
and develop long, finger-like, pseudopodia on their surface. The pseudopodia from 
separate platelets merge together resulting in the formation of platelet clumps or 
plugs.
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Figure 2.3 Time course of 22Na uptake into acid-loaded platelets in the presence 
and absence of amiloride at extracellular Na+ concentration of 15 mmol/l. Results 
shown are the mean replicates from one representative experiment.
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Figure 2.4 Double-reciprocal (Lineweaver Burk) plot of amiloride-sensitive Na+ 
uptake over a range of extracellular Na+ concentrations. Results are mean ± SE of 
6 separate experiments. Km and Vmax values for amiloride-sensitive Na+ uptake 
were 25.2 ± 6.0 mmol/l and 108.9 ±17.1 pmol/106cells/min respectively.
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Figure 2.5 Dixon plot of 22Na uptake over a range of amiloride concentrations. 
Results shown are mean ± SE of 6 separate experiments. Ki for amiloride inhibition 
of Na+ uptake was 16 nmol/l.
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Figure 2.7 Scanning electron micrograph of acid-loaded platelets illustrating shape 
change. Magnification; x 15 000.
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Figure 2.8 Scanning electron micrograph of acid-loaded platelets illustrating shape
change. Magnification; x 10 000.
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Figure 2.9 Scanning electron micrograph of acid-loaded platelet illustrating shape
change. Magnification; x 14 000.
9 7
Figure 2.10 Scanning electron micrograph of platelet aggregation after addition of
Na+ propionate buffer (final concentration 120mmol/l). Magnification; x 2300.
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2.3.3 3H-MIA BINDING EXPERIMENTS
Initial time course experiments with whole platelets, using the Millipore 
apparatus, showed that 3H-MIA binding reached equilibrium after a 40 minute 
incubation at 37°C (Figure 2.11). The time needed for equilibration to be achieved 
may be explained by the recruitment or activation of non-active Na+/H+ exchanger 
sites to the membrane as a result of the binding process. Figure 2.12 illustrates 
Scatchard analysis and competition curve (insert) of a representative experiment of 
3H-MIA binding to acid loaded human platelets. The Scatchard plot suggests that 
two classes of binding site exist for MIA. The higher affinity binding site having a Kd 
of 0.75 pmol/l and a capacity of 8x103 sites per platelet while the lower affinity site 
has a Kd of 114 pmol/l and a capacity of 2000x103 per platelet. A large degree of 
the total binding in these experiments, however, was due to non-specific binding (ie 
approximately 30% of the total binding was non-specific), which may influence the 
linearity of the Scatchard plot. Furthermore, non-specific binding was also extremely 
variable between samples when using the millipore apparatus.
The use of a cell harvester improved efficiency of handling samples, 
reduced non-specific binding (ie. NSB reduced to 20% of total binding) and 
dramatically improved non-specific binding variability. Figure 2.13 illustrates the 
competition curve for 3H-MIA binding to platelets in a representative experiment. 
The curve shows a consistent peak at the MIA concentration range of 1-100 pmol/l. 
A possible explanation for this phenomenon is that there is more than one amiloride 
binding site and that occupation of one site facilitates binding to the second site (ie. 
cooperativity). When competition curve results were analysed with a model which
99
assumes cooperativity the Scatchard analysis (illustrated in Figure 2.14) indicated a 
Kd, for MIA binding, of 109 pmol/l. The peculiar increase in 3H-MIA binding (despite 
increasing concentrations of unlabelled MIA) was not observed in similar 
experiments using the original platelet separation and washing procedure ie. 
Millipore apparatus (Figure 2.12). The effects of external Na+ on the competition 
curve for 3H-MIA binding (cell harvester method) are illustrated in Figure 2.15. The 
peak of the competition curve is more prominent and is shifted to the right with 
increasing extracellular Na+.
It is possible that the results from the above binding experiments represent 
uptake of radioactivity into platelets rather than 3H-MIA binding. In order to eliminate 
this possibility, platelet membranes, rather than whole platelets were used. Figure 
2.16 illustrates the competition curve produced for 3H-MIA binding to platelet 
membranes. The peculiar competition curve peak displayed by whole platelets 
(Figure 2.13) was not observed in platelet membranes. Scatchard analysis 
suggests a single binding site with a Kd of 206 pmol/l. This value does not agree 
with the Ko.5 value previously obtained for MIA inhibition of Na+ uptake (i.e. 
0.3pmol/l).
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Figure 2.11 Time course of 3H-MIA binding in whole platelets using 12-well Millipore 
apparatus. Results are mean ± SE of triplicate measurements from one 
representative experiment.
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Figure 2.12 Scatchard plot and competition curve (insert) of a representitive 
experiment of 3H-MIA binding to acid-loaded platelets using the Millipore apparatus. 
Mean ± SE of triplicate measurements. Scatchard analysis suggests two classes of 
binding site exist for MIA. The higher affinity site having a Kd Of 0.75 ^mol/l and a 
capacity of 8x103 sites/platelet, whilst the lower affinity site has a Kd of 114 pimol/I 
and a capacity of 2000 sites/platelet.
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Figure 2.13 Competition curve for 3H-MIA binding to platelets using the cell 
harvester method. Results shown are quadruplicate measurements (mean ± SE) 
from one representative experiment.
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Figure 2.14 Scatchard analysis of 3H-MIA binding in whole platelets using the cell- 
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2.3.4 PLATELET Ca2+ METABOLISM
Figure 2.17 is a representative trace obtained during the measurement of 
basal and AVP-stimulated [Ca2+]j, (in the presence and absence of EGTA), using 
quin-2. Fmax and Fmin values are used for the calculation of basal [Ca2+]j. On the 
addition of 1 jamol/l AVP [Ca2+]j steadily rises, reaches a peak and gradually returns 
to resting levels over an approximate 40 sec period. The height of the AVP- 
stimulated peak is reduced in the presence of 5 mmol/l EGTA by approximately 
65%. The mean ± SE for basal and AVP-stimulated [Ca2+]j, (in the absence and 
presence of EGTA), for 25 normal subjects (measured in triplicate) were 88.8 ± 5.6 
nmol/l, 736.9 ± 96.7 nmol/l and 134.7 ± 8.4 nmol/l respectively.
The time course of basal 45Ca uptake is illustrated in Figure 2.18. Uptake 
remained linear over the initial 60s of incubation, at 37°C, and reached a plateau 
after approximately 90s. Platelets for measurement of Ca2+ uptake were obtained 
from buffy coats. The large platelet numbers obtained from buffy coats provided 
enough material for three or more experiments. Platelets were stored for up to two 
days, at 4°C, allowing experiments to be undertaken on three consecutive days 
from one preparation. The rate of basal 45Ca uptake in platelets stored for two days, 
and then incubated for 30 min in platelet buffer containing 0.1 mmol/l CaCI2, was 
not significantly different from that of freshly isolated platelets. The effect of a range 
of AVP concentrations on platelet 45Ca uptake is illustrated in figure 2.19. Maximum 
stimulation of 45Ca uptake was achieved with 1 i^mol/l AVP. Figure 2.20 illustrates 
the effect of 1 fimol/l AVP on the rate of basal 45Ca uptake. AVP stimulated uptake
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approximately 1.4 fold, however like basal uptake, it remained linear over the initial 
60 sec of incubation.
The time course of basal and AVP-stimulated Ca2+ efflux from platelets 
preloaded with 45Ca is shown in Figure 2.21. Efflux remained linear between 5 - 3 0  
min of measurement. AVP did not significantly effect efflux rates.
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Figure 2.17 Representative trace for the measurement of basal and AVP-stimulated 
[Ca2+]i (in the absence and presence of EGTA).
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Figure 2.18 Time course of basal Ca2+ uptake in platelets. Results shown are mean 
± SE of 6 separate experiments. Uptake remains linear over the initial 60 sec of 
incubation at 37°C.
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Figure 2.19 Effect of a range of AVP concentrations on the rate of platelet Ca2+ 
uptake. Results shown are mean ± SE of 4 separate experiments. Maximum 
stimulation of uptake was achieved with 1 nmol/l AVP.
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shown are mean ± SE of 6 separate experiments.
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Figure 2.21 Time course of basal and AVP-stimulated Ca2+ efflux from platelets 
preloaded with 45Ca. Results are mean ± SE of quadruplicate measurements from 
one representative experiment. Efflux remained linear between 5 - 3 0  min after the 
start of incubation.
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2.4 DISCUSSION
2.4.1 Na+/H+ EXCHANGE
The rate of amiloride-sensitive 22Na uptake, in the presence of 0.5mmol/l 
ouabain, has been used to measure Na+/H+ exchanger activity in the plasma 
membrane of human platelets. The rate of Na+ uptake was dependent on both 
extracellular Na+ and amiloride concentration. The Km for Na+ uptake being 
25.2±6.0 mmol/l and the Ki for amiloride inhibition being 16jamol/l. These values are 
comparable to Km and Ki values previously reported for platelets and other cell 
types using either initial rates of Na+ uptake (involving 22Na) or proton efflux rates 
(using BCECF) [67, 159, 162, 164, 191, 192, 193, 194].
The 5-N disubstituted analogue methyl-isobutyl-amiloride, (MIA), was found 
to be approximately 50 times more potent than amiloride. This is in agreement with 
a previous study by L'Allemain et al. using fibroblasts [77]. A radiolabelled form of 
this analogue was used to investigate binding characteristics of the Na+/H+ 
exchanger. Scatchard analysis of the data from experiments using cellulose nitrate 
filters produced a curvilinear plot. The LIGAND computer programme interpreted 
this as evidence of two apparent binding sites. Curvilinear Scatchard plots are, 
however, often artefacts resulting from non-specific binding [195]. Generally the 
greater the non-specific binding, the more pronounced the curvature. Non-specific 
binding in the present investigation, using the 12 well manifold apparatus and 
cellulose nitrate filter paper, accounted for 29% of the total binding. Non-specific 
binding is defined as 'the binding of labelled ligand occurring in the presence of 
excess unlabelled ligand', but in reality this definition is not strictly correct. Non­
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specific binding actually comprises two components; the first represents binding to 
non-biological materials (eg. assay tube, filtration apparatus) which are not 
saturable and can be measured accurately without addition of excess unlabelled 
ligand. The second represents binding to sites within biological material other than 
the target receptor (eg. cells, membranes, protein extracts) which like the target 
receptors are saturable but at much higher concentrations of ligand. When 
measuring non-specific binding, ideally a limited excess, for example 100x Kd, 
which will normally block about 99% of the target receptors, is preferred over a 
larger excess because it is less likely to cause a significant saturation of the non­
specific sites leading to artefactual curvature of the Scatchard plot [195], Bearing in 
mind the problems associated with non-specific binding, subsequent experiments 
were carried out using a cell harvester and glass fibre filters, in an effort to reduce 
and improve the variability of the non-saturable component of non-specific binding. 
These changes resulted in a very different biphasic binding profile. With unlabelled 
MIA in the concentration range of 1 nmol/l to 10 pmol/l there was an initial decrease 
and then an increase in apparent 3H-MIA binding. Displacement was only observed 
at concentrations >1 pmol/l. The Kd (109pmol/l) for this displacement however did 
not correspond to the Ki (0.19pmol/l) for MIA inhibition of Na+ uptake.
There are three different possible causes of the peculiar competition curve 
profile. The first is receptor heterogeneity (eg allosteric activity or cooperativity), the 
second is internalization of MIA, and the third is the saturable component of non­
specific binding (ie binding to receptors other than the Na+/H+ exchanger),
i) allosteric activity.
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Previous studies have shown that Na+/H+ exchange has a greater than 
linear dependence on intracellular H+ concentration. It has been suggested [196] 
that this striking stimulatory effect is due to the transport system possessing one or 
more functional groups on its inner cytoplasmic surface, which are allosterically 
activated by internal H+. It is possible that the competition curve for 3H-MIA binding 
also represents an allosteric effect. Analysis of the data, using the LIGAND 
programme, indicates that the curve can be fitted to a model involving positive 
cooperativity. Positive cooperativity can occur when two or more receptor sites are 
available for ligand binding. The binding of ligand to one of the receptors modifies 
(ie increases in the case of positive cooperativity) the affinity of the second (and 
subsequent) receptor site(s) for further ligand binding.
The peak of the competition curve is shifted to the right with increasing 
extracellular Na+ concentration (Figure 2.6). This shift to the right suggests 
competition between 3H-MIA and extracellular Na+ for the same binding site. It may 
be concluded that MIA is binding to an external site which is possibly the same as 
that which binds amiloride since amiloride is also competitive with extracellular Na+. 
Previous studies with lymphocytes [197] and renal brush border membrane vesicles 
(BBMV) [198] have demonstrated MIA binding to a single site with Kd's of 170 
nmol/l and 9.5 nmol/l respectively. In both studies MIA binding was not competitive 
with extracellular Na+ but was strongly dependent on extracellular pH. In renal 
BBMV MIA binds to a high affinity internal site which is distinct from the external 
amiloride inhibitory site. MIA binding in lymphocytes was assayed using very short 
(ie. 5s) incubations to minimise non-specific binding. In this study the authors claim
116
that equilibration was achieved after 5s. This is suprising since, in my experience 
with platelets, a 40min incubation period was necessary to achieve equilibrium. 
Despite the very short incubation period used in the lymphocyte study, non-specific 
binding still accounted for a large part of the total binding (ie 90%). Differences in 
cell type, exchanger subtype (in the case of renal BBMV) and experimental 
conditions may account for discrepancies observed between my study and other 
investigations.
ii) MIA internalization.
An alternative explanation for the biphasic 3H-MIA competition curve may 
involve non-specific uptake by a non Na+/H+ exchange mechanism. MIA is a lipid 
soluble weak base which may therefore be transported into acid-loaded cells down 
the pH gradient. Internalisation is known to produce experimental artefacts in 
receptor-binding studies which can influence the pattern of the Scatchard plot [195]. 
The use of membranes rather than whole cells may overcome possible intracellular 
accumulation of the amiloride analogue. Preliminary MIA binding experiments using 
platelet membranes displayed much smoother displacement curves than observed 
with intact cells. However, as with the intact platelets, the affinity for MIA was not 
comparable to the Ki value for MIA inhibition of Na+ uptake. The use of platelet 
membranes therefore did not improve the method for measuring the distribution of 
the platelet Na+/H+ exchanger.
iii) Non-specific binding to receptors other than Na+/H+ exchanger.
Results from a previous investigation [166] which studied structure-activity 
relationships of amiloride and two of its analogues, namely benzamil and the 5-
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amino substituted analogue, ^-(N.N-hexamethyleneJamiloride (HMA) indicate that 
the compounds are non-selective ligands for a variety of neurotransmitter 
receptors, including adenosine A1, a & G adrenergic, dopamine, 5-HT, histamine, 
muscarinic, and cholecystokinin (CCK) receptors, from a wide variety of tissue 
types. In addition Ca2+ channels are also affected. Amiloride and two of its 
analogues, namely EIPA and benzamil, have also been shown to bind to Vi AVP 
receptors in platelets, glomerular mesanglial cells and smooth muscle cell [199]. 
The non-specific binding of amiloride and its analogues to these receptors is not 
related to any Na+ transport-inhibiting properties of the compounds (ie the Ki of 
binding is not correlated with the physiological response of Na+ transport). The 
problems encountered with 3H-MIA binding experiments in platelets in the present 
study, may be the result of the widespread presence of amiloride (and amiloride 
analogue) binding sites on receptors and other membrane proteins (ie. a saturable 
non-specific binding component) in addition to the Na+/H+ exchanger.
2.4.2 CALCIUM METABOLISM
The mean value of basal cytosolic free calcium concentration, in platelets 
from normal volunteers, (ie. 88.8±5.6 nmol/l), is in agreement with results from 
previous investigations [181, 200, 201]. Addition of AVP caused a rapid but 
transient increase in [Ca2+]j (736.9±96.7 nmol/l) in the presence of 1 mmol/l 
extracellular Ca2+. When extracellular Ca2+ was reduced to negligible (nanomolar) 
concentrations by adding 5 mmol/l EGTA the AVP-induced rise in [Ca2+]i was 
significantly reduced (134.7±8.4 nmol/l). These results suggest that AVP-induced
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Ca2+ mobilization occurs as a result of two mechanisms which are; i) the opening of 
Ca2+ channels in the plasma membrane allowing uptake of extracellular Ca2+ and ii) 
release of Ca2+ from intracellular stores. These results are again in agreement with 
previous investigations [181, 200].
The rate of basal 45Ca uptake remained linear over the initial 60 sec of 
incubation. One min was chosen as a suitable incubation period for investigation of 
the effects of varying AVP concentrations on platelet 45Ca uptake. Maximum 
stimulation of uptake was achieved with > 1 ^ mol/l AVP.
Methodologically, the measurement of 45Ca uptake into platelets is difficult, 
because of the minute amount of calcium taken up, when compared to the large 
amount in the extracellular medium. The use of the cell harvester has a number of 
advantages over previously published techniques. It provides a very rapid and 
efficient way of separating and washing cells free from the incubation medium.
The use of buffy coats greatly improved the scope of the 45Ca uptake 
expriments by providing enough cellular material for many replications. 
Furthermore, since platelets remained viable for up to 2 days when stored at 4°C, 
experiments could be undertaken on three consecutive days from one batch of 
platelets.
It was essential, for uptake experiments, that all platelets were preincubated 
in buffer containing 0.1 mmol/l Ca2+, at 37°C, for at least 30 min before 
measurement of calcium uptake. This was necessary to restore intraplatelet calcium 
stores after exposure to chelators, (EGTA and citrate), which were used in the 
platelet preparation. Also during storage at 4°C, intraplatelet calcium stores would
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be further depleted as a result of suspension in calcium poor buffer Depletion of 
intracellular calcium stores may affect the rate of both unstimulated and stimulated 
45Ca uptake.
The rate of basal and AVP-stimulated Ca2+ efflux remain linear between 5 - 
30 min of incubation. Ca2+ efflux in the presence of AVP was not significantly 
different from that of basal. However AVP may have affected efflux before the first 
measurement was taken, at 5 min.
Although the present study did not measure Na+/H+ exchange and Ca2+ 
mobilization simultaneously, other studies indicate that Na+/H+ exchange and Ca2+j 
are closely linked via the IP3 pathway. In platelets there are conflicting reports 
regarding the exact relationship between pH and Ca2+ mobilization. Siffert and 
Akkerman [27, 202] proposed that cellular alkalinization resulting from Na+/H+ 
exchanger activation is a prerequisite for Ca+ mobilization. Others disagree pointing 
out that Ca2+ release occurs before changes in pHj [203, 204]. Kimura et al [205] 
suggest that cytosolic Ca2+ is in fact a prerequisite for the agonist-evoked alkaline 
shift of the cytosolic pH set point for activation of Na+/H+ exchange. This Ca2+ 
induced activation of Na+/H+ exchange may be mediated, in part, by a protein 
kinase C-independent Ca2+/calmodulin pathway since calmodulin binding sites have 
recently been identified on the carboxyl terminal of the NHE-1 molecule [69].
In fura-2 loaded platelets, changes in pHs imposed by the addition of C 02, 
nigericin or NH4CI (which alter pH* directly without affecting Na+/H+ exchange 
activity), do not appear to alter resting [Ca2+]j [203]. In vascular smooth muscle cells, 
however, intracellular alkalinization, achieved by exposure to NH4CI or removal of
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C 02) produces a rapid elevation of [Ca2+]j by promoting Ca2+ release from AVP and 
TMB-8 sensitive stores. Vascular smooth muscle cell acidification (addition of C 0 2 
or removal of NH4CI), also increases [Ca2+]j, possibly as a result of the 
displacement of Ca2+ from Ca2+ binding proteins by cytosolic H+ [206].
In conclusion, this chapter describes the development of a number of 
methods including i) characterisation of the capacity and affinity of platelet plasma 
membrane Na+/H+ exchanger, ii) measurement of platelet [Ca2+]j, and iii) 
measurement of platelet Ca2+ influx and efflux. The method which attempted to 
characterise amiloride binding sites was unsuccessful. Regulation of ion transport is 
an important factor in the control of platelet function. Abnormal platelet functions 
have been identified in cardiovascular disease. The above methods of measuring 
cation transport and metabolism will be used to investigate platelet function under 
various pathophysiological circumstances.
121
CHAPTER 3
EFFECTS OF HDL SUBFRACTIONS ON PLATELET SECOND MESSENGER 
SYSTEMS IN VITRO.
3.1 INTRODUCTION
Plasma lipoproteins are involved in the pathogenesis of coronary artery 
disease. Elevated concentrations of low density lipoprotein-cholesterol (LDL-chol) 
are considered a risk factor, whereas high density lipoprotein-cholesterol (HDL- 
chol) appear to be protective. Lipoproteins may alter the function of specific cells 
such as vascular smooth muscle cells and platelets which participate in the 
atherogenic process. A number of studies have shown a close relationship between 
increased platelet activity and cardiovascular disease. Platelets from patients with 
hyperlipidaemia and atherosclerosis show increased adhesiveness, aggregability, 
secretory activity and a reduced lifespan [116, 140, 207, 208]. This abnormal state 
of platelet activation has been related to high plasma levels of VLDL and LDL.
In vitro studies have shown that platelets respond to physiological 
concentrations of lipoproteins. LDL not only enhances agonist-induced platelet 
activation but also activates platelets directly [209, 210, 211, 212]. HDL on the other 
hand has been shown to have anti-aggregatory properties [209, 213, 214]. The 
mechanisms which have been suggested to explain lipoprotein effects on
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cardiovascular cells generally involve changes in plasma membrane function due to 
altered cholesterol content.
When the cholesterol content of platelet membranes is enriched by 
incubation with cholesterol-rich liposomes platelet sensitivity to certain aggregating 
agents is increased [215]. The cholesterol content of the plasma membrane 
controls membrane fluidity and may influence the function of integral proteins 
including those associated with ion transport and signal transduction [125, 216].
Most of the observed platelet responses to vasoactive agonists are 
mediated by variations in intracellular Ca2+ concentration. The systems which 
control platelet [Ca2+]j are illustrated in Figure 3.1. The mechanisms whereby 
agonists stimulate increases in [Ca2+]i are well established. On receptor stimulation 
there is rapid hydrolysis of phosphatidyl 4,5-bisphosphate by phospholipase C 
which results in the formation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DG). IP3 triggers an increase in the concentration of intracellular free Ca2+ through 
the mobilization of Ca2+ from intracellular stores [217]. Release from intracellular 
stores is followed by influx of extracellular Ca2+ through plasma membrane Ca2+ 
channels [218, 219]. Several mechanisms for the activation of receptor-operated 
Ca2+ channels have been proposed in different tissues including direct coupling to 
the receptor through G-proteins [220], indirect coupling via a second messenger 
such as IP3 or 1,3,4,5-tetrakisphosphate [221, 222, 223], or by a mechanism 
whereby plasma membrane Ca2+ influx is regulated by the filling state of the 
intracellular stores [224] which may involve cytochrome p450 [225, 226]. To date 
the precise mechanism is still uncertain [227]. Once the intracellular concentration
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has been raised, Ca2+ acts as a cofactor for the activation of certain hormones e.g. 
phospholipase A2, and also combines with calmodulin to form a complex which 
stimulates myosin light chain kinase which is responsible for platelet shape change 
[228].
The second product of phosphatidyl 4,5-bisphosphate breakdown, 
diacylglycerol (DG), activates the enzyme protein kinase C (PKC). PKC shifts the 
pH sensitivity of the plasma membrane Na+/H+ exchanger resulting in its activation 
[67] thus raising intracellular pH. Cytosolic alkalinization is an important modulator 
of platelet function including phosphlipase A2 activation which in turn controls the 
formation of prostaglandins, endoperoxidases and thromboxane A2 [229, 230, 231]. 
Intracellular alkalinization also enhances the effects of IP3 during stimulation with 
low concentrations of thrombin [27] and modifies the activity of the calmodulin-Ca2+ 
interaction [232]. Platelet Ca2+ content is negatively controlled by cyclic AMP 
(cAMP) which activates plasma membrane Ca2+ ATPase pumps via 
phosphorylation of the rap1 protein [233], Ca2+ ATPase pumps are responsible for 
the removal of intracellular Ca2+ and thereby lowering cytosolic Ca2+ levels.
The effects of lipoproteins on platelet responsiveness may in theory be due 
to influences on one or more of the mechanisms involved in intracellular [Ca2+] or 
pH regulation. In vitro studies have demonstrated that during LDL-induced platelet 
activation, LDL stimulates the phosphoinositol cycle, elevating IP3 and DG levels 
and raising intracellular [Ca2+] [210, 211 234, 235]. In addition to increasing platelet 
[Ca2+]i, low concentrations of LDL have been shown to promote Na+/H+ exchange 
across plasma membranes of vascular smooth muscle cells [87]. Furthermore
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Figure 3.1 Diagram of platelet calcium regulatory systems. Calcium homeostasis is 
maintained by active Ca2+ pumps (ATP dependent) in the plasma membrane and 
the mobilisation of intracellular stores. Na+/Ca2+ exchange may also act as an 
additional calcium extrusion mechanism. Ca2+ influx across the plasma membrane 
occurs via receptor- and voltage-operated Ca2+ channels and leak channels.
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previous in vitro investigations have demonstrated that LDL reverses PGI2-induced 
inhibition of platelet aggregation by decreasing the stimulated synthesis of cAMP 
[236, 237, 238].
In contrast to the numerous studies of LDL-induced platelet activation, little is 
known of the cellular events underlying the anti-aggregatory properties of HDL. 
Preincubation with physiologic concentrations of HDL, particularly the Apo E rich 
subfraction, HDL2i inhibits release of secretory substances including serotonin and 
thromboxane B2 and reduce LDL-induced platelet aggregation [209, 211, 214]. We 
have also previously demonstrated, in vitro [239] that HDL inhibits arginine 
vasopressin (AVP)-induced platelet aggregation. This anti-aggregatory action 
occurred, at least in part, through a reduction in AVP-stimulated [Ca2+]j. Basal 
unstimulated [Ca2+]i was not affected. This HDL-induced reduction in platelet [Ca2+]j 
may result from changes in one or more of the mechanisms involved in platelet 
Ca2+ homeostasis, such as membrane Ca2+ transport or the phosphatidylinositol 
second messenger pathway or by influencing the size or turnover of intracellular 
calcium stores. The results of investigating some of these possibilities are 
presented in this chapter. The effect of two HDL subfractions HDL2 and HDL3 on 
platelet Ca2+ metabolism and Na+/H+ exchanger activity have been considered.
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3.2 METHODS
3.2.1 REAGENTS AND EQUIPMENT 
(In addition to those listed in chapter 2)
Flurbiprofen (Sigma).
Dialysis buffer (containing in mmol/l: 144 NaCI, 3.7 KCI, 1 MgS04l 5 TRIS/HCI, pH 
7.4).
3.2.2 LIPOPROTEIN PREPARATION
HDL subfractions were prepared by Dr M Caslake, Department of 
Pathological Biochemistry, Royal Infirmary, Glasgow, according to the method 
based on that of Havel et al [240]. Briefly, HDL2 and HDL3 (specific gravities 1.063- 
1.125 and 1.125-1.21g/l respectively) were isolated from the blood of normal 
volunteers using sequential isopycnic ultracentrifugation, after progressively raising 
solvent density of the serum by the addition of a concentrated salt solution. The two 
subfractions were dialysed for 24 hours using at least 4 changes of dialysis buffer. 
Protein concentration was measured using the Lowry method [241].
3.2.3 MEASUREMENT OF PLATELET [Ca2*], IN PRESENCE OF HDL2 OR HDL3
Platelets were prepared from the blood of normal volunteers or from buffy 
coats and loaded with Quin 2 as described in Chapter 1 (methods section).
Intracellular ionised calcium concentration was measured using the calcium 
fluorecent dye quin-2. Platelets were suspended in calcium-poor platelet buffer and 
loaded with dye by incubating at 37°C for 30 min with 10 pmol/l quin-2 AM. Whilst
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loading with dye, platelets were also preincubated with either HDL2, HDL3 (500pg 
protein/ml) or vehicle. Similar concentrations of HDL have been shown to inhibit 
AVP-induced platelet aggregation [239]. After incubation excess dye and HDL were 
removed by centrifugation and platelets were resuspended in calcium poor buffer at 
a concentration of 2x108/ml. It was essential to remove all excess lipoprotein before 
[Ca2+]j measurement since HDL3 and HDL2 autofluoresce. Initial investigations 
demonstrated that after removing lipoproteins by centrifugation and resuspension of 
platelets in HDL-free buffer (in absence of Quin 2) autofluorescence was negligible 
(data not shown). Fluorescence was measured in individual samples under basal 
conditions (with 1 mmol/l Ca2+) and after stimulation with 1 pmol/l vasopressin (AVP) 
with and without 5 mmol/l EGTA, using a Perkin Elmer LS-3B fluorescence 
spectrometer at 339nm excitation and 492nm emission wavelengths.
3.2.4 MEASUREMENT OF PLATELET Ca2+ UPTAKE IN PRESENCE OF HDL2 OR 
HDL3
Platelets, isolated from the blood of normal volunteers, were suspended in 
buffer containing a range of concentrations of HDL2 (50-500pg protein/ml), HDL3 
(500-3000pg protein/ml) or vehicle and incubated for 30 min at 37°C. After 
incubation, HDL was removed by centrifugation. Ca2+ uptake was measured 1-30 
min after adding aliquots of platelet suspension to buffer containing ^Ca  
(0.15MBq/ml) with and without the presence of 1 (xmol/l AVP. The reaction was 
stopped by harvesting the cells, using a Titretek Cell Harvester and Whatman GFB
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filters and ice cold platelet buffer (containing 5mmol/l Ca2+). Cell 45Ca was 
measured using a IS liquid scintillation counter.
3.2.5 MEASUREMENT OF PLATELET Ca2+ EFFLUX IN PRESENCE OF HDL2 OR 
HDL3
Platelets, isolated from the blood of normal volunteers, were loaded with 
45Ca, by preincubating in platelet buffer containing 0.48MBq/ml 45Ca for 30 min in 
the presence of either HDL2 (500pg protein/ml), HDL3 (500pg protein/ml) or vehicle. 
Once loaded, the platelets were washed and resuspended in fresh platelet buffer by 
centrifuging for 10 min at 37°C at 1600g. At 5min intervals aliquots of platelet 
suspension were harvested (using a Titretek Cell Harvester) with ice cold platelet 
buffer. The platelet 45Ca content was counted using a ft liquid scintillation counter.
3.2.6 MEASUREMENT OF PLATELET Na+/H+ EXCHANGE IN PRESENCE OF 
HDL2OR h d l 3
Platelets were initially preincubated at 37°C for 30 min in platelet buffer 
containing either HDL2 (500pg protein/ml), HDL3 (500pg protein/ml) or vehicle 
(dialysis buffer). Flurbiprofen was added to the incubation medium (final 
concentration 30 ^mol/l) to prevent platelet aggregation. The platelets were then 
washed and resuspended in potassium propionate buffer pH 6.7. Na+/H+ exchange 
was measured as previously described (chapter 2).
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3.3 RESULTS
3.3.1 EFFECT OF HDL3 AND HDL2 ON PLATELET [Ca2+]i
Figure 3.2 illustrates [Ca2+]j responses in untreated platelets. Results show 
[Ca2+]j under basal conditions, after AVP stimulation and after AVP stimulation in 
the presence of 5mmol/l EGTA. AVP, in the absence of EGTA, produced a 4.3 fold 
increase in [Ca2+]j (592 ± 60 nmol/l) compared to basal (138 ± 5 nmol/l). This 
increase represents both release of Ca2+ from intracellular stores and extracellular 
Ca2+ influx. In the presence of (5mmol/l) EGTA, which chelates extracellular Ca2+, 
the AVP induced rise in [Ca2+]j was only 1.5 fold that of basal and represents 
release of stored Ca2+ only.
The effect of 30 min preincubation with HDL2 and HDL3 on basal and AVP 
stimulated [Ca2+]i is illustrated in Figure 3.3. Results shown are expressed as % 
change in [Ca2+]j compared to that of untreated platelets (see Figure 3.2). Basal 
and AVP-stimulated [Ca2+]j in the presence of EGTA were not significantly altered 
by either lipoprotein subfraction. However the AVP-induced rise in [Ca2+]j was 
significantly increased (30%) by HDL3 and significantly reduced (21%) by HDL2.
3.3.2 EFFECT OF HDL3 AND HDL2 ON PLATELET Ca2+ INFLUX AND EFFLUX
The effects of HDL2 and HDL3 treatment on platelet Ca2+ uptake are 
illustarted in Figures 3.4 (a) & (b). The results are expressed as a % of the rate of 
basal Ca2+ uptake (approximately 0.57 pmol/106ce!ls/min) by platelets not treated
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Figure 3.2 [Ca2+]j responses in untreated platelets. Results shown are mean ± SE in 
platelets from 6 different volunteers. AVP produced a 4.3 fold increase in [Ca2+]j 
compared with basal. This increase represents both release of Ca2+ from 
intracellular stores and extracellular Ca2+ influx. In the presence of EGTA the AVP- 
induced rise in [Ca2+]i was only 1.5 fold that of basal and represents release of 
stored Ca2+ only.
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Figure 3.3 Effect of HDL3 and HDL2 treatment on basal and AVP-stimulated [Ca2+]j. 
Results shown are mean ± SE in platelets from 6 different volunteers. Basal [Ca2+]j 
and release of Ca2+ from intracellular stores were not significantly altered by either 
lipoprotein subfraction. AVP-stimulated [Ca2+]j was significantly increased (30% of 
control) by HDL3 and significantly reduced (21% of control) by HDL2. * p<0.05, * * 
p<0.01 (paired student t-test).
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with HDL. A 30 min. preincubation with either HDL2 or HDL3 caused a dose 
dependent inhibition of basal and AVP-stimulated Ca2+ uptake. However the net 
difference between basal and AVP-stimulated uptake was not significantly affected 
by any HDL concentration. Figure 3.5 illustrates 45Ca equilibration in untreated 
platelets and platelets incubated with either HDL2 or HDL3. Calcium content was 
reduced by approximately 20% after incubation with either lipoprotein fraction.
The effects of HDL2 and HDL3 on basal platelet Ca2+ efflux are illustrated in 
Figure 3.6. The rate of Ca2+ efflux in the presence of HDL3 was marginally, but not 
significantly, slower than that of basal and in the presence of HDL2.
3.3.3 EFFECT OF HDL3 AND HDL2 ON PLATELET Na+/H+ EXCHANGE
The effects of HDL2 and HDL3 on amiloride-sensitive Na+ uptake are shown 
in Figure 3.7. Km and Vmax values for platelet Na+/H+ exchange in the presence of 
HDL2 were not significantly different to that in untreated platelets (38.3±4.5 mmol/l 
and 377.4±29.6 pmol/106cells/min versus 46.5±6.3 mmol/l and 428.8±25.5 
pmol/106cells/min respectively). Vmax was significantly increased in the presence of 
500 jag/ml HDL3 (545.9±43.5 pmol/106cells/min) compared to that in untreated 
platelets (p<0.05). Km values remained unchanged (48.1 ±2.7 mmol/l).
Table 3.1 summerises the results of HDL2 and HDL3 effects on platelet Ca2+ 
metabolism and Na+/H+ exchanger activity.
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Figures 3.4 (a) & (b) Effect of increasing concentrations of HDL2 and HDL3 on basal 
and AVP-stimulated Ca2+ uptake. Results shown are mean ± SE in platelets from 5 
different volunteers. Both HDL2 and HDL3 caused a dose dependent inhibition of 
basal and AVP-stimulated Ca2+ uptake. However the net difference between basal 
and AVP-stimulated uptake was not significantly affected by any of the HDL 
concentrations. * p<0.05, * * p<0.01, * * * p<0.005 (t-test).
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Figure 3.5 Time course of Ca2+ uptake in platelets equilibrated with 45Ca. Results 
are mean ± SE of 3 separate experiments. Ca2+ uptake reached equilibrium 
approximately 1 0 - 2 0  min after the start of incubation. The Ca2+ content of the 
platelets preincubated with either HDL subfraction was reduced by approximately 
20% compared to that of untreated platelets.
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Figure 3.6 Effect of HDL2 and HDL3 treatment on basal Ca2+ efflux in platelets. 
Results are mean ± SE in platelets from 6 different volunteers. Neither HDL2 or 
HDL3 significantly altered basal Ca2+ efflux.
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Figure 3.7 Effect of HDL3 on amiloride sensitive Na+ uptake in platelets. Results are 
mean ± SE in platelets from 6 different volunteers. HDL3 significantly increased 
Vmax of amiloride sensitive Na+ uptake. * p<0.05.
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3.4 DISCUSSION
Fluorometric data from the present study demonstrated that HDL3 increases 
and HDL.2  decreases AVP-stimulated platelet [Ca2+]j. Since platelet function is 
dependent on the levels of intracellular Ca2+ concentration then this result may 
explain the pro- and anti-aggregatory action of HDL3 and HDL2 on platelet 
aggregability demonstrated by others [214]. A similar stimulatory effect of HDL3 on 
[Ca2+]j has also been reported in cultured fibroblasts. In this case the increase in 
mobilized Ca2+ was derived mainly from intracellular calcium stores [242], The 
present data show no significant effect of either HDL2 or HDL3 on the [Ca2+]j 
response to AVP in platelets treated with EGTA. From this it may be concluded that 
the differential effects of HDL are due to changes in Ca2+ influx or efflux across the 
plasma membrane or calcium store refilling rather than release from intracellular 
stores. Ca2+ influx and efflux data, however, do not provide a simple explanation for 
the observed lipoprotein-induced effects.
Both HDL2 and HDL3 caused a dose dependent inhibition of basal but not 
AVP-stimulated 45Ca uptake. Furthermore no significant effect on 45Ca efflux was 
demonstrated with either HDL subfraction. Data from Ca2+ equilibration 
experiments, which indicate the filling state of the intracellular stores also show an 
inhibitory effect for both HDL2 and HDL3.
It is possible that the inhibitory action of HDL2 on platelet [Ca2+]s in the 
absence of any significant effect on 45Ca influx or efflux across the plasma 
membrane may occur as a result of influx direct to the intracellular stores. In this 
situation Ca2+ would enter stores directly rather than the cytoplasm so remaining
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undetected by Quin 2. This would suggest inhibition, by HDL2i of the normal IP3 
mediated entry of extracellular Ca2+. Evidence from refilling experiments in platelets 
where the stores were discharged in the absence of extracellular Ca2+ and then 
recharged after brief exposure to Ca2+ with no apparent elevation of [Ca2+]j during 
the refilling stage, indicated an exclusive pathway between the extracellular space 
and the intracellular store [243, 244]. In 1986 Putney [224] proposed a model for 
receptor-regulated Ca2+ entry which indicated the existence of an intracellular 
calcium store directly linked to the plasma membrane, in non-excitable cells. Recent 
investigations with a number of different cell types, including platelets, have 
demonstrated the existence of at least two types of calcium store, including one 
sensitive to IP3 and an other insensitive to IP3 but sensitive to [Ca2+]it both of which 
are involved in the regulation of Ca2+ influx [245, 246]. The [Ca2+]rsensitive store is 
believed to be linked directly with the plasma membrane (see Figure 3.8).
It is difficult to explain the source of the elevated AVP-induced rise in [Ca2+]j 
in HDL3 treated platelets since HDL3 appeared to have no effect on either Ca2+ 
influx, efflux or release from intracellular stores. However platelets preincubated 
with HDL3 (but not HDL2) showed increased amiloride sensitive Na+ uptake. This 
effect appeared to be due to an increased turnover or number of exchanger sites 
since Vmax but not Km for Na+ was increased. A previous investigation with VSMC 
has also demonstrated elevated [Ca2+]j and increased Na+/H+ exchange after 
treatment with HDL [247]. HDL3-induced activation of Na+/H+ exchange may occur 
as the result of the observed elevation in [Ca2+]j, since Ca2+-calmodulin binding 
sites, which exist on the C-terminal of the NHE-1 molecule, have been shown to
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Figure 3.8 Diagram representing the function of two distinct non-mitochondrial Ca2+ 
stores within cell. IP3 directly induces release of Ca2+ to the cytosol from one store 
only (store A). The rise of cytosolic Ca2+ induces release of Ca2+ from store B. After 
release the A store is refilled by the B store which is replenished by extracellular 
Ca2+ entry via a direct link with the plasma membrane. Calcium may be transferred 
between these pools via a GTP activated process.
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regulate exchanger activity [70]. On the other hand, activation of a Ca2+- 
independent signalling mechanism has been demonstrated in platelets when 
exposed to HDL3 [248, 249, 250]. Binding of HDL3 (<50ng/ml) to platelet membrane 
receptors stimulates, via phospholipase C hydrolysis of phosphatidylcholine, 
generation of diacylglycerol which activates protein kinase C [251]. This intracellular 
signalling pathway is responsible for transfer and efflux of intracellular cholesterol 
during 'reverse cholesterol transport’ [135]. It is well known that Protein kinase C 
also plays an important role in Na+/H+ exchanger activition [252]. Our results do not 
preclude the possiblity that changes in pHs or [Na+]j are responsible for elevated 
[Ca2+]j after exposure to HDL3. It may be argued that an increase in exchanger 
activity could contribute to the raising of [Ca2+]j by two separate mechanisms i.e. 
through intracellular alkalinization or changes in Na+/Ca2+ exchanger activity.
The role of intracellular pH and Na+/H+ exchange in platelet Ca2+ mobilization 
is controversial. It appears that a change in pHj is not essential for Ca2+ mobilization 
but it can modulate the process [36, 253]. To demonstrate this, intracellular 
alkalinization which results from increased Na+/H+ exchanger activity has been 
implicated in the enhancement of Ca2+ mobilization during thrombin stimulated 
platelet activation [27]. This influence of pHj is very much dependent on agonist 
concentration. The lower the thrombin concentration the greater the enhancement, 
by raised pHj, on intracellular store Ca2+ release.
In both stimulated and unstimulated platelets the normal role of the Na+/Ca2+ 
exchanger is extrusion of Ca2+ from the cytosol in exchange for extracellular Na+ 
[37], However it has also been demonstrated in VSMC that raising [Na+]j through
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the stimulation of Na+/H+ exchange (as a result of increased pH0) activates the 
reverse mode of Na+/Ca2+ exchange (Ca2+ influx with Na+ efflux) leading to a rise in 
[Ca2+]i [254],
If one or both of these mechanisms were involved in the observed HDL3- 
induced rise in [Ca2+]i then a change in 45Ca influx or efflux or release from 
intracellular stores would be expected. One important difference between the 
method employed for measuring 45Ca influx and those used for measurement of 
[Ca2+]i and Na+/H+ exchanger activity is extracellular Ca2+ concentration. It is 
necessary to carry out Ca2+ influx experiments in the presence of low extracellular 
Ca2+ concentrations (ie 0.1 mmol/l) to allow sufficient 45Ca uptake. Other methods 
were carried out with extracellular Ca2+ concentrations of 1 mmol/l. Low extracellular 
Ca2+ concentrations influence platelet activation and may effect the normal action of 
HDL subfractions on platelet second messenger systems.
A further explanation for the apparent discrepancy between [Ca2+]j 
measurements and 45Ca influx/efflux data is the use of Quin 2 for [Ca2+]j 
measurements. Despite early widespread use, Quin 2 has a number of drawbacks 
including the millimolar intracellular concentration required to obtain a useful signal- 
to-noise ratio [255, 256]. It is possible that agonist-induced transient rises in [Ca2+]j 
are buffered, leading to blunting of Quin 2 responses. The approximate five fold 
increase in fluorescence signal in the presence of AVP in this study demonstrates 
that Quin 2 is more than adequate for measurement of [Ca2+]j changes in stimulated 
cells. However it is uncertain that this technique could detect a local [Ca2+]j rise if it 
were confined to a small portion of the cytoplasm and therefore exposed to only a
142
small fraction of the intracellular Quin 2. Compartmentalization or buffering of Ca2+ 
by Quin 2 during [Ca2+]j measurement may have masked significant changes in 
release of Ca2+ from intracellular stores in this study. In recent years, the use of 
Quin 2 for [Ca2+]j measurement has declined in favour of another fluorescent probe, 
Fura 2 [169], which requires much lower intracellular concentrations and exhibits an 
excitation wavelength shift from 380-390 to 340-350 on Ca2+ binding, thus allowing 
the calculation of a fluorescence signal ratio. Fura 2, however is by no means an 
ideal probe for measurement of [Ca2+]j due to its leakiness [257, 258].
In conclusion (see Table 3.1), previous observations of pro- and anti­
aggregatory effects of HDL2 and HDL3 are explained by increases and decreases 
respectively in AVP-stimulated [Ca2+]j. Since neither HDL subfraction altered AVP- 
stimulated [Ca2+]j in platelets treated with EGTA the differential effects of HDL 
appeared to be due to changes in membrane Ca2+ transport rather than release 
from intracellular stores. However both HDL2 and HDL3 caused a dose dependent 
inhibition of basal but not AVP-stimulated Ca2+ uptake and had no influence on 
either basal or AVP-stimulated Ca2+ efflux. Both HDL subfractions reduced the 
calcium content of platelets under equilibrium conditions. Since [Ca2+]j under basal 
conditions were not effected by HDL, this would suggest that bound calcium stores 
may be reduced by both fractions. Na+/H+ exchanger activity, which enhances Ca2+ 
mobilisation through increases in pHs, was enhanced by HDL3 but not effected by 
HDL2.
The discrepancy between [Ca2+]j measurements and 45Ca influx/efflux data 
may simply result from methological differences (ie Ca2+ concentration of media in
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which platelet are suspended), or may imply that other factors are influencing 
intracellular [Ca2+] which were undetected by our methods.
The effects on platelet [Ca2+]j and Na+/H+ exchanger activity observed in the 
presence of HDL2 and HDL3 may be the result of direct hormone/receptor type 
interaction or may occur as a result of HDL-induced changes on platelet membrane 
cholesterol content which, by controlling membrane fluidity, might effect membrane 
ion transport and hence the cellular distribution of cations.
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TABLE 3.1 Summary of HDL2 and HDL3 effects on platelet function, Ca2+ 
metabolism and Na+/H+ exchanger activity.
EFFECT HDL2 HDL3
Platelet Function Anti-aggregatory Pro-aggregatory
Basal [Ca2+]i <-> <->
AVP-stim [Ca2+]j I t
AVP-stim [Ca2+]j + EGTA <-> <->
Basal 45Ca influx I 1
AVP-stim 45Ca influx <-> <->
Ca2+ stores I I
Basal 45Ca efflux <-> <->
AVP-stim 45Ca efflux - -
Km Na+/H+ exchange <-> <->
Vmax Na+/H+ exchange <-> t
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CHAPTER 4
IN VIVO STUDIES OF THE EFFECTS OF PLASMA LIPIDS ON PLATELET 
SECOND MESSENGER SYSTEMS.
4.1 INTRODUCTION
Abnormalities of a number of cell membrane, ion transport processes have 
been described in essential hypertension. As a result of these findings it has been 
proposed that alteration in the regulation of cytosolic Na+, Ca2+ and H+ 
concentrations contribute to the increased tone, hypertrophy and hyperplasia of 
vascular smooth muscle cells [9, 259, 260, 261].
Several groups have provided evidence for elevated intracellular free 
calcium, [Ca2+]j, in platelets from hypertensive subjects [262, 263, 264, 265]. A 
number of studies have also indicated a positive correlation between platelet [Ca2+]j 
and diastolic blood pressure [6, 263, 264, 266, 267, 268]. Several factors may 
contribute to increased [Ca2+]j including: enhanced Ca2+ influx into the cell; 
increased mobilization of Ca2+ from intracellular stores; and a decrease in the rate 
of Ca2+ efflux (ie. abnormalities in the activity of the Ca-ATPase pump) [269]. Similar 
changes could occur in vascular smooth muscle cells. If so, then raised [Ca2+]j 
could explain increased vascular tone, hypertrophy and raised vasoactive 
responsiveness in patients with essential hypertension.
In addition to changes in Ca2+ metabolism, several aspects of 
transmembrane Na+ transport have been shown to be altered in hypertensive
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patients. These include increased Na+/H+ exchange [47, 161, 270, 271, 272, 273, 
274, 275], increased Na+/Li+ countertransport [47, 276, 277] and reduced Na+/K* 
ATPase pump activity [278, 279]. One of these, increased red cell Na+/Li+ 
countertransport, has been suggested as a genetic marker of essential 
hypertension because it is so consistently and reproducibly observed [46, 276, 280, 
281, 282, 283, 284]. Elevated Na+/Li+ exchange has also been reported in insulin- 
dependent diabetic (IDDM) patients with renal complications (nephropathy) [285, 
286, 287] and coincides with a family history of hypertension [287, 288]. Cation 
transport in non-insulin dependent diabetes (NIDDM) is less well documented. One 
recent investigation suggests that Na+/Li+ countertransport is raised in NIDDM 
patients, but found no association with diabetic nephropathy [289]. Another, more 
recent, investigation suggests that Na+/H+ exchange kinetics are unchanged in 
NIDDM patients with and without microalbuminuria and/or hypertension [290].
Under physiological conditions, in the absence of Li+, the red cell Na+/Li+ 
countertransporter mediates 1:1 Na+/Na+ exchange which would therefore not be 
expected to influence intracellular electrolyte content. However, it is believed by 
some that Na+/Li+ countertransport is a mode of operation of the Na+/H+ exchanger 
since a number of similarities exist between the two ion transport mechanisms [47, 
291]. Both mediate 1:1 monovalent cation exchange (with similar affinities for both 
Na+ and Li+); both are ouabain insensitive; both use concentration gradients across 
the membrane to drive cation transporters; both are independent of ATP-hydrolysis; 
both are subject to allosteric stimulation by internal H+ [292, 293]. Furthermore, 
similar kinetic alterations in both transport systems can be induced in vitro by
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physiological doses of insulin (i.e. reduced affinity for extracellular Na+) [294]. The 
hypothesis that Na+/Li+ countertransport is a mode of operation of Na+/H+ 
exchange, however, remains unproven since a number of important differences 
remain irreconciled. For example, Na+/Li+ countertransport is insensitive to the 
Na+/H+ exchange inhibitor, amiloride, whereas phloretin, an inhibitor of Na+/Li+ 
countertransport, has no effect on Na+/H+ exchange. Although the Na+/H+ 
exchanger has an affinity for Li+, phloretin-sensitive Na+/Li+ countertransport is only 
assayable in erythrocytes. In addition, erythrocyte Na+/Li+ countertransport operates 
at pHj>7.0, whereas erythrocyte Na+/H+ exchange only operates at pHj<7.0 [292, 
293]. Furthermore, a recent study which compared lymphocyte Na+/H+ exchange 
and erythrocyte Na7l_i+ countertransport in familial hypercholesterolaemic (FH) 
patients [295], and another study which compared the two transport systems in 
erythrocytes from normotensive and hypertensive individuals [296] both failed to 
demonstrate significant correlations between the two parameters. The role of 
abnormal Na7l_i+ countertransport in the pathogenesis of hypertension and 
diabetes therefore remains obscure.
Raised Na+/H+ exchange has been found in platelets [161, 263, 270, 271, 
297], leucocytes [272, 273], lymphocytes [275], erythrocytes [274] and skeletal 
muscle [298] from essential hypertensive subjects and has also been observed in 
various types of blood cells from IDDM patients with nephropathy [299, 300, 301, 
302]. Results from investigations with Epstein-Barr virus immortalized lymphoblasts 
from essential hypertensive patients suggest that altered Na+/H+ exchanger activity 
must be under genetic control, at least in a certain group of hypertensive subjects,
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since the hypertensive NHE-1 phenotype persists in these cells even after 
prolonged culture in the absence of potentially influencial metabolic and hormonal 
factors [303]. However neither mutations or overexpression of the NHE-1 gene 
appear to be responsible for abnormal activity. Genetic linkage analysis by two 
separate groups has suggested that mutations at the NHE-1 gene locus are not 
responsible for elevations in Na+/Li+ countertransport [304, 305], The significance of 
these results is questionable since Na+/H+ exchange was not directly measured (but 
does provide further evidence that Na+/Li+ countertransport and Na+/H+ exchange 
are mediated by different proteins). However, in agreement with linkage analysis, 
no sequence changes have been identified for cDNA's encoding NHE-1 in 
immortalized lymphoblast cell lines from essential hypertensive subjects [303]. 
Several studies (in immortalized human lymphoblasts [303] and vascular smooth 
muscle cells from SHR and WKY animals [306, 307]) have failed to demonstrate 
altered NHE-1 mRNA expression in essential hypertension. One group has 
reported elevated mRNA levels in human lymphocytes, although the significance of 
this finding remains obscure since they failed to demonstrate correlations between 
these mRNA levels and either pHj or Na+/H+ exchanger activity [308]. These results 
have led to the conclusion that post-transcriptional events play an important role in 
elevated exchanger activity in hypertension. Alterations in the kinases and 
phosphatases that regulate the exchanger pH 'set point' by modifying the affinity of 
the Na+/H+ exchanger for H+ may be reponsible [303, 309]. Further recent 
suggestions for the underlying causes of enhanced NHE-1 activity include
149
alterations in the role of Ca2+-calmodulin control or activation of pertussis toxin- 
sensitive G proteins [310, 311].
Assuming that exchanger activity in blood cells and skeletal muscle is 
representative of that in vascular smooth muscle cells and renal cells, then Na+/H+ 
exchange could contribute to the development of hypertension by several 
mechanisms, i) Increased exchanger activity in vascular smooth muscle cells, by 
raising intracellular sodium concentration could, via activation of the Na+/Ca2+ 
exchanger, lead to an increase in [Ca2+]i, thereby increasing vascular tone [312, 
313]. ii) A rise in the intracellular pH of vascular smooth muscle cells, due to greater 
Na+/H+ exchange activity could stimulate smooth muscle cell proliferation and 
vascular hypertrophy leading to increased peripheral resistance [314]. iii) Increased 
Na+/H+ exchange in the proximal renal tubule could lead to greater sodium 
reabsorption and extracellular volume expansion [314, 315].
Previous studies have suggested a link between cation transport systems 
and plasma lipids [46, 316, 317]. Na+/Li+ countertransport was found to be 
increased in hyperlipidemic subjects [318] and was correlated significantly with 
plasma triglyceride and cholesterol concentrations [317, 318, 319]. Plasma 
triglycerides have also been shown to be significantly correlated with NaVK* 
ATPase pump, Na7K* cotransport and passive Na+ permeability [316, 320] whilst 
HDL is inversely correlated with NaVK" ATPase pump, Na+/K+ cotransport [316, 
320] and Na7l_i+ countertransport [46, 317]. There is evidence that cation transport 
activity within an individual can change in association with changes in plasma lipid 
concentration. Dietary manipulation or lipid-lowering therapy in hyperlipidaemic
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patients with high Na+/Li+ countertransporter activity has been shown to lead to a 
fall in Na+/Li+ countertransport which was related to changes in triglyceride levels 
[321].
The simultaneous presence of several different ion transport abnormalities in 
cells from hypertensive and diabetic subjects could reflect complex 
interrelationships involved in maintaining cell electrolyte homeostasis. An alternative 
explanation might be that an underlying alteration in the cell membrane structure 
affects all transport functions [4, 43, 322]. In this case, altered membrane fluidity 
which is determined by lipid composition could be a common factor. Plasma lipids 
are in constant and dynamic equilibrium with cell membrane lipids, and membrane 
fluidity is markedly reduced as membrane cholesterol/phospholipid ratio and 
membrane cholesterol content increase [323, 324], The fluidity of the lipid bilayer 
modulates the function of membrane bound proteins such as receptors and ion 
transporters [124, 325]. Since essential hypertension and diabetes are commonly 
associated with abnormal plasma lipid profiles [101, 326, 327, 328], in addition to 
increased membrane cholesterol/phospholipid ratios [329, 330, 331], it is possible 
that the observed ion transport defects are a reflection of abnormal membrane 
fluidity.
The previous chapter described the in vitro effects of high-density lipoprotein 
subfractions on platelet second messenger systems. These in vitro observations 
with HDL led us to speculate that the relative amounts of HDL2, HDL3 and LDL in 
plasma might influence the aggregatory responsiveness of platelets in vivo. 
Accordingly, the following in vivo investigations have been carried out, using the
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same methods, to determine whether relationships between circulating lipids and 
cation transport might explain aspects of cardiovascular disease and diabetes.
The in vivo study was divided into three main sections, i) We compared 
measurements of [Ca2+]j, and Na+/H+ exchanger activity, which are major 
determinants of platelet function, with various plasma lipoprotein and apolipoprotein 
profiles of normotensive subjects. Measurement of lipoprotein Lp(a), which has a 
similar protein and lipid composition to that of LDL, was included in this investigation 
since recent findings indicate that high levels of Lp(a) may be an independent risk 
factor for CHD [332, 333]. Although similar in composition to LDL, Lp(a) does not 
appear to be derived from LDL, or from any of the other lipoproteins involved in the 
classic VLDL-IDL-LDL cascade [334]. It has been speculated that Lp(a) may 
promote atherosclerotic changes by increasing the formation of atheromatous foam 
cells in the artery wall, and/or by promoting thrombus formation (through its 
structural similarity to plasminogen) [333, 334, 335]. In addition the Apo E 
phenotype of the normotensive population was determined and the impact of this 
genetic profile on plasma lipids, Na+/H+ exchanger activity and [Ca2+]j was also 
considered, ii) An investigation was made of the association between platelet 
Na+/H+ exchange, platelet membrane microviscosity and serum lipids in essential 
hypertensive patients, iii) A similar investigation was carried out to determine 
relationships between Na+/H+ exchange, platelet membrane microviscosity and 
plasma lipids in type 2 diabetic (NIDDM) subjects.
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4.2 METHODS
4.2.1 NORMOTENSIVE SUBJECTS
Samples for analysis of lipid profiles and second messenger systems were 
obtained from members of a normal working population. These volunteers had 
either been screened as part of the 'Good Hearted Glasgow' campaign or were 
involved in routine medical examinations at their place of employment. The subjects 
came from the work forces based at Scottish Nuclear, East Kilbride and Scottish 
Power, Cathcart; samples were obtained at the place of work or G.P. surgery.
4.2.2 ESSENTIAL HYPERTENSIVE AND TYPE 2 DIABETIC SUBJECTS
Blood samples were obtained from patients with (untreated) essential 
hypertension (n=17) and type 2 diabetes mellitus (n=17) attending outpatient clinics 
at the Western Infirmary. Hypertensive and diabetic patients were age and sex 
matched with normotensive volunteers from the staff of The Department of 
Medicine and Therapeutics, Western Infirmary.
All the studies took place in the morning after a 12 hour fast. Blood pressure 
was measured after 5 min in sitting position with a Hawksley random zero 
sphygmomanometer. Venous blood was used for routine haematological and 
biochemical profiles, blood glucose, plasma lipid and lipoprotein profiles, in addition 
to measurement of either platelet Na+/H+ exchange (as previously described in 
chapter 1; 22Na method) and platelet membrane microviscosity or platelet [Ca+]i (as 
previously described in chapter 1; Quin-2 method).
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4.2.3 PLATELET MEMBRANE MICROVISCOSITY
The platelets used for investigation of membrane microviscosity were 
prepared from the same blood sample as that used for Na+/H+ exchange 
measurement. Membrane microviscosity was measured as fluorescence 
anisotropy, (inversely related to membrane fluidity), of the fluorophore 
trimethylammonium diphenylhexatriene (TMA-DPH) using a computer controlled 
spectrofluorometer (Perkin Elmer LS-50B). Platelets suspended in platelet buffer 
(pH 7.3) were incubated with 5nmol/l TMA-DPH at 37°C for 10 minutes. 
Fluorescence intensity (I) was measured at excitation and emission wavelengths 
360nm and 430nm respectively (slits 5nm). Anisotropy was calculated according to 
the equations 
A =(lw-G IVh)/(lw+2Glvh)
G —lvh^ lhh
where v = vertical excitation orientation, 
h = horizontal excitation orientation,
G = correction factor for optical system.
4.2.4 PLASMA LIPID AND LIPOPROTEIN PROFILE ANALYSIS
Plasma lipids (total cholesterol and triglycerides), lipoproteins (VLDL, LDL, 
HDL, HDL2l and HDL3) and apolipoproteins (Al and B) were measured using 
standard lipid research clinic methodology [336]. Apo E phenotype was determined 
by isoelectric focusing of plasma as previously described [337]. All lipid and
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lipoprotein analyses were performed by Muriel Caslake, Department of Pathological 
Biochemistry, Royal Infirmary, Glasgow.
4.2.5 STATISTICAL ANALYSIS
The data were analysed using Mann-Whitney U-tests since a number of the 
variables were not normally distributed (ie. triglycerides, VLDL, HDL, HDL2, Apo Al, 
Lp(a), Vmax and AVP-stimulated [Ca2+]j ± EGTA). Values are expressed as 
means±SEM with 95% confidence intervals. Where applicable, medians are 
included in brackets. The influence of Apo E phenotype on plasma lipid profiles and 
platelet cation transport was analysed using the Kruskal-Wallis test (nonparametric 
multivariate test). Analyses were performed using single and multiple linear 
regression. Variables included in multiple regression models were identified by best 
subset regression. Variables, which were not normally distributed were normalized 
by log™ transformation. Correlation coefficients (r values) were calculated by the 
Spearman rank method. P values of less than 0.05 were regarded as statistically 
significant.
For clarity, correlation tables are included in appendix rather than results 
section.
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Table 4.1 Clinical details of normotensive subjects. Values are mean±SEM.
p<0.05,**p<0.01,***p<0.005.
Male Female 95% Confidence
(n=77) (n=47) Interval
Age (years) 39±1 36±2 (-0.8,6.8)
Height (cm) 178±1 16311"“ (12.57,17.34)
Weight (Kg) 79.5±1.2 66.511.9”* (10.901,21.403)
Systolic BP. (mmHg) 118±1 11712 (-2.8,5.0)
Diastolic BP. (mmHg) 76.5±1.0 74.011.3 (2.664,10.666)
Alcohol (units/week) 14±2
_ . ***
711 (-2.00,8.00)
Smokers 7/77 8/47
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Table 4.2 Plasma lipid profiles of normotensive subjects. Values are mean±SEM.
* p<0.05, “ p<0.01, “* p<0.001.
Male (n=77) (Female n=47) 95% Cl
Cholesterol (mmol/I) 5.28±0.15 4.99±0.15 (-0.18,0.78)
Triglyceride (mmol/l) 1.16±0.07 (1.04) 0.94±0.08 (0.77)“ (-0.39,-0.06)
VLDL (mmol/l) 0.60±0.03 (0.55) 0.47±0.04 (0.41)*“ (-0.22,-0.04)
LDL (mmol/l) 3.34±0.13 3.11±0.14 (-0.65,0.18)
HDL (mmol/l) 1.32±0.05 (1.25) 1.45±0.05 (1.49)* (0.05,0.31)
Cholesterol: HDL ratio 4.2±0.2 (3.99) 3.7±0.2 (3.25)*“ (0.23,1.03)
HDL2 (mg/100ml) 52.4±4.1 (47.0) 88.7±7.4 (85.0)*“ (19.0,47.0)
HDL3 (mg/100ml) 278±45 267±10 (-2.0,55.9)
HDI2:HDL3 ratio 0.27±0.03 (0.20) 0.36±0.04 (0.26)“ (-0.14,-0.02)
Apo Al (g/l) 1.22±0.02 (1.22) 1.29±0.05 (1.23) (-0.11,0.05)
Apo B (g/l) 0.96±0.04 0.83±0.04* (-0.25,-0.03)
Lp(a) (mg/100ml) 34.3±5.7 (11.0) 32.5±8.7 (7.0) (-8.00,2.00)
Apo E phenotype 2/2 3/2 3/3 4/2 4/3 4/4
n (M:F)= (1:0) (6:2) (38:30) (21:10) (2:1) (2:0)
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Table 4.5 Characteristics of hypertensive patients and normal age/sex matched
control subjects. Values are meantSEM. * p<0.05.
Hypertensive Control 95%
Subjects Subjects Confidence
(n=17) (n=14) Interval
Age (years) 42±3 40±3 (-8.0,10.0)
Systolic BP. (mmHg) 160±6 125±5* (18.0,50.0)
Diastolic BP. (mmHg) 103±3 77±4* (15.0,37.0)
Microviscosity 0.342±0.015 0.317±0.009 (-0.018,0.054)
Cholesterol (mmol/l) 5.56±0.32 5.23±0.30 (-1.25,0.71)
Triglyceride (mmol/l) 1.43±0.19 (1.13) 1.26±0.26 (0.96) (-0.26,0.83)
VLDL (mmol/l) 0.74±0.10(0.75) 0.54±0.09 (0.50) (-0.03,0.45)
LDL (mmol/l) 3.35±0.22 3.51±0.31 (-1.05,0.62)
HDL (mmol/l) 1.29±0.09 (1.29) 1.26±0.10(1.24) (-0.28,0.29)
Cholesterol:HDL ratio 4.37±0.32 (4.10) 4.57±0.45 (4.19) (-1.04,0.87)
HDL2 (mg/100ml) 57.5±14.7 (44.0) 60.5±15.3 (44.0) (-30.0,23.0)
HDL3 (mg/100ml) 279.7±15.2 229.4±17.5 (-3.0,107.0)
HDL2:HDL3 ratio 0.21±0.05 (0.14) 0.29±0.09 (0.19) (-0.15,0.06)
Apo Al (g/l) 1.23±0.06 (1.20) 1.19±0.07 (1.22) (-0.15,0.23)
Apo B (g/l) 1.06±0.09 0.88±0.07 (-0.08,0.43)
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Table 4.6 Characteristics of diabetic patients and normal age/sex matched control
subjects. Values are mmean±SEM. * p<0.05, ** p<0.01.
Diabetic Control 95%
Subjects Subjects Confidence
(n=17) (n=11) Interval
Age (years) 53±3 51 ±3 (3.0,11.0)
Systolic BP. (mmHg) 152 ±5 130±5** (7.9,39.0)
Diastolic BP. (mmHg) 93±3 82±4* (2.0,18.0)
Microviscosity 0.305±0.010 0.304±0.009 (-0.036,0.029)
Cholesterol (mmol/l) 5.54±0.21 5.49±0.26 (-0.82,0.68)
Triglyceride (mmol/l) 2.16±0.22 (1.93) 1.29±0.18 (1.11)* (0.18,1.52)
VLDL (mmol/l) 0.92±0.11 (0.89) 0.57±0.09 (0.51)* (0.01,0.72)
LDL (mmol/l) 3.45±0.17 3.67±0.21 (-0.85,0.34)
HDL (mmol/l) 1.21±0.09 (1.14) 1.31±0.14 (1.21) (-0.50,0.24)
Cholesterol:HDL ratio 4.86±0.32 (5.04) 4.82±0.55 (4.42) (-1.32,1.45)
HDL2 (mg/100ml) 30.1 ±5.1(26.0) 72.5±20.9 (56.0) (-48.0,-0.01)
HDL3 (mg/100ml) 258.1±17.3 210.1±15.3 (-7.01,97.9)
HDL2:HDL3 ratio 0.11 ±0.02 (0.10) 0.37±0.13 (0.22)** (-0.18,-0.04)
Apo Al (g/l) 1.25±0.06 (1.22) 1.27±0.09 (1.24) (-0.24,0.19)
Apo B (g/l) 1.21 ±0.08 0.987±0.06 (-0.00,0.44)
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4.3 RESULTS
4.3.1 NORMOTENSIVE SUBJECTS
Clinical details and plasma lipid values for male and female normotensive 
subjects are given in Tables 4.1 and 4.2. Significant differences between sexes 
were obtained for height (p<0.0001), weight (p<0.0001) and alcohol consumption 
(p<0.05). Significant differences between the sexes were also obtained for 
triglycerides (p<0.05), VLDL (p<0.02), HDL2 (p=0.0001) and Apo B (p<0.05). Of the 
subjects, 60% were apo E phenotype E3/E3, 28% were phenotype E4/E3 and the 
remaining four phenotypes (ie E2/E2, E3/E2, E4/E2 and E4/E4) represented 1%, 
6%, 3% and 2% of the subject population respectively.
No significant differences between sexes were observed for Km (49.7±2.4 
mmol/l, male v 51.2±2.4 mmol/l, female) or Vmax (325.8±28.2 v 338.5±54.2 
pmol/106cell/min) of Na+/H+ exchange in normotensive subjects. Results of the 
measurement of intraplatelet [Ca2+]i in the presence and absence of AVP ± EGTA 
for male and female subjects are illustrated in Figure 4.1. No significant differences 
were observed between sexes for basal [Ca2+]j (88.4±5.4 v 88.0±5.0 nmol/l) and 
AVP-stimulated [Ca2+]j in the presence of EGTA (149.3±9.8 v 136.4±9.1 nmol/l). 
AVP-stimulated [Ca2+]s (in the absence of EGTA) was higher (but not significantly) in 
females subjects compared with males (1011 ±182 v 670±69 nmol/l).
The results of single linear regression analysis between platelet Na+/H+ 
exchange kinetics, plasma lipids, blood pressure and age are given in Table A1 of 
appendix. A significant positive correlation was observed between Vmax of Na7H+ 
exchange and the ratio of cholesterol:HDL (r=0.376, p=0.014, Figure 4.2(a)) and a
162
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Figure 4.1 Intraplatelet [Ca2+]j in male and female normotensive subjects. Results 
are mean±SEM.
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negative correlation between Vmax and HDL (r=-0.364, p=0.018, Figure 4.2(b)) in 
male subjects but not in males. Vmax in male subjects was also negatively 
correlated with systolic blood pressure (r=-0.330, p=0.031, Figure 4.3). No other 
significant correlations were identified, by single linear regression, between plasma 
lipids, blood pressure or age and Na+/H+ exchange kinetics for males, females or 
the whole group.
Multiple regression analysis was performed to confirm the results of single 
linear regression. Variables included in the multiple regression model, identified by 
best subset regression as those having greatest influence on Vmax in male 
subjects, were systolic blood pressure, triglycerides, VLDL and cholesterol:HDL 
ratio (Table A7 of appendix). Only the effect of systolic blood pressure on Vmax was 
still evident (p=0.032) after adjusting for the effect of the other variables. Together, 
the pedictor variables accounted for only 33.2% (p=0.033) of the observed variance 
in Vmax. In female subjects the best subset model for influence on Vmax included 
systolic blood pressure, triglycerides, VLDL, HDL3, Apo B and cholesterol:HDL ratio 
(Table A7 of appendix). Together these predictor variables accounted for 69.4% of 
the variance in Vmax (p=0.020), with Apo B (p=0.001), cholesterol:HDL ratio 
(p=0.003), and VLDL (p=0.012) showing significant influence. Multiple regression 
for Km in males and females revealed no significant correlations.
The results of single linear regression between platelet calcium metabolism 
plasma lipids, blood pressure and age are given in Table A2 of appendix. There 
was a general lack of correlation between [Ca2+1 and the lipid parameters in males
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Figure 4.2 Vmax of platelet Na+/H+ exchange (log10 scale) against (a) cholesterol 
:HDL ratio (logio scale) and (b) HDL (logi0 scale) in male (•) and female (o) 
normotensive subjects. Correlation coefficients and p values are for male subjects 
only.
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Figure 4.3 Vmax of platelet Na+/H+ exchange (logi0 scale) against systolic blood 
pressure in male (•) and female (o) normotensive subjects. Correlation coefficient 
and p value are for males only.
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and females, with one exception; AVP-stimulated [Ca2+]j + EGTA (ie. calcium 
release from intracellular stores) correlated positively with Apo B concentration 
(r=0.439, p=0.036) in female subjects (Figure 4.4). Significant positive correlations 
were observed between age and [Ca2+]j (both basal and AVP-stimulated ± EGTA) in 
female subjects only (Figure 4.5).
In females the best subset regression model associated with variation in 
intraplatelet Ca2+ metabolism indicated that of age, triglycerides, VLDL, Apo Al, Apo 
B and systolic blood pressure are important, see Table A7 (of appendix). These 
variables accounted for 74.6% of variance in basal [Ca2+]j (p=0.0001) and 75.9% of 
variance in AVP-stimulated [Ca2+]i + EGTA (p=0.001). Of the variables in this 
model, triglycerides, Apo Al, Apo B and systolic blood pressure were significantly 
correlated with [Ca2+]j (p<0.05). Multiple regression analysis of [Ca2+]i metabolism in 
males revealed no significant correlations.
Normotensive subjects were subdivided into their respective Apo E 
phenotypes for analysis of the influence of Apo E polymorphism on the relationships 
between plasma lipids and platelet cation transport. Plasma lipid profiles for each of 
the Apo E phenotypes are given in Table 4.3. Multivariate comparisons, using 
Kruskal-Wallis (non-parametric) analysis identified significant differences in levels of 
cholesterol (p=0.04) and LDL (p=0.019) between phenotypes (ie. lipid levels were 
significantly greater in subjects with the Apo E4 isoform compared with Apo E2). 
Clinical details and results of platelet cation transport measurements for each of the 
Apo E phenotypes are given in Table 4.4. Multivariate comparisons identified only 
basal [Ca2+]j as significantly different between Apo E phenotypes
167
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Figure 4.4 AVP-stimulated [Ca2+]i +EGTA (log™ scale) against Apolipoprotein B in 
female (•) and male (o) normotensive subjects. Correlation coefficient and p value 
are for females only.
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(p=0.039) (ie. platelet [Ca2+]i was significantly lower in subjects with isoform Apo 
E4). Considering the very low subject numbers in certain Apo E phenotype 
subgroups, especially those with isoform Apo E2, we concentrated on just one 
aspect of the differential effects of Apo E polymorphism ie. whether the presence of 
Apo E4 phenotype was associated with pro-aggregatory changes in platelet cation 
transport. Accordingly, we compared plasma lipid profiles, cation transport and 
single regression analysis of subjects bearing the Apo E4/E3 isoform with Apo 
E3/E3 subjects.
Analysis by Mann-Whitney U-test identified significant elevations of both Km 
of Na+/H+ exchange and basal [Ca2+]j in Apo E3/E3 subjects compared with Apo 
E4/E3 subjects (Table 4.4). No significant differences in lipid profiles were 
observed. Correlations between Na+/H+ exchanger kinetics, plasma lipids and blood 
pressure in normotensive subjects bearing either Apo E3/E3 or Apo E4/E3 are 
given in Table A3 of appendix. Vmax of Na+/H+ exchange in subjects with 
phenotype E4/E3 was positively correlated with HDL3 (r=0.523, p=0.046) (Figure 
4.6 (a)) and Lp(a) (r=0.532, p=0.050) (Figure 4.6(b)). No significant correlation were 
observed for subjects with phenotype E3/E3. Correlations between platelet [Ca2+]j, 
plasma lipids and blood pressure in normotensive subjects bearing either Apo 
E3/E3 or Apo E4/E3 are given in Table A4 of appendix. Basal [Ca2+]j was negatively 
correlated with HDL2 (r=-0.368, p=0.042) (Figure 4.7 (a)) and AVP-stimulated [Ca2+]j 
was negatively correlated with HDL2:HDL3 ratio (r=-0.387, p=0.032) (Figure 4.7(b)) 
in subjects with phenotype E3/E3. No significant correlations were observed
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between platelet Ca2+ metabolism and plasma lipid concentration in subjects 
bearing phenotype Apo E4/E3.
4.3.2 Na+/H+ EXCHANGE AND MEMBRANE MICROVISCOSITY IN ESSENTIAL 
HYPERTENSIVE SUBJECTS
Clinical details, lipid profiles and membrane microviscosity results for 
hypertensive patients and normal controls are given in Table 4.5. As expected, 
systolic and diastolic blood pressure were significantly raised in essential 
hypertensive subjects compared with controls (p<0 . 0 0 1  and p=0 . 0 0 0 1  respectively). 
Na+/H+ exchange kinetics results for hypertensive subjects and controls are 
illustrated in Figure 4.8. Vmax of Na+/H+ exchange was slightly raised (but did not 
reach statistical significance) in essential hypertensive subjects compared with 
controls (407±49 v 283±37 pmol/106cells/min). Km was unchanged (47.5±3.0 v 
45.2±4.4 mmol/l). The Hill coefficient for extracellular Na+ was not significantly 
different between hypertensive and control subjects (i.e. slopes =1.17 and 1.18 
respectively) (Figure 4.9).
Correlations between Na+/H+ exchange kinetics, platelet membrane 
microviscosity, plasma lipids, blood pressure and age in hypertensive and controls 
are given in Table A5 of appendix. Km of Na+/H+ exchange was inversely correlated 
with HDL2 (r=-0.550, p=0.034) (Figure 4.10(a)) and positively correlated with Apo B 
(r=0.591, p=0.016) (Figure 4.10(b)) in hypertensive subjects. Best subsets 
regression identified models containing systolic blood pressure, HDL3 and Apo B 
which accounted for 51% of variation in Vmax (p = 0.009), and systolic blood
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pressure, triglycerides, VLDL, HDL2 and microviscosity which accounted for 98.1% 
of variation in Km (p = 0.013) Table A8  (of appendix). Membrane microviscosity did 
not correlate significantly (single or multiple regression) with either Km or Vmax of 
Na+/H+ exchange or lipids in hypertensives and control subjects.
4.3.3 Na+/H+ EXCHANGE KINETICS AND MEMBRANE MICROVISCOSITY IN 
TYPE 2  DIABETIC SUBJECTS.
Clinical details, lipid profiles and membrane microviscosity results for type 2 
diabetic patients and normal controls are given in Table 4.6. Plasma triglyceride and 
VLDL concentrations were significantly higher in diabetic patients compared with 
controls (2.2±0.2 v 1.3±0.2 mmol/l (p<0.02) and 0.92±0.11 v 0.57±0.1 mmol/l 
(p<0.05) respectively). Systolic and diastolic blood pressure were also significantly 
raised in diabetic subjects (152±5 v 130±5 mmHg (p<0.005) and 93±3 v 82±4 
mmHg (p<0.02) respectively). Na+/H+ exchanger kinetics results for diabetic 
subjects and controls are illustrated in Figure 4.11. Neither Km or Vmax were 
significantly different between diabetic and control subjects (41.7±3.2 v 50.9±5.3 
mmol/l and 372±56 v 348±57 pmol/106cell/min respectively).
Correlations between Na+/H+ exchange kinetics, platelet membrane 
microviscosity, plasma lipids, blood pressure and age in diabetic and control 
subjects are given in Table A6  of appendix. Plasma triglycerides and VLDL were 
both negatively correlated with Vmax of Na+/H+ exchange (r=-0.546, p=0.024 and 
r=-0.560, p=0.019) (Figures 4.12(a) & (b) respectively) in diabetic patients. 
Membrane microviscosity was inversely related with plasma cholesterol (r=-0.513,
177
p=0.042) (Figure 4.12(a)), cholesterol:HDL ratio (r=-0.537, p=0.032) (Figure 
4.13(b)) and LDL (r=-0.520, p=0.039) (Figure 4.14) in diabetic subjects and 
negatively correlated with Apo Al (r=-0.735, p=0.010) (Figure 4.15) in controls. 
Neither Km or Vmax of Na+/H+ exchange were significantly correlated with 
membrane microviscosity in diabetics or control subjects using single linear 
regression. Furthermore, multiple regression was unable to identify models which 
accounted for significant variation in either Km or Vmax in diabetic subjects. Best 
subset regression did however identify a combination of cholesterol, triglycerides, 
LDL, HDL, HDL2 and HDL3 as having greatest significant influence on variation in 
platelet membrane microviscosity in diabetic patients (accounting for 98.1% 
variation, p = 0.014) Table A9 (of appendix).
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4.4 DISCUSSION
4.4.1 RELATIONSHIPS BETWEEN PLASMA LIPIDS AND PLATELET CATION 
TRANSPORT IN NORMOTENSIVE SUBJECTS.
In common with many other studies, the present analysis indicated a number 
of differences in lipid profiles between males and females. One might expect, 
therefore, that if plasma lipids were to influence membrane function and hence 
cation exchange properties of platelets, key sex-dependent differences in calcium 
metabolism and Na+/H+ exchange characteristics might be observed. There were 
no such differences. However, as discussed more fully below, many of the lipid 
factors which differ between the sexes (ie. triglycerides, HDL, VLDL, Apo B etc) are 
the ones which account for variations in cation transport when analysed by single 
and multiple regression in sex-dependent fashion. In other words, net differences in 
platelet metabolism between males and females may be obscured by sex-specific 
control of plasma lipids.
i) [Ca2+]j METABOLISM: Mean values for basal platelet [Ca2+]j in the present 
study are broadly similar to those observed for normotensive subjects in previous 
studies using the fluorescent probe Quin 2  [181, 200, 267, 268], (and also similar to 
a number of studies using Fura 2 [265, 268, 338, 339]). The magnitude of the 
[Ca2+]i rise in response to AVP, in the presence of 1 mmol/l extracellular Ca2+ was 
also similar to that in other studies [181, 2 0 0 ] with no evidence of quenching due to 
the buffering capacity of Quin 2. Blood pressure and basal [Ca2+]i were not 
correlated. Again this is in agreement with a number of other investigators [200,
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265, 340, 341], but at variance with the remarkably high correlations originally 
observed by Erne etal. (1984) [6 ] in both normotensive and hypertensive subjects.
When subjected to single linear regression analysis [Ca2+]s did not correlate 
with any of the lipids measured in the normotensive subject group as a whole or 
when subgrouped by sex. This is in agreement with previous findings [239] although 
Le Quan-Sang et al. did note positive correlations with plasma triglyceride 
concentrations and cholesterol: HDL ratios when platelets from 
hypercholesterolaemic patients were incubated in essentially calcium free medium 
(but not in medium containing 1mM Ca2+) [342].
Our previous in vitro studies (see Chapter 3) have demonstrated differential 
effects of HDL2 and HDL3 on AVP-stimulated [Ca2+]j. In vivo, neither HDL2i HDL3 or 
the ratio of HDL2 :HDL3 were significantly correlated with AVP-stimulated [Ca2+]j, 
indicating that incubation conditions ex vivo (ie. the absence of circulating 
cholesterol and lipoproteins) influence individual lipoprotein-induced effects on 
cation transport.
One of the most interesting findings in the present investigation was the 
relationship between age and calcium metabolism in female subjects. Basal and 
AVP-stimulated (±EGTA) [Ca2+]j were positively correlated with age. The fact that all 
three indices were correlated perhaps indicates the involvement of a process which 
is independent of Ca2+ uptake across the membrane or the stimulated release of 
Ca2+ from intracellular stores. For example, if the total free and bound calcium 
content of platelets varied with age in females, this might affect all calcium 
variables. The underlying cause of this age-dependent process is unclear. In
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previous in vitro studies (chapter 3), platelets equilibrated with HDL subfractions did 
appear to accumulate less radioactive calcium. However, neither HDL2 nor HDL3 
plasma concentrations correlated with basal calcium metabolism in vivo. Another 
possible candidate is Apo B which does vary as a function of age and does appear 
to correlate with calcium metabolism. Unfortunately, there are inconsistencies which 
undermine this theory. Firstly, Apo B varies as a function of age in both males and 
females but, in the present study, only females show a relationship between age 
and intraplatelet calcium metabolism. (Others, however, have shown a relationship 
between subject age and intraplatelet calcium levels which are not sex-dependent 
[343]). Secondly, whereas age affects all aspects of of calcium metabolism, Apo B 
only correlates with AVP-stimulated [Ca2+]i in the presence of EGTA and not with 
AVP alone or with baseline values.
Assuming that the age/calcium relationship is sex-dependent, an important 
factor may be the female sex hormone oestrogen. Oestrogen is known to to be a 
potent factor in whole body calcium turnover and has profound effects particularly 
on bone metabolism [344]. In addition oestrogen offers protection against 
cardiovascular disease by reducing vascular tone [345, 346]. The effects on smooth 
muscle contractility have been attributed to altered (ie. reduced) Ca2+ mobilization 
and flux [347]. In the present study, plasma oestrogen concentrations were not 
measured but changes might be predicted at extremes of the age range. For 
example, oestrogen levels will be depeleted in older, post-menopausal women and 
could be increased in younger women taking oral contraceptive pills. Further 
analysis of the present data to exclude predictable influences of oestrogen proved
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inconclusive. Ommitting subjects > 50 years (n=4) did not affect the relationship 
between calcium metabolism and age. However, the relationship was no longer 
significant when pill users (29±4 years, n=10) were excluded. Although one might 
consider that too few data remained after excluding pill users to make a definitive 
conclusion, it is noteworthy that the relationship between Apo B and calcium was 
still significant in non-pill users.
Bearing in mind that the mechanism of oestrogen action, like all steroid 
hormones, involves binding to receptors which are themselves transcription factors 
in nuclear DNA synthesis, any action of oestrogens on platelets (which lack a 
nucleus) must be secondary. If, as univariate analysis suggests, there is no single 
lipoprotein fraction which correlates with all aspects of platelet calcium metabolism, 
it is possible that oestrogens produce a pattern of changes which are all 
contributory. Multiple regression analysis supports this hypothesis. A number of 
factors, notably those that differ from males (triglycerides, VLDL, Apo B) account for 
variations in intraplatelet calcium metabolism. In contrast, uni- and multivariate 
analysis indicate that none of the measured variables are significantly involved in 
determining calcim metabolism in males.
ii) Na+/H+ EXCHANGE KINETICS: In a recent review [310], Siffert and 
Dusing suggested that factors which influence sodium proton exchange could be 
categorised as "intrinsic" (genetic modification), "intracellular" or "systemic". 
Obviously the effects of lipoproteins are likely to be "systemic". However, the 
existence of specific calmodulin binding sites in the cytoplasmic domain of NHE-1
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provide evidence of a link between the "intracellular" factor, Ca2+, and Na+/H+ 
exchange. Intracellular ionized Ca2+ by binding to calmodulin, can influence the 
activations of Na+/H+ exchange independent of activation of protein kinase [70, 
310]. It follows therefore that factors which correlate with differences in calcium 
metabolism will also secondarily affect Na+/H+ exchange. To some extent, this 
theory is supported by the present results. In females, multiple regression analysis 
indicated that three lipid components which affected calcium metabolism, 
triglycerides, VLDL and Apo B, also contribute to the variation in Vmax values. In 
males, multivariate analysis indicated that none of these lipid variables significantly 
affected Vmax just as none affected calcium metabolism.
A second factor, which to some extent is common to males and females, 
involves the possible negative influence of HDL. Single linear regression analysis in 
males indicated a negative relationship between Vmax and HDL and a positive 
relationship between Vmax and cholesterol:HDL ratio. In females, multiple 
regression analysis (but not single linear regression) suggested that Vmax was 
influenced by cholesterol:HDL ratio. It would appear that in both males and females, 
the effect of cholesterol:HDL on Na+/H+ exchange is not secondary to effects on 
calcium metabolism, since [Ca2+]j was not related to this lipid factor.
Although platelets lack nuclei, they retain a limited capacity to synthesize 
cholesterol via the mevalonate pathway [348, 349]. It has been suggested that 
mevalonate in addition to being an intermediate in cholesterol biosynthesis, is also 
necessary for glycoprotein synthesis [350, 351]. Since Na+/H+ exchanger is a 
glycoprotein, it could be argued that plasma cholesterol, by down regulating intra­
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platelet mevalonate, could limit Vmax values. Indeed, De Figueiredo et al have 
demonstrated, in vitro, that enrichment of lymphocyte membranes with cholesterol 
significantly reduces Vmax of Na+/H+ exchange [352]. Furthermore, an in vivo study 
by Ng et al demonstrated a strong negative correlation between lymphoblast Na7H+ 
exchanger activity and total cholesterol and LDL-cholesterol levels [131]. In 
platelets, however, this down-regulatory effect of cholesterol would depend on 
whether platelets retain any ability to synthesize de novo protein.
In the present study cholesterol itself was not significantly correlated with 
Na+/H+ exchange kinetics. However, cholesterol:HDL ratio may may provide a 
better marker of net cholesterol transport which might reflect cholesterol content of 
the plasma membrane and, hence, platelet reactivity. Platelets incubated for 
several hours with cholesterol-rich liposomes to enhance membrane cholesterol 
content show activiation of Na+/H+ exchange [353]. It has been suggested that this 
process is caused by activation of phospholipase A2 which leads to an 
accumulation of intra-platelet protons which necessitates activation of Na+/H+ 
exchange [353]. In vivo, in patients with hypercholesterolaemia (high cholesterol:low 
HDL plasma ratios), increased platelet membrane cholesterol leading to increased 
Na+/H+ exchange may explain hypersensitivity to aggregatory factors. Our previous 
in vitro results with HDL are perhaps contradictory. HDL3, but not HDL2, caused an 
increase in Vmax rather than than a decrease as might be expected by reverse 
cholesterol transport. However, the process of reverse cholesterol involves the 
esterification of cholesterol by the enzyme LCAT [354], a ubiquitous plasma 
enzyme in vivo which was not present in in vitro tests. Under these circumstances,
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the relatively high free cholesterol content of HDL3 compared with HDL2 may be the 
cause of the increase in Vmax of Na+/H+ exchange.
Since our in vitro studies (see Chapter 3) demonstrated differential effects of 
HDL2 and HDL3 on Vmax of Na+/H+ exchange, then it is possible that the 
association between HDL and Vmax, observed in vivo, is due to the relative 
quantities of circulating HDL2 and HDL3. However, individually neither HDL2 nor 
HDL3 correlated significantly with Vmax of Na+/H+ exchange in either males or 
females. Furthermore, we were unable to demonstrate a significant relationship 
between the ratio of HDL2 :HDL3 and Vmax of Na+/H+ exchange, therefore the 
relative quantities of circulating HDL subfractions do not appear to influence the 
relationship observed between HDL and Vmax in normotensive subjects.
Aside from plasma lipid factors, systolic blood pressure was also correlated 
with Vmax in males (single and multiple regression) and females (multiple 
regression only). In both cases the relationship was negative. It is difficult to account 
for this negative relationship considering that many of the circulating factors which 
tonically maintain blood pressure under normal control conditions are also known to 
activate exchanger activity in both platelets and vascular smooth muscle cells.
In conclusion it would appear that variation in platelet Na+/H+ exchange 
activity is due to the actions of more than one variable. Furthermore, factors which 
alter the cholesterol content of membranes appear to influence exchanger activity 
by calcium dependent and independent means.
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4.4.2 INFLUENCE OF APOLIPOPROTEIN E PHENOTYPE ON RELATIONSHIPS 
BETWEEN PLASMA LIPIDS AND PLATELET CATION TRANSPORT: Apo E 
polymorphism has previously been shown to have an impact on plasma lipid levels 
in the population [141]. In subjects bearing the E2 allele (i.e. phenotypes E2/E2, 
E3/E2), Apo E fails to bind normally to lipoprotein receptors resulting in reduced 
conversion of VLDL to LDL and decreased clearance of VLDL and chylomicron 
remnants from the circulation [141]. This defect is the result of a single amino acid 
substitution (cysteine for arginine) in the amino sequence of Apo E [142]. In 
individuals bearing the E4 allele (i.e. phenotypes E4/E4, E4/E3) Apo E4, on the 
other hand, enhances VLDL conversion to LDL and is thus associated with 
elevated circulating levels of LDL and cholesterol [141]. Again this defect is the 
result of a single amino acid substitution. Epidemiologic studies have demonstrated 
increased frequency of the E4 allele in subjects who suffered coronary artery 
disease (CAD) and myocardial infarction (Ml) [355, 356], whereas Apo E2 is 
associated with type III hyperlipoproteinemia and premature atherosclerosis [149]. 
In the present context, Apo E phenotype may influence platelet function directly by 
altering intraplatelet cholesterol metabolism or secondarily because of associated 
changes in plasma lipoprotein profiles.
The percentage distribution of the six phenotypes, in the present study, was 
consistent with earlier findings by Schaefer et al [357]. Our results also confirm 
previous studies associating Apo E4 with elevated levels of cholesterol and LDL, 
but cannot confirm the influence of Apo E2 on VLDL because of insufficient data. 
Apo E2 is the least common of the alleic variants and our data had too few Apo E2
191
representatives to draw significant conclusions. However, we were able to analyse 
the influence of the Apo E4 isoform on platelet cation transport by comparing 
calcium metabolism and Na+/H+ exchange kinetics in Apo E3/E3 and Apo E4/E3.
Differences in plasma concentrations of the various lipid and lipoprotein 
components did not differ between E3/E3 and E4/E3 subjects. It would appear 
unlikely therefore that quantitative differences in plasma lipoprotein concentrations 
per se are the the explanation of reduced basal [Ca2+] and reduced Km values for 
Na+/H+ exchange in E4/E3 subjects. It is possible, however, that Apo E phenotype 
might affect the mechanisms of cholesterol exchange between lipoproteins and 
platelets which secondarily affect cation transport.
Bearing in mind previous in vitro studies indicating that HDL2 is associated 
with decreased basal [Ca2+]j whereas HDL3 is associated with positive increases in 
Vmax, it is interesting that, in vivo, these associations are the ones which are 
particularly affected by E4/E3 phenotype. Since HDL2 is derived from HDL3, it is 
tempting to speculate that Apo E phenotype subtly alters, in a reciprocal manner, 
the properties of HDL by modifying the interconversion of HDL subtypes. HDL3 and 
HDL2 differ in at least two respects: (i) HDL3 is a better substrate for cholesterol 
esterification by plasma LCAT [145, 358]; (ii) HDL2 is characterized by a higher Apo 
E content [136, 214, 359]. If one were to argue that the incorporation of Apo E and 
the esterification of cholesterol in the circulation are linked in some way, then Apo E 
phenotype could modify these processes and hence simultaneously affect HDL2 
and HDL3 properties. Thus, Apo E4 phenotype by impairing esterification of HDL3 
cholesterol could enhance the influence that HDL3 has on Na+/H+ exchange activity
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which would explain why the correlation between HDL3 and Vmax is stronger for 
E4/E3 than E3/E3 subjects. Simultaneously, HDL2 particles may differ in Apo E 
content and/or degree of cholesterol esterification in individuals with different Apo E 
phenotypes. Although the mechanism whereby HDL2 affects [Ca2+]j is not known, it 
is not unreasonable to suppose that altered composition of HDL2 will modify its 
effects on calcium metabolism. Thus, if HDL2 formation in E3/E3 individuals is 
relatively more efficient than those with the E4/E3 phenoype then this could explain 
why the relationship between platelet [Ca2+]j and HDL2 is stronger for E3/E3 than 
E4/E3 subjects.
An influence of Lp(a) on Na+/H+ is perhaps explicable because of its affect 
on platelet adhesion and because of the close homology of one of its constituent 
proteins, apoprotein a, with plasminogen [333, 335, 360]. It is less easy to reconcile 
differences between Apo E phenotype. However, bearing in mind that HDL3 has 
been shown to potentiate aggregatory reponses to a number of agonists, one might 
suggest that the association between Lp(a) and Na+/H+ exchanger actions are only 
apparent when the potentiating effects of HDL3 are also prominent ie. in E4/E3 not 
E3/E3 subjects.
In summary, platelet cation transport is differentially influenced by Apo E 
phenotype. Individuals with the Apo E4 allele carry a greater cardiovascular risk 
because of an adverse plasma lipoprotein profile. Also the inhibitory effects of HDL2 
on platelet calcium metabolism are less and the stimulatory effects of HDL3 and 
Lp(a) on Na+/H+ exchange are more prominent in these individuals. It is proposed
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that these cation transport effects are caused by altered cholesterol esterification 
and Apo E content of HDL particles from individuals of different Apo E phenotype.
4.4.3 RELATIONSHIPS BETWEEN PLASMA LIPIDS, PLATELET MEMBRANE 
MICROVISCOSITY AND Na+/H+ EXCHANGE IN HYPERTENSIVE AND TYPE 2 
DIABETIC PATIENTS.
It is known that patients with hypertension often have higher circulating 
insulin concentrations and appear to be resistant to the effects of insulin on plasma 
glucose concentrations [361, 362, 363]. Conversely, patients with diabetes 
demonstrate an approximate twofold greater risk of developing hypertension than 
the non-diabetic population [364]. This overlap of symptoms together with evidence 
that both diabetic and hypertensive patients have a tendency for dyslipidemia and 
abnormal renal function have lead to the suggestion that they share a common 
aetiology [261, 364].
Diabetes and hypertension are often but not invariably linked with 
hyperlipidemia [365, 366, 367] and with abnormal cation transport in red blood cells 
[314, 364]. From the working hypothesis that plasma lipids, by affecting cell 
membrane composition and function, influence cation transport functions, one 
would predict that platelet microviscosity and Na+/H+ exchange should also be 
altered in hyperlipidemic states. In the present studies, however, plasma cholesterol 
concentrations in both control and patient groups were at the upper end of the 
normal range and did not differ significantly. Not surpisingly, therefore, membrane 
microviscosity (which increases as membrane cholesterol: phospholipid ratio
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increases) and Na+/H+ exchange characteristics of platelets from hypertension and 
diabetic patients were not significantly different from controls. However, other 
plasma lipid variables e.g. triglycerides, VLDL, HDL2 :HDL3 ratio, were affected. 
Multivariate regression analysis indicated that, in patients, the plasma lipid profile 
and platelet metabolism of lipids may have some bearing on the control of cation 
transport. These associations and possible linking mechanisms are discussed 
below in relation to the pathogenesis of diabetes and hypertension.
i) MEMBRANE MICROVISCOSITY: Numerous studies suggest altered 
membrane microviscosity in blood cells from hypertensive and Type 1 diabetic 
(IDDM) subjects. An increase in membrane microviscosity has been demonstrated 
in platelets [368], polymorphonuclear leucocytes [369] and erythrocytes [329, 370] 
isolated from patients with IDDM. Generally an increase in membrane 
microviscosity has also been reported, for a range of cell types, in essential 
hypertension [128, 130, 371, 372] although contrary results have been reported for 
platelets [373, 374].
Platelet membrane microviscosity, in type 2 diabetics, in the present study, 
was not significantly different to that of age/sex matched controls. Microviscosity 
measurements were made using cationic TMA-DPH which, under our incubation 
conditions (ie. 1 0 min at 37°C), binds at the outer (exofacial) leaflet of the plasma 
membrane. If incubated for longer periods (ie up to 30 minutes) TMA-DPH is able to 
'flip' to the negatively charged cytoplasmic (endofacial) leaflet but does not enter the 
core of the plasma membrane [375]. Our results therefore give no indication of the 
fluidity of the membrane core. A recent study also failed to demonstrate a change in
195
fluidity of the superficial region of leucocyte membranes from NIDDM patients [376]. 
In this previous investigation, core fluidity of NIDDM leucocyte membranes was 
measured using the probe, DPH, and was found to be significantly raised compared 
to than that of control subjects.
In the present study, diabetic subjects had raised plasma triglyceride and 
VLDL concentrations and showed a reduction in HDL2 :HDL3 ratios. These variables 
were also ones which appeared to be important in determining microviscosity and 
Na7H+ exchange characteristics in diabetic subjects. In contrast to what might be 
predicted from in vitro studies showing that membrane enrichment with cholesterol 
increases microviscosity [125, 377], plasma cholesterol, LDL and cholesterol:HDL 
values were all negatively correlated with microviscosity. These negative 
correlations are difficult to interpret, but may reflect altered platelet cholesterol 
metabolism in diabetic subjects. Unlike nucleated cells, platelets have only a limited 
capacity for endogenous cholesterol synthesis [348]. As in other cell types this 
process is negatively regulated by circulating cholesterol levels [349]. It has been 
suggested that platelets lack the conventional LDL receptor which nucleated cells 
use to take up cholesterol [378]. Instead, they possess a novel glycoprotein 
receptor of smaller molecular weight which has an affinity for cholesterol (free as 
opposed to esterified) rather than apolipoprotein B, which is the ligand for the 
conventional LDL receptor [378]. It is possible that sensitivity of the platelet 
membrane receptor for plasma cholesterol is significantly reduced in type 2  diabetic 
patients. Subsequent activation of endogenous cholesterol synthesis, albeit limited 
in platelets, may be sufficient to maintain relatively normal membrane cholesterol
196
levels, and hence membrane microviscosity, despite altered plasma 
cholesterol/membrane cholesterol relationships.
A second difficulty in analysing the determinants of microviscosity is the 
question of why, in diabetic subjects, plasma cholesterol is of overriding importance 
whereas, in control subjects, Apo A1 and not cholesterol is implicated despite the 
fact that plasma cholesterol, LDL and apo A1 levels in the two groups are broadly 
similar. The answer may require us to consider both the supply and the removal of 
cholesterol from the membrane. In diabetic subjects the ratio of HDL2:HDL3 is 
much reduced compared with controls and could reflect an impairment of 
cholesterol esterification. In my analysis of Apo E phenotype (see above) I 
suggested that this might be associated with reduced reverse cholesterol transport. 
If one accepts this hypothesis, it follows that cholesterol content (and hence 
microviscosity) of diabetic platelets will be more dependent on cholesterol supply 
rather than removal whereas microviscosity in control platelets is influenced by 
factors involving both supply and removal of cholesterol.
In the controls for the diabetic study, Apo A1 appears to be particularly 
important in determining microviscosity. This factor also seemed to be of minor 
importance in determining microviscosity of the control group (but not the 
hypertensive group) in the study of hypertensive patients and in cation metabolism 
in the previous analysis of normotensive individuals. One might consider again that 
these observations reflect the availability of free cholesterol for platelet membranes. 
Bearing in mind that Apo A1 activates LCAT, increased Apo A1 will promote 
cholesterol esterification which reduces platelet uptake of cholesterol. Thus the
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inverse relationship between Apo A1 and membrane microviscosity reflects the role 
of Apo A1 in reverse cholesterol transport.
Previous in vivo studies of the influence of plasma lipids on membrane 
microviscosity in normotensive subjects have been conflicting. Carr et al. 
demonstrated a negative correlation between lymphocyte membrane microviscosity 
and triglyceride but not cholesterol [379]. Le Quan Sang et al. found decreased 
microviscosity in platelets of patients with serum cholesterol levels >6 . 2  compared 
with normolipidaemic controls [380]. Malle et al. [381] were unable to show any 
significant relationships between serum lipids and TMA anisotropy whereas Muller 
et al. [382] found a negative association between fluidity and triglyceride in both 
platelet and erythrocyte membranes, but not with cholesterol. Differences in cell 
type (nucleated versus non-nucleated) and subject population may, in part, account 
for these discrepant results.
Platelet membrane microviscosity in hypertensive subjects, in the present 
study, was slightly (but not significantly) raised compared to normotensive subjects. 
Single and multiple regression analysis failed to indicate any one variable or group 
of variables which determined microviscosity. It is possible that multiple factors are 
involved in these patients and that my data are insufficient to indicate which are the 
most important. A recent study by Carr et al. described similar results [383]. A 
significant increase in membrane microviscosity was only observed by Carr et al. in 
patients with a family history of hypertension.
In the present studies, microviscosity had little bearing on Na7H+ exchange. 
This could be interpretted in several ways: (i) Na+/H+ exchange is not affected by
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membrane microviscosity. This seems unlikely given that in vitro manipulations by 
of membrane cholesterol content of leucocytes, red blood cells and platelets have 
been shown to profoundly affect calcium uptake and intracellular pH; (ii) Although 
the means of controlling microviscosity may be different in normotensive and 
hypertensive subjects, the net result was the same. Thus if microviscosity was 
unchanged, cation transport would also be unaffected; (iii) There are other factors, 
independent of micro viscosity (including intrinsic, systemic and intracellular 
regulators) [310] which also affect Na+/H+ exchange. These other factors may 
obscure the influence of microviscosity.
ii) Na+/H+ EXCHANGE: Although Vmax and Km values did not differ 
between groups a number of correlations between these variables and plasma lipid 
measurements were observed. In diabetic patients, triglyceride and VLDL 
concentations, which were markedly elevated, were negeatively correlated with 
Vmax. This suggests that down regulation of exchanger activity has occurred in 
response to chronically increased circulating triglycerides and VLDL. Note that 
blood samples were obtained under fasting conditions (ie no chylomicrons) so that 
the triglyceride content of plasma is endogenous and is mostly associated with 
VLDL. The association between circulating triglyceride concentration and Vmax 
values could be explained in one of three ways. Firstly, that triglycerides directly 
affect protein kinase C activation. Since there is no precedent for this process, even 
in tissues like liver and fat which metabolise triglycerides, this seems unlikely. 
Secondly, it is understood that phospholipids in cell membranes are in a constant 
state of flux (i.e. futile cycling). It is possible, therefore, that high circulating
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triglycerides could affect membrane phospholipid turnover. Diacylglycerol, the 
intracellular activator of protein kinase C and hence Na+/H+ exchange, is derived 
from membrane phospholipids. It follows that triglyceride-induced changes in 
phospholipid pools could explain the negative relationship with platelet Vmax values 
for Na+/H+ exchange. Finally, raised levels of plasma triglycerides, in type 2 
diabetics, suggests poor glycemic control. A recent investigation has shown that 
activity and expression of the Na+/H+ exchanger are significantly reduced in human 
endothelial cells cultured in high glucose [384]. The authors suggest that this 
inhibitory action of glucose is compatible with an effect of non-enzymatic 
glycosylation on a critical binding domain of the Na+/H+ exchanger.
Previous studies of Na+/H+ exchange in red blood cells [274] and platelets 
[270] of hypertensive patients have suggested that Vmax values are distributed 
bimodally whereas normotensive values are best represented by a skewed 
unimodal model. The distribution of Vmax values in the present study are not 
incompatible with this the bimodal hypothesesis but data are too few to draw 
definitive conclusions. Taking the value of 400pmol Na+/106 platelets/min as the 
point separating high and low subgroups, it is interesting that twice as many 
hypertensive as normotensive individuals are in the higher subgroup in the present 
study. The underlying cause of this bimodality is not known. No differences in the 
Na+/H+ exchange gene have been found although immortalised cells from low and 
high subgroups retain their phenotype in culture [303]. Using intracellular pH rather 
than sodium uptake as an index of Na+/H+ exchange, immortalised cells from 
hypertensive individuals had higher Vmax values (without altered expression of
200
exchanger) and higher Km (lower pHo.s) values than those from normotensives. No 
significant differences were noted in the present study perhaps because of different 
incubation conditions. Firstly, the measurements in cell lines were made in the 
presence of a phorbol ester to maximally stimulate protein kinase C to 
phosphorylate the exchanger. Similar treatment of platelets leads to aggregation 
and invalidates measurements of sodium uptake. The present platelet 
measurements will reflect both intrinsic activity differences and, possibly 
secondarily, the degree of influence of activating factors which the platelet has been 
exposed to in vivo. The possible influence of these secondary factors may be seen 
in the associations between Vmax and and various lipoproteins (i.e. HDL3 and Apo 
B in hypertensives, and triglycerides, VLDL, HDL3i Apo B and cholesterol:HDL ratio 
in controls) revealed by multivariate analysis. A second difference between present 
observations and those in cell lines is that, whereas with measurements of pH, the 
counter ion, Na+, is present at a maximally effective concentration, the present 
platelet studies were carried out at pH 6.7. Subsequent, to these platelet studies, it 
has been shown that Vmax was not achieved with pH values greater than 6.0 and 
that this value is shifted even lower in hypertensives. It is likely, therefore, that the 
present study has underestimated Vmax values particularly in hypertensives.
Although Km values for Na+ in the hypertensive group were not significantly 
different, they did correlate with other variables in both normotensive and 
hypertensive groups. It is notable that HDL3 negatively affects Km in normotensive 
controls, whereas HDL2 and HDL2 :HDL3 ratio are negative and ApoB is positive in 
the hypertensive group. Again, it is tempting to speculate that these associations
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relate to the supply and removal of free cholesterol to platelets except that there is 
no clear effect on microviscosity. Also, whereas cholesterol metabolism has been 
linked to turnover of glycoproteins and hence exchanger activity, there is no 
precedent for intrinsic or extrinsic factors affecting sodium affinity for the exchanger. 
Unlike for H+, no allosteric binding site for Na+ has been identified. Thus, whereas 
the Hill coefficient and pH0.s does vary in line with pH activation in lymphoblasts 
[303] and red blood cells [274], the Hill coefficient for sodium uptake is around 1 for 
platelets from both normotensive and hypertensive individuals. I would suggest 
therefore that correlations of Km with HDL2 are indirectly caused by either: (i) the 
influence of some amiloride-insensitive cation exchange process which affects the 
supply of substrate (Na+) (ii) allosteric regulation of H+ activation, under in vitro 
conditions, where intracellular pH is fixed at > 6.7.
In conclusion, Na+/H+ exchange ex vivo in platelets is influenced by a variety 
of lipoprotein factors. Some, but not all changes are associated with altered 
microviscosity which in turn are a function of factors which influence the supply, 
synthesis and removal of cholesterol in platelets. The pattern of associations are 
different for diabetic and hypertensive patients. Both Vmax and Km for sodium 
uptake into platelets appeared to be independently controlled and may be a 
function of intrinsic differences in Na+/H+ exchange characteristics.
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CHAPTER 5
Na+/H+ EXCHANGE AND PLASMA CHOLESTEROL CONCENTRATION IN 
NORMAL PREGNANCY AND PREGNANCY-INDUCED HYPERTENSION
5.1 INTRODUCTION
During pregnancy a number of cardiovascular changes occur which are 
necessary in order to meet the changing requirements of the mother, developing 
fetus and placental tissue. These changes, which are summarised in Table 5.1, 
include increased cardiac output, expanded plasma volume, raised exchangeable 
sodium and elevated circulating levels of renin, angiotensin II and aldosterone [385, 
386]. These processes are normally involved in maintaining Na+ homeostasis and 
blood pressure regulation. The renin-angiotensin-aldosterone system plays a 
central role in Na+ balance through the regulation of Na+ reabsorption in the kidney. 
Although overall activity of the renin-angiotensin system is substantially raised in 
pregnancy it remains under similar control mechanisms as those in non-pregnant 
conditions [387].
In addition to their role in renal Na+ reabsorption, angiotensin II and 
aldosterone also enhance vascular reactivity. The pressor actions of angiotensin II 
and possibly also aldosterone are mediated, in part, through plasma membrane 
Na+/H+ exchange [388, 389].
During normal pregnancy, despite increased cardiac output and expanded 
plasma volume there is an initial fall in systemic blood pressure in the first trimester 
with a slow progressive rise to non-pregnant values towards term (Figure 5.1)[390].
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HEMODYNAMICS
PLASMA VOLUME 
CARDIAC OUTPUT 
EXCHANGEABLE SODIUM 
PERIPHERAL RESISTANCE
EXPANDED
INCREASED
INCREASED
REDUCED
RENAL FUNCTION
GLOMERULAR FILTRATION 
PLASMA URIC ACID
INCREASED
DECREASED
RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
PLASMA RENIN ACTIVITY 
PLASMA ANGIOTENSIN II 
PLASMA ALDOSTERONE
INCREASED
INCREASED
INCREASED
HORMONE LEVELS
ESTROGEN
PROGESTERONE
INCREASED
INCREASED
TABLE 5.1 Physiological changes occurring during pregnancy.
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Figure 5.1 Blood pressure changes during the course of normal pregnancy. 
(Adapted from; A Halligan et al (1993) [390]). 24 h ambulatory blood pressure 
measurements were performed with SpaceLabs 90207 Ambulatory System during 
the trimesters of pregnancy and in the puerperium in normotensive healthy 
primigravidae.
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The initial fall in blood pressure is paralleled by a reduction in vascular 
sensitivity to vasoconstrictors such as angiotensin II [391, 392]. Increased 
production of vasodilator prostaglandins from the endothelium of the vessel wall 
[387, 393] or, as recently suggested, reduced circulating levels of inhibitors of the L- 
arginine-nitric oxide pathway [394], may be responsible for the reduced vascular 
sensitivity.
Pregnancy-induced hypertension (PIH) normally becomes apparent after the 
24th week of pregnancy and is characterised by increased vascular reactivity and 
relatively low plasma volume. Hepatic dysfunction, platelet activation, coagulation 
changes, proteinuria and abnormal vascular endothelial function may occur when 
the disease progresses to a severe form known as pre-eclampsia (PET) [386, 395, 
396].
There is considerable evidence to implicate platelets in the pathophysiology 
of PIH. Studies have shown a reduction in platelet number and platelet lifespan 
which have been interpreted as evidence of increased platelet consumption [397, 
398].AIso platelet reactivity [399] and mean platelet volume [400] are enhanced in 
women with PIH. Reactivity, however, is reduced in PET [401, 402], possibly due to 
consumption of already activated platelets. Raised platelet volume in PIH may 
simply be due to increased platelet turnover or may reflect increased Na+/H+ 
exchange since platelet volume is controlled, at least in part, by plasma membrane 
Na+/H+ exchanger activity. The transport of Na+ into the cells during exchanger 
activation is accompanied by an osmotic water shift resulting in cell swelling [153].
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The apparent initial success of small controlled trials of antiplatelet therapy, 
particularly low-dose asprin, in the prevention of of pre-eclampsia and intrauterine 
growth retardation suggested further evidence for the role of platelets in the 
pathophysiology of the PET [403, 404]. However results from larger, randomised 
controlled trials including the CLASP study have not confirmed these results. The 
use of low-dose asprin may be justified in women at especially high risk of early 
onset pre-eclampsia, however results do not support the routine prophylactic or 
therapeutic administration of antiplatelet therapy in pregnancy to all women at 
increased risk of PET. [405].
The mechanisms underlying the vascular hypersensitivity during PIH are not 
clearly understood. However reports of excessive Na+ retention [406] (which is not 
due to the renin-angiotensin II system since this system is supressed in PIH [407]) 
as well as increased red cell membrane permeability to Na+ [408] suggest that 
abnormal cell sodium homeostasis may be involved.
Intracellular [Na+] and pH which influence smooth muscle contractility, renal 
Na+ reabsorption and cell growth are all regulated at least in part by Na+/H+ 
exchange. Abnormalities in the activity of this exchanger have been described in 
platelets [161, 271] and leucocytes [272] from patients with essential hypertension 
and in insulin-dependent diabetics with nephropathy [409]. It is possible, therefore, 
that Na+/H+ exchanger activity is also altered during PIH.
The aim of this study was to characterise platelet Na+/H+ exchange during 
normal pregnancy and in women with PIH. Platelets were chosen because they are 
readily available, they respond to the same agents as those which control smooth
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muscle function, and they appear to play a crucial role in the pathophysiology of PIH 
by promoting vascular damage and obstruction within the uteroplacental circulation 
[386]. Plasma cholesterol was also measured since this has been shown to 
influence Na+/H+ exchange [352, 353], and increases progressively through 
pregnancy [410], PET subjects were excluded from this study due to excessive 
platelet turnover and reduced platelet responsiveness observed in this condition.
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5.2 METHODS
5.2.1 REAGENTS AND EQUIPMENT 
(In addition to those listed in chapter 2.)
Cholesterol kit (Boehringer Mannheim, Germany).
5.2.2 SUBJECTS
Platelet Na+/H+ exchange was characterised in a cross sectional study of 
primigravidas at 12-16 weeks (n=9), 28-32 weeks (n=7), 38-42 weeks (n=8 ), 6  
weeks postpartum (n=3) and in non-pregnant women. Clinical details recorded for 
each of the different groups of pregnant and non-pregnant women included; age, 
booking blood pressure, maximal blood pressure, proteinuria, maternal platelet 
count and uric acid concentration, gestational age at delivery and birthweight of 
neonate. In each pregnancy the outcome was normal with birthweight >10th centile 
for gestation and gestational age >37 weeks at delivery (except for one preterm 
normal birth at 33 weeks, included in the 2nd trimester group).
In addition Na+/H+ exchange was characterised in 15 primigravidae with 
pregnancy-induced hypertension (PIH) at gestational age of 37±0.6 weeks. PIH was 
defined by agreed criteria [411], which included normal blood pressure at booking, 
and serial blood pressure readings >140/90mmHg, with a rise in phase IV diastolic 
blood pressure >20 mmHg (mercury sphygmomanometer). No patient received 
antihypertensive drugs or asprin during pregnancy. None had any significant 
proteinuria (mean 24h protein in the PIH group was 0.04±0.02g/24hrs) thereby
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excluding PET. Blood samples were obtained under standardised conditions 
between 0900 and 1200hrs.
Na+/H+ exchanger kinetics were measured as previously described in 
chapter 2 .
Plasma cholesterol concentration was measured by an enzymic method 
using a commercial kit (Boehringer Mannheim, Germany). The coefficient of 
variation for day to day variability was 4% and for intra-assay variability was 0.5%.
5.2.3 STATISTICAL ANALYSIS
Results are expressed as mean±SEM. Differences between groups were 
tested by one way analysis of variance. Correlations were examined by analysis of 
single linear regression. Cholesterol data was log transformed because it was not 
normally distributed, p values <0.05 were considered significant.
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5.3 RESULTS
Clinical details for each of the groups studied are given in Table 5.2. There 
were no significant difference in maternal age between groups. Platelet number did 
not differ significantly between normal pregnant women and women with PIH.
The kinetics of Na+/H+ exchange in the normal groups and in women whose 
pregnancies were complicated by PIH are shown in Figure 5.2. Vmax increased as 
pregnancy advanced returning to baseline values post-partum (ANOVA). No 
significant differences were present between the PIH group and the normal 3rd 
trimester group for either Vmax or Km. Km values were also similar in all other 
groups (Figure 5.3). Basal Na+ uptake (amiloride insensitive Na+ uptake), was not 
significantly different between groups.
Plasma cholesterol concentration increased with gestational age (Figure 
5.4). There was no significant difference in cholesterol concentration between the 
PIH group and gestational age matched controls. The relationship between Na+/H+ 
exchanger activity and plasma cholesterol concentration during pregnancy is shown 
in Figure 5.5. Plasma cholesterol concentration was positively correlated with Vmax 
of Na+/H+ exchange during normotensive pregnancy (regression coefficient = 
0.493, p = 0.017). When correlations were sought within the various groups, Vmax 
and plasma cholesterol were most closely related during the 1st trimester (r=0.730, 
p<0.02), less so during the 2nd trimester (r=0.46, p=0.3) and not at all during the 
final trimester (r=0.12) or in the PIH group (r=-0.014).
By chance the PIH group were sampled at a slightly earlier stage of 
pregnancy than the equivalent control group (37±0.6 v. 39±0.4 weeks). Four of the
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PIH group had blood samples taken earlier than 36 weeks and when these subjects 
are excluded the mean sampling age for the PIH group becomes 38.1 ±0.5 weeks 
(not significantly different from the control group). Corresponding changes to 
plasma cholesterol (6.3±0.3 to 6.6±0.4mmol/l), Km (46.8±3.3 to 48.4±3.7mmol/l) 
and Vmax (712±44 to 686±57pmol Na+/106cells/min) were not significant and did 
not alter the comparisons with the control pregnancy groups.
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Age Average Protein- Platelet Gest Age Birth -
(years) B.P uria Number Delivery weight
(mmHg) (g/24hr) (109/l) (weeks) (g)
0 nr na naNon-pregnant 26±0.99 130/81 
n=8
1st Trimester 24±2.05 113/70
n=9
2nd Trimester 25±2.88 135/83 
n=7
218±16.5 39±0.50 3154±178
251 ±18.0 37±0.94* 2723±156*
3rd Trimester 25±1.54 133/84 
n=8
225±14.1 40±0.58 3341±152
PIH 25±1.07 169/107 0.041 219±22.8 39±0.40 3379±143
n=15 ±0.02
0 277±15.6 40±0.33 3310±260Postnatal
n=3
27±3.79 130/80
TABLE 5.2 Clinical details for non-pregnant, normal pregnant, postnatal women 
and women with PIH. Mean±SEM 
nr = not recorded, na = not applicable.
* denotes statistical significance at p<0.05 (ANOVA).
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Figure 5.2 Maximum rate of amiloride-sensitive sodium uptake by platelets in non­
pregnant controls (NPC), in normal pregnant women at gestational ages of 12-16 
weeks (1st Trim), 28-32 weeks (2nd Trim) and 38-42 weeks (3rd Trim), in women with 
pregnancy-induced hypertension (PIH) and in post natal subjects (PN).
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Figure 5.3 Michaelis Constants for amiloride-sensitive sodium uptake by platelets in 
non-pregnant controls (NPC), in normal pregnant women at gestational ages of 12- 
16 weeks (1st Trim), 28-32 weeks (2nd Trim) and 38-42 weeks (3rd Trim), in women 
with pregnancy-induced hypertension (PIH) and in post natal subjects (PN).
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Figure 5.4 Plasma cholesterol concentration in non-pregnant controls (NPC), in 
normal pregnant women at gestational ages of 12-16 weeks (1st Trim), 28-32 weeks 
(2nd Trim) and 38-42 weeks (3rd Trim), in women with pregnancy-induced 
hypertension (PIH) and in post natal subjects (PN).
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Figure 5.5 Positive correlation between plasma cholesterol concentration and 
amiloride-sensitive sodium uptake (Vmax) in platelets during normotensive 
pregnancy (regression coefficient = 0.493, p value = 0.017). Plasma cholesterol 
was not significantly correlated with Vmax in PIH.
217
5.4 DISCUSSION
Na+/H+ exchange is one of the major pathway of sodium entry into many 
cells and if unopposed would lead not only to a rise in intracellular sodium but also 
to intracellular alkalinization. It has been proposed that alterations in the regulation 
of cytosolic Na+ and H+ concentrations contribute to increased VSMC sensitivity and 
tone leading to hypertrophy of vascular tissue [412]. Raised Na+/H+ exchanger 
activity has previously been described in several cell types eg platelets, 
erythrocytes and leucocytes from essential hypertensive patients and also cells (eg 
erythrocytes, platelets, smooth muscle cells, lymphocytes) from animal models such 
as spontaneously hypertensive rats (SHR).
The present study demonstrates that Vmax, but not Km, for amiloride- 
sensitive sodium uptake by platelets increases throughout pregnancy and appears 
to return to normal values by 6  weeks post-partum. No significant difference in 
exchanger activity was observed between PIH and gestational age matched 
controls. Similarily, previous studies have failed to demonstrate a difference in red 
cell Na+/Li+ countertransport between normal pregnancy and in PIH [413, 414, 415, 
416], This transport pathway is believed by some to reflect the activity of the Na+/H+ 
exchanger [47].
Raised platelet Na+/H+ exchanger activity may reflect increased proximal 
tubule Na+ reabsorption which is largely dependent on Na+/H+ exchange. It follows, 
therefore, that plasma volume expansion and raised exchangeable Na+ of normal 
pregnancy could be attributed to altered renal exchanger activity. This possibility 
needs further investigation. It has been demonstrated recently that the Na+/H+
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exchanger localized on the plasma membrane of non-epithelial cells (eg. platelet 
plasma membrane) is a different subtype to that found in the apical membrane of 
renal, intestinal and gall bladder epithelia [57, 59]. The two exchanger subtypes are 
differentiated not only by tissue specificity but also by pharmacological and 
regulatory properties. It is not known whether factors which affect the activity of one 
subtype will necessarily influence the other.
Increased Na+/H+ exchange in platelets during normal pregnancy would be 
expected to raise intracellular sodium content (but not necessarily intracellular Na+ 
concentration since cell swelling occurs during exchanger activation as a result of 
uptake of osmotically obliged water). Previous studies, however, have 
demonstrated a fall in erythrocyte sodium content during normal gestation [417, 
418] and thus another factor must act to oppose the Na+/H+ exchanger induced 
increases in cellular sodium content.
Under normal circumstances alterations in cellular sodium content are 
compensated for by changes in Na+/K* ATPase pump activity. Net intracellular Na+ 
depends on the balance between Na+ influx and Na+ efflux. Previous studies have 
demonstrated that Na+/K+ ATPase pump numbers and activity [416, 419, 420, 421, 
422] are increased during normal pregnancy. This increase in Na+ pump number 
and activity may occur as an adaptive response to maintain normal intracellular 
sodium in the face of increased Na+/H+ exchange. On the other hand raised Na+/H+ 
exchange may occur in response to the increase in Na+/K* ATPase activity.
During PIH, cell sodium content has been observed to be significantly 
elevated [423]. Raised circulating levels of ouabain-displacing factor (ODF), (a
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Na+/K+ ATPase pump inhibitor), which have been measured in PIH patients [422, 
424, 425] may be responsible for this elevated cell sodium content. Our data show 
no significant difference in Na+/H+ activity between PIH and gestational age 
matched controls. The exchanger, therefore, appears not to play a primary role in 
the development of PIH. However, changes in Na+/H+ exchanger activity may be 
secondary to Na+/K+ ATPase activity and may not be apparent in vitro when plasma 
is absent.
In normal pregnancy, serum cholesterol increases with gestational age 
[410]. Our data show that plasma cholesterol concentration and Na+/H+ exchanger 
activity are positively correlated during normal pregnancy. The association seemed 
most marked in the first two trimesters but was absent during the last trimester and 
in PIH. However, the span of cholesterol values and the small numbers in the 
different groups makes interpretation of these findings difficult. Cholesterol is a 
major component of cell membranes, and maintains the lipid bilayer matrix in a fluid 
state. In turn, this may influence the activity of membrane bound receptors and ion 
transporters [124] including Na+/H+ exchange [352, 353]. Our data suggest that 
plasma cholesterol concentration influences platelet Na+/H+ exchanger activity in 
vivo during normal pregnancy. A similar relationship between plasma cholesterol 
and erythrocyte Na+/Li+ countertransport during pregnancy has been reported [413]. 
In addition, increased cholesterol content of erythrocyte membranes has been 
demonstrated in PIH [427]. The influence of circulating plasma cholesterol levels on 
membrane cholesterol content and its direct or indirect effect on ion transport 
mechanisms in vivo have still to be clearly identified. The fact that Vmax (and not
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Km) of amiloride-sensitive Na+ uptake is raised during pregnancy suggests that 
either (I) the rate of activity of already existing exchangers has been enhanced or
(ii) that additional exchanger sites have been revealed or recruited to the plasma 
membrane, whereas the affinity of the exchanger for Na+ is unchanged. Circulating 
cholesterol levels may influence the number of active exchanger sites by altering 
membrane fluidity. On the other hand, circulating cholesterol may influence the rate 
of exchanger activation, since it has been proposed, that in addition to its affect on 
the mevalonate pathway, exogenous cholesterol induces ‘initiator-promotor* 
coupling of phospholipases D an A2 resulting in the activation of Na+/H+ exchange 
in platelets [353].
In summary, Na+/H+ exchanger activity increases progressively with 
gestational age and gradually returns to normal postnatally. These changes may 
relate to total body sodium content or altered cell sodium homeostasis and could 
reflect changes induced by plasma lipoproteins. Activation of Na+/H+ exchange is 
important in mediating the actions of vasoconstrictors like angiotensin II [388]. If 
pregnancy induced changes of Na+/H+ exchanger activity occur in vascular smooth 
muscle cells, this would explain alterations in vascular reactivity which occur during 
normal pregnancy. Neither the capacity nor the affinity for Na+ was altered in PIH 
platelets suggesting that Na+/H+ exchange is not responsible for the previously 
observed elevation in cell sodium content. Further studies of platelet Na+/H+ 
exchanger activity in the more severe pregnancy-induced condition, pre-eclampsia, 
would be useful. Basal [428] and Angiotensin ll-stimulated [429] platelet intracellular 
free Ca2+ concentrations are significantly increased in subjects whose pregnancies
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are complicated by pre-eclampsia. Furthermore, it has been shown that the 
development of PET is preceded, in most cases, by an increase in platelet Ca+ 
sensitvity to arginine vasopressin [430]. Na+/H+ exchange is believed by some to be 
capable of modulating Ca+ mobilization in platelets [27], (described more fully in 
chapter 3), and may play a role in the increased platelet sensitivity prior to PET 
development.
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DISCUSSION
Over the past 15 years several different cation transport systems in 
numerous cell types have been described as being altered in subsets of patients 
with essential hypertension. Altered activation of these transport systems have 
been hypothesized to be causally related to the development of hypertension. The 
underlying cause of such general disturbances in cation transport has never been 
established, however, a combination of both genetic and environmental factors may 
be involved.
One important group of physiological variables which are often altered in 
essential hypertension are circulating plasma lipids and lipoproteins. Results from 
the present investigations demonstrate that platelet Na7H+ exchange and [Ca2+]j 
are indeed influenced by particular lipoprotein subfractions both in vitro, and in vivo. 
Furthermore, relationships between platelet Na+/H+ exchange and circulating lipids 
are altered in hypertensive and diabetic disease states. Lipid-induced changes in 
platelet cation transport may occur as a result of a number of mechanisms 
including: i) alteration in platelet membrane fluidity; ii) direct 'hormone like' action, 
whereby lipids bind to membrane receptors and in doing so stimulate intracellular 
events; iii) or possibly via a process similar to that of lipid-induced inhibition of nitric 
oxide (NO)-induced relaxation of vascular smooth muscle [431]. It is well 
established that NO is involved in the negative control of platelet activity whilst 
[Ca2+]i and Na+/H+ exchange play important roles in platelet activation. Recent 
evidence suggests that NO and/or cGMP have a role in cell Ca2+ homeostasis
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[432]. cGMP appears to have a biphasic, concentration-dependent effect providing 
a negative feedback mechanism that inhibits Ca2+ entry during periods of high cell 
[Ca2+]j, whilst lower cGMP concentrations, allow the oscillatory behaviour of Ca2+ 
entry (i.e. Ca2+ cycling) [432]. The direct effect of NO inhibition on Na+/H+ exchanger 
activity in platelets or VSMC has not been previously investigated, however ANP 
and cGMP are known to inhibit exchanger activity in VSMC [433], Lipid-induced 
changes in the tightly-controlled feedbeck mechanisms between NO and/or cGMP 
and Ca2+ cycling, and possibly Na+/H+ exchange, may play a role in the 
pathogenesis of cardiovascular disease.
It has been proposed that cation transport activity and circulating lipids may 
be indirectly related [300], For example the biosynthetic pathway which controls 
endogenous cholesterol synthesis (mevalonate pathway) also regulates isoprenoid 
synthesis. Isoprenoids play an important role in enzymatic glycosylation of the N' 
terminal of the Na+/H+ exchanger molecule. The degree of glycosylation may 
influence exchanger activity.
In addition to lipoprotein-induced effects, Na+/H+ exchanger activity is 
stimulated by or associated with a wide variety of other physiological variables 
(some of which are influenced by environmental factors) eg. high salt intake [434], 
metabolic acidosis [435], hyperosmolarity [436], cell spreading [437], growth factors 
and vasoactive agents [60, 438, 438]. The effects of two physiological variables, ie. 
insulin and glucose, on Na+/H+ exchanger activity have been proposed as the link 
between the development of essential hypertension in certain NIDDM patients with 
hyperinsulinemia [314, 364] and in patients with abnormal glucose homeostasis
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[384, 439], It is important to account for such relationships when investigating cation 
transport in vivo.
Environmental factors must be reponsible for the observed increase in 
Na+/H+ exchanger activity during normal pregnancy. However, despite the positive 
relationship between plasma cholesterol concentration and Na+/H+ exchange our 
results do not prove conclusively that cholesterol is the cause of this increase. Any 
one of a number of physiological variables (eg. hormones, coagulation factors etc.) 
which are raised during pregnancy may be reponsible. Furthermore raised Na+/H+ 
exchange may be secondary to alterations in other intracellular signalling events, 
eg. changes in intracellular Ca2+ metabolism, since the recently identified Ca2+- 
calmodulin (Ca-CaM) binding site on the Na+/H+ exchanger has finally provided a 
link between Ca2+ metabolism and Na+/H+ exchange.
The importance of genetic factors in enhanced Na+/H+ exchanger activity in 
essential hypertension has recently been demonstrated by studies with 
immortalized human lymphoblasts [303]. This approach allows the exclusion of 
effects potentially arising from the hypertensive environment. The fact that altered 
kinetic behaviour persists in cultured transformed cells, suggests that elevated 
Na+/H+ exchange does not arise secondary to the elevation in blood pressure in 
vivo. Recent studies have demonstrated that elevated Na+/H+ exchanger activity in 
essential hypertension is not associated with NHE-1 gene mutation or 
overexpression but may be related to increased exchanger phosphorylation [303]. 
The persistance of enhanced exchanger phosphorylation in cells from hypertensive
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subjects, despite culture in vitro., indicates that genetic factors may play an 
important role in the development of this abnormality.
The role of Na+/H+ exchange in cell growth and proliferation has long been 
controversial. pHj plays a key role in the proliferative cascade. Furthermore, Na+/H+ 
exchange is central to pHj regulation and is activated by mitogens. A number of 
studies, however, have demonstrated that exchanger activation is not essential to 
the development of the growth reponse, but appears to play a permissive role, 
perhaps by optimizing growth conditions [440]. Recent studies with immortalized 
lymphoblasts have provided evidence against an essential role for Na+/H+ 
exchange in enhanced proliferation of hypertensive cell lines [311]. Enhanced 
sensitivity of the growth response to pertussis toxin in these hypertensive cell lines 
suggests a cellular alteration which resides upstream of Na+/H+ exchange activity 
and proliferation control ie. an alteration in the pathways controlled by Gj proteins.
Essential hypertension is a complex polygenic disease with a strong 
environmental component. It is therefore not suprising that it has been difficult to 
show a causal relationship between any one ion-transport abnormality and 
hypertension in different patient populations. The role of an inherited defect in 
Na+/H+ exchange or its regulation (ie. G proteins, protein kinase C, Ca2+-CaM) in 
the susceptability to hypertension needs further investigation. Studies of signaling 
pathways in human immortalized cultured cells should generate important new 
information on the molecular and genetic mechanisms underlying cation transport 
abnormalities in hypertension and diabetes.
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APPENDIX
Table A1. Correlations (r) between plasma lipid values, blood pressure, age and 
Na+/H+ exchange kinetics in platelets form normotensive subjects. * p<0.05.
All Male Female
Km Vmax Km Vmax Km Vmax
Cholesterol -0.013 0.090 -0.026 0.091 0.032 0.085
Triglyceride 0.123 0.097 0.121 0.118 0.179 0.053
VLDL 0.011 0.116 -0.082 0.080 0.183 0.177
LDL 0.023 0.125 0.034 0.083 0.012 0.208
HDL -0.186 -0.274* -0.125 -0.364* -0.403 -0.075
ChoLHDL 0.162 0.293* 0.529 0.376* 0.176 0.324
hdl2 -0.122 -0.015 -0.215 0.089 0.254 -0.088
hdl3 -0.192 0.134 -0.191 -0.076 -0.037 -0.200
HDL2:HDL3 -0.018 0.045 -0.037 -0.063 -0.170 -0.395
Apo Al -0.034 -0.020 0.105 -0.068 0.105 -0.320
Apo B 0.080 0.038 0.016 0.098 -0.105 0.221
Lp(a) 0.118 -0.058 0.115 0.091 0.140 -0.354
Systolic BP. -0.078 -0.244 -0.067 -0.330* -0.113 -0.053
Diastolic BP. 0.085 -0.205 -0.031 -0.276 0.267 -0.074
Age 0.047 -0.134 -0.089 -0.114 0.417 -0.213
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Table A2. Correlations (r) between plasma lipid values, blood pressure, age and 
platelet calcium metabolism in normotensive subjects. C1 represents basal [Ca2+]j, 
C2 represents AVP-stimulated [Ca2+]j, and C3 represents AVP-stimulated [Ca2+]j + 
EGTA. * p<0.05.
All Male Female
C1 C2 C3 C1 C2 C3 C1 C2 C3
Cholesterol -0.118 -0.100 0.077 -0.282 -0.339 -0.166 0.123 0.191 0.309
Triglyceride 0.009 0.047 0.099 -0.038 -0.018 0.025 0.058 0.115 0.139
VLDL -0.026 0.049 0.083 -0.076 -0.012 0.008 0.022 0.143 0.084
LDL -0.130 -0.131 0.070 -0.245 -0.308 -0.123 0.051 0.096 0.264
HDL -0.060 0.057 -0.048 -0.147 -0.050 -0.116 0.059 0.122 0.039
Chol:HDL -0.025 -0.105 0.107 -0.065 -0.189 0.001 0.022 0.022 0.178
h d l2 -0.178 -0.068 -0.144 -0.113 -0.015 -0.023 -0.210 -0.230 -0.164
h d l3 -0.138 0.084 -0.072 -0.077 0.169 -0.026 -0.125 -0.073 0.035
HDL2:HDL3 -0.107 -0.133 -0.101 -0.062 -0.089 -0.027 -0.182 -0.231 -0.197
Apo Al 0.103 0.146 0.194 -0.147 -0.066 -0.008 0.370 0.263 0.378
Apo B -0.099 -0.039 0.074 -0.356 -0.289 -0.286 0.325 0.299 0.439*
Lp(a) -0.003 -0.015 -0.078 -0.024 -0.154 -0.247 0.014 0.110 0.061
Systolic BP. -0.127 -0.089 0.040 -0.112 0.049 0.189 -0.165 -0.190 -0.197
Diastolic BP. 0.071 -0.019 0.164 0.076 0.120 0.211 0.070 -0.033 0.046
Age 0.195 0.130 0.268* -0.080 -0.213 0.075 0.552** 0.501* 0.540*
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Table A3. Correlations between Na7H+ exchanger kinetics, plasma lipids and blood 
pressure in normotensive subjects bearing Apo E phenotype E3/E3 or E4/E3. * 
denotes p<0.05.
Apo E3/E3 Apo E4/E3
Km Vmax Km Vmax
Cholesterol 0.078 0.070 0.236 0.290
Triglyceride 0.179 0.239 0.225 0.111
VLDL 0.140 0.027 0.092 0.083
LDL 0.140 0.027 0.233 0.274
HDL -0.259 -0.287 0.034 0.109
Cholesterol:HDL 0.265 0.232 0.185 0.168
HDL.2 -0.152 -0.185 -0.359 0.154
hdl3 -0.109 -0.131 -0.103 0.523*
HDL2:HDL3 -0.229 -0.235 -0.288 -0.201
Apo Al -0.094 -0.135 0.498 0.322
Apo B 0.162 0.098 0.291 0.264
Lp(a) 0.236 -0.258 0.034 0.532*
Systolic BP. 0.047 -0.223 -0.160 -0.325
Diastolic BP. 0.144 -0.098 -0.040 -0.344
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Table A4. Correlations between platelet [Ca2+]j, plasma lipids and blood pressure in 
normotensive subjects bearing Apo E phenotype E3/E3 or E4/E3. C1 represents 
basal [Ca2+]j, C2 represents AVP-stimulated [Ca2+]i, and C3 represents AVP- 
stimulated [Ca2+]j + EGTA. * denotes p<0.05.
Apo E3/E3 Apo E4/E3
C1 C2 C3 C1 C2 C3
Cholesterol 0.160 0.201 0.226 -0.096 -0.261 0.401
Triglyceride 0.189 0.199 0.148 0.031 -0.251 0.236
VLDL 0.191 0.179 0.241 -0.064 -0.163 0.323
LDL 0.157 0.170 0.222 0.007 -0.220 0.480
HDL -0.159 -0.151 -0.091 -0.022 0.122 -0.052
ChohHDL 0.315 0.289 0.304 -0.045 -0.178 -0.255
hdl2 -0.368* -0.307 -0.250 -0.099 0.026 -0.320
hdl3 -0.011 0.238 0.199 -0.003 -0.034 -0.162
HDL2:HDL3 -0.326 -0.387* -0.300 -0.159 -0.054 -0.231
Apo Al 0.074 0.148 0.220 0.056 0.165 0.176
Apo B 0.285 0.287 0.308 -0.237 -0.244 0.100
Lp(a) -0.092 -0.071 -0.195 0.284 0.183 0.378
Systolic BP. 0.202 0.209 0.228 -0.380 -0.299 -0.112
Diastolic BP. 0.419 0.336 0.441 -0.252 -0.028 -0.062
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Table A5. Correlations between Km, Vmax, membrane microviscosity and plasma 
lipid concentrations, blood pressure and age in hypertensive and control subjects.! 
denotes p<0.05.
Hypertensives Controls
Km Vmax Micro. Km Vmax Micro.
Microvis. 0.110 0.260 -0.197 0.468
Cholesterol 0.424 0.093 -0.206 -0.041 -0.021 -0.339
Triglyceride 0.406 0.126 -0.214 0.033 -0.361 -0.418
VLDL 0.467 0.351 -0.261 -0.043 -0.416 -0.297
LDL 0.443 0.024 -0.261 0.298 -0.097 -0.192
HDL -0.227 -0.386 -0.091 0.042 -0.429 -0.254
ChohHDL 0.493 0.339 -0.129 0.085 0.232 0.075
hdl2 -0.550* -0.448 -0.240 0.043 0.441 0.036
hdl3 -0.115 -0.259 -0.125 -0.327 -0.227 0.119
HDL2:HDL3 -0.530* -0.395 -0.235 0.227 0.467 -0.004
Apo Al 0.150 0.060 -0.193 0.053 -0.496 -0.484
Apo B 0.622* 0.490 0.106 -0.032 -0.308 -0.325
Systolic BP 0.046 -0.224 0.149 -0.204 -0.321 -0.168
Diastolic BP -0.265 0.116 0.330 0.247 -0.139 0.252
Age 0.194 0.261 0.412 0.259 0.154 -0.356
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Table A6. Correlations between Km, Vmax, membrane microviscosity and plasma 
lipid concentrations, blood pressure and age in diabetic and control subjects. 
* denotes p<0.05.
Diabetics Controls
Km Vmax Micro. Km Vmax Micro.
Micro. 0.051 -0.263 -0.098 0.412
Cholesterol -0.207 -0.443 -0.513' 0.084 0.237 -0.418
Triglyceride -0.324 -0.546' -0.393 0.107 -0.251 -0.268
VLDL -0.179 -0.560' -0.231 0.070 -0.011 -0.245
LDL -0.040 -0.078 -0.520' 0.339 -0.509 -0.369
HDL -0.314 -0.218 0.348 -0.321 -0.416 -0.621
Chol:HDL 0.153 -0.127 -0.537* 0.454 0.363 0.547
hdl2 -0.075 0.135 0.398 -0.259 0.336 -0.007
hdl3 -0.394 -0.292 -0.008 -0.139 -0.177 -0.331
HDL2:HDL3 0.282 0.383 0.467 -0.200 0.344 0.087
Apo Al -0.407 -0.416 0.123 -0.110 -0.498 -0.735'
Apo B -0.171 -0.446 -0.506 0.212 -0.060 -0.251
Systolic BP -0.181 -0.002 -0.483 -0.345 0.167 -0.219
Diastolic BP -0.426 -0.164 -0.078 -0.084 0.098 0.207
Age -0.020 0.105 -0.316 -0.423 0.389 -0.230
305
Table A7. Multiple regression analysis of models identified by Best Subsets 
Regression (BREG) for Km and Vmax of platelet Na+/H+ exchange in male and 
female normotensive subjects and platelet [Ca2+]j in normotensive female subjects. 
ANOVA, analysis of variance p value and % influence of combined predictor 
variables in model.
Vmax (Males) Vmax (Females) [Ca2*]; (Females)
Systolic B.P. p = 0.032 Systolic B.P. p = 0.073 Age p = 0.084
Triglycerides p = 0.235 Triglycerides p = 0.102 Triglyceride p = 0.001
VLDL p = 0.188 VLDL p = 0.012 VLDL p = 0.074
Chol:HDL ratio p = 0.077 hdl3 p = 0.093 Apo A1 p = 0.015
Apo B p = 0.001 Apo B p = 0.001
ChoLHDL ratio p = 0.003 Systolic B.P. p = 0.004
ANOVA p = 0.033, 33.2% ANOVA p = 0.020, 69.4% ANOVA p = 0.001, 75.9%
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Table A8. Multiple regression analysis of models identified by Best Subsets 
Regression (BREG) for Km and Vmax of platelet Na+/H+ exchange in essential 
hypertensive subjects. No model was identified for membrane microviscosity. 
ANOVA, analysis of variance p value and % influence of combined predictor 
variables in model.
Vmax
Systolic B.P. p = 0.037
HDL3 p = 0.079
Apo B p= 0.0001
ANOVA p = 0.009, 51.0%
Km
Systolic B.P. p = 0.021
Triglyceride p = 0.004
VLDL p = 0.005
HDL2 p = 0.004
Microviscosity p = 0.005
ANOVA p = 0.013, 98.1%
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Table A9. Multiple regression analysis of model identified by Best Subsets 
Regression (BREG) for platelet membrane microviscosity in type 2 diabetic 
patients. No models were identified identified for Km or Vmax of platelet Na+/H+ 
exchange. ANOVA , analysis of variance p value and % influence of combined 
predictor variables in model.
Microviscosity
Cholesterol p = 0.006
Triglyceride p = 0.009
VLDL p = 0.008
HDL p = 0.003
h d l 2 p = 0.005
h d l 3 p = 0.005
ANOVA p =0.014, 98.1%
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